0001460702 2025-01-01 2025-12-31 0001460702 2025-06-30 0001460702 2026-03-23 0001460702 2024-01-01 2024-12-31 0001460702 2025-12-31 0001460702 2024-12-31 0001460702 us-gaap:RelatedPartyMember 2025-12-31 0001460702 us-gaap:RelatedPartyMember 2024-12-31 0001460702 us-gaap:NonrelatedPartyMember 2025-12-31 0001460702 us-gaap:NonrelatedPartyMember 2024-12-31 0001460702 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001460702 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001460702 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001460702 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001460702 us-gaap:CommonStockMember 2024-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001460702 us-gaap:RetainedEarningsMember 2024-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001460702 us-gaap:CommonStockMember 2023-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001460702 us-gaap:RetainedEarningsMember 2023-12-31 0001460702 2023-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0001460702 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0001460702 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001460702 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001460702 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001460702 us-gaap:CommonStockMember 2025-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001460702 us-gaap:RetainedEarningsMember 2025-12-31 0001460702 us-gaap:NonrelatedPartyMember 2025-01-01 2025-12-31 0001460702 us-gaap:NonrelatedPartyMember 2024-01-01 2024-12-31 0001460702 us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0001460702 us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0001460702 AIXC:NanoSynexLtdMember 2022-12-31 0001460702 AIXC:SubscriptionAgreementMember 2025-09-01 2025-09-30 0001460702 AIXC:SeriesBConvertiblePreferredStockMember AIXC:SubscriptionAgreementMember 2025-09-30 0001460702 AIXC:SubscriptionAgreementMember 2025-01-01 2025-09-30 0001460702 us-gaap:SeriesBPreferredStockMember AIXC:AmendmentAndSettlementAgreementMember 2023-07-20 2023-07-20 0001460702 2024-11-05 2024-11-05 0001460702 AIXC:IRAgencyLLCMember 2025-01-01 2025-12-31 0001460702 2025-07-01 2025-07-31 0001460702 2025-12-01 2025-12-31 0001460702 AIXC:CardanoADAMember 2025-12-31 0001460702 AIXC:NativeBNBMember 2025-12-31 0001460702 AIXC:BitcoinMember 2025-12-31 0001460702 AIXC:DogecoinMember 2025-12-31 0001460702 AIXC:EthereumMember 2025-12-31 0001460702 AIXC:ChainLinkMember 2025-12-31 0001460702 AIXC:SolanaMember 2025-12-31 0001460702 AIXC:TronMember 2025-12-31 0001460702 AIXC:USDTetherMember 2025-12-31 0001460702 AIXC:RippleMember 2025-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001460702 AIXC:IncomeOtherMember 2025-01-01 2025-12-31 0001460702 AIXC:IncomeOtherMember 2024-01-01 2024-12-31 0001460702 AIXC:MarizymeNotesMember 2025-01-01 2025-12-31 0001460702 AIXC:MarizymeNotesMember 2025-12-31 0001460702 AIXC:ChembioDiagnosticsMember 2023-07-20 2023-07-20 0001460702 AIXC:ChembioDiagnosticsMember 2023-01-01 2023-12-31 0001460702 AIXC:UntilJanuaryTwentyTwoThousandTwentyFiveMember 2023-07-20 0001460702 2024-06-04 2024-06-04 0001460702 AIXC:AlphaCapitalMember AIXC:SeriesCWarrantsMember AIXC:SecuritiesPurchaseAgreementMember 2024-02-26 0001460702 AIXC:AlphaCapitalMember AIXC:SeriesCWarrantsMember AIXC:SecuritiesPurchaseAgreementMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:SeriesCWarrantsMember AIXC:SecuritiesPurchaseAgreementMember 2024-03-31 0001460702 AIXC:AlphaCapitalMember AIXC:SeriesCWarrantsMember AIXC:SecuritiesPurchaseAgreementMember 2024-06-26 2024-06-26 0001460702 AIXC:SeriesCWarrantMember 2025-12-31 0001460702 AIXC:SeriesCWarrantMember 2024-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-20 0001460702 AIXC:PreFundedWarrantsMember AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-20 0001460702 AIXC:PreFundedWarrantsMember AIXC:SeriesA2ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2024-01-01 2024-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2024-12-31 0001460702 AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-01-01 2025-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-01-01 2025-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2023-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2023-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2023-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2023-01-01 2023-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-01-01 2024-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:PreFundedWarrantsMember 2025-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2024-01-01 2024-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2024-01-01 2024-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-12-31 0001460702 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001460702 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001460702 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001460702 us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001460702 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001460702 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001460702 us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001460702 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001460702 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001460702 us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001460702 us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2022-12-22 2022-12-22 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2022-12-22 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2023-07-13 2023-07-13 0001460702 AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2022-12-22 2022-12-22 0001460702 AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2023-12-01 0001460702 AIXC:AlphaCapitalMember AIXC:SecuritiesPurchaseAgreementMember 2023-12-05 0001460702 AIXC:AlphaCapitalMember AIXC:SecuritiesPurchaseAgreementMember 2023-12-05 2023-12-05 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2023-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-02-26 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-01-01 2024-12-31 0001460702 AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-06-01 2024-06-30 0001460702 AIXC:AlphaCapitalMember AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-07-01 2024-07-31 0001460702 AIXC:TwoThousandTwentyTwoSeniorConvertibleDebentureMember 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-02-27 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-09-05 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-09-06 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember 2024-02-27 2024-02-27 0001460702 srt:MaximumMember AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-02-27 0001460702 srt:MaximumMember AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-02-27 2024-02-27 0001460702 AIXC:AlphaCapitalOtherThirdPartiesMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember 2024-02-27 0001460702 AIXC:AlphaCapitalOtherThirdPartiesMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember 2024-02-27 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-09-09 2024-09-09 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourAlphaDebentureMember us-gaap:RelatedPartyMember AIXC:SecuritiesPurchaseAgreementMember 2024-09-09 0001460702 AIXC:TwentyTwentyFourAlphaDebentureMember 2024-01-01 2024-12-31 0001460702 AIXC:TwentyTwentyFourAlphaDebentureMember 2024-11-20 2024-11-20 0001460702 AIXC:TwentyTwentyFourAlphaDebentureMember 2024-12-31 0001460702 srt:MaximumMember AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-04-01 2024-04-30 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-04-30 0001460702 srt:MaximumMember AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-04-30 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-09-05 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-09-06 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-04-01 2024-04-30 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-04-12 2024-04-12 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-04-12 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-11-20 2024-11-20 0001460702 AIXC:TwentyTwentyFourChenDebentureMember 2025-12-31 0001460702 AIXC:TwentyTwentyFourChenDebentureMember 2024-12-31 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-04-28 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-04-28 2025-04-28 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-06-04 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-01-01 2025-12-31 0001460702 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001460702 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001460702 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001460702 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460702 us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0001460702 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001460702 us-gaap:ConvertibleDebtMember 2025-01-01 2025-12-31 0001460702 us-gaap:ConvertibleDebtMember 2024-01-01 2024-12-31 0001460702 2025-01-29 2025-01-29 0001460702 2025-10-09 2025-10-09 0001460702 AIXC:UpfrontPaymentMember AIXC:LicenseAgreementMember 2022-01-01 2022-01-31 0001460702 AIXC:LicenseAgreementMember 2022-01-01 2022-01-31 0001460702 AIXC:LicenseAgreementMember 2025-01-01 2025-12-31 0001460702 AIXC:LicenseAgreementMember 2024-01-01 2024-12-31 0001460702 AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2019-03-01 2019-03-31 0001460702 AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2023-01-01 2023-12-31 0001460702 AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 srt:MinimumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 srt:MaximumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:PhaseOneClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:PhaseTwoClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:PhaseThreeClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:LicensedProductSalesMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 srt:MinimumMember AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-31 0001460702 srt:MaximumMember AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-31 0001460702 AIXC:SponsoredResearchAgreementsAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2025-01-01 2025-12-31 0001460702 AIXC:SponsoredResearchAgreementsAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2024-01-01 2024-12-31 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember 2018-06-01 2022-04-30 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 srt:MinimumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 srt:MaximumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:PhaseOneClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:PhaseTwoClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:PhaseThreeClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:LicensedProductSalesMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember 2025-01-01 2025-12-31 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember 2024-01-01 2024-12-31 0001460702 AIXC:CoDevelopmentAgreementMember 2024-04-11 2024-04-11 0001460702 AIXC:CoDevelopmentAgreementMember 2024-04-11 0001460702 AIXC:CoDevelopmentAgreementMember 2024-04-12 0001460702 us-gaap:InvestorMember AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:LegalFirmMember AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:FaradaySubscriptionAgreementMember 2025-09-29 0001460702 AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:AdvisorMember AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:FaradaySubscriptionAgreementMember 2025-12-31 0001460702 srt:MaximumMember us-gaap:CommonStockMember AIXC:CommonStockPurchaseAgreementMember 2024-11-19 2024-11-19 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2025-09-29 2025-09-29 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2025-09-29 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-07-28 2025-07-28 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-07-28 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-20 2024-11-20 0001460702 AIXC:YiHuaChenMember AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-18 2024-11-18 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesA2AndA3ConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001460702 srt:MaximumMember AIXC:SeriesA2AndA3ConvertiblePreferredStockMember 2025-12-31 0001460702 srt:MinimumMember AIXC:SeriesA2AndA3ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2024-11-20 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2024-11-20 0001460702 us-gaap:EmployeeStockOptionMember AIXC:TwoThousandTwentyStockIncentivePlanMember 2025-12-31 0001460702 us-gaap:EmployeeStockOptionMember AIXC:TwoThousandTwentyStockIncentivePlanMember 2024-12-31 0001460702 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001460702 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001460702 AIXC:GeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001460702 AIXC:ResearchAndDevelopmentExpensesMember us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001460702 AIXC:GeneralAndAdministrativeExpensesMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001460702 AIXC:ResearchAndDevelopmentExpensesMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001460702 us-gaap:EmployeeStockOptionMember 2025-12-31 0001460702 us-gaap:WarrantMember 2025-12-31 0001460702 us-gaap:WarrantMember 2024-02-27 0001460702 us-gaap:WarrantMember 2024-02-26 0001460702 us-gaap:WarrantMember 2024-02-27 2024-02-27 0001460702 us-gaap:WarrantMember 2024-09-06 0001460702 us-gaap:WarrantMember 2024-09-05 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2025-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2022-12-22 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2023-12-05 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2025-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember 2024-02-27 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-06 0001460702 AIXC:AlphaCapitalMember 2024-09-06 2024-09-06 0001460702 AIXC:YiHuaChenMember AIXC:SecuritiesPurchaseAgreementMember 2024-04-12 0001460702 AIXC:AlphaCapitalMember 2024-09-09 0001460702 AIXC:AlphaCapitalMember 2024-09-09 2024-09-09 0001460702 AIXC:PreFundedWarrantsMember 2024-09-06 0001460702 AIXC:PreFundedWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:PreFundedWarrantsMember 2025-12-31 0001460702 us-gaap:WarrantMember 2024-09-06 2024-09-06 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-11-20 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-11-20 2024-11-20 0001460702 us-gaap:ConvertibleDebtMember 2025-04-28 0001460702 us-gaap:ConvertibleDebtMember 2025-04-27 0001460702 us-gaap:ConvertibleDebtMember 2025-04-28 2025-04-28 0001460702 AIXC:PlacementAgentWarrantsMember 2025-09-29 0001460702 AIXC:PlacementAgentWarrantsMember 2025-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2025-12-31 0001460702 us-gaap:ConvertibleDebtMember 2025-12-31 0001460702 us-gaap:WarrantMember 2025-12-31 0001460702 AIXC:EmployeesAndNonemployeeServiceProviderMember 2024-12-31 0001460702 srt:MinimumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2024-12-31 0001460702 srt:MaximumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2024-12-31 0001460702 AIXC:EmployeesAndNonemployeeServiceProviderMember 2024-01-01 2024-12-31 0001460702 AIXC:EmployeesAndNonemployeeServiceProviderMember 2025-01-01 2025-12-31 0001460702 srt:MinimumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2025-01-01 2025-12-31 0001460702 srt:MaximumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2025-01-01 2025-12-31 0001460702 AIXC:EmployeesAndNonemployeeServiceProviderMember 2025-12-31 0001460702 srt:MinimumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2025-12-31 0001460702 srt:MaximumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2025-12-31 0001460702 AIXC:EmployeesAndNonemployeeServiceProviderMember 2023-12-31 0001460702 srt:MinimumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2023-12-31 0001460702 srt:MaximumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2023-12-31 0001460702 AIXC:EmployeesAndNonemployeeServiceProviderMember 2023-01-01 2023-12-31 0001460702 srt:MinimumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2024-01-01 2024-12-31 0001460702 srt:MaximumMember AIXC:EmployeesAndNonemployeeServiceProviderMember 2024-01-01 2024-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2025-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2025-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2023-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2023-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2023-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2023-01-01 2023-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2023-12-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2023-12-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2023-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2023-01-01 2023-12-31 0001460702 us-gaap:PrivatePlacementMember 2025-12-31 0001460702 us-gaap:ExecutiveCommitteeMember AIXC:LeadInvestorAgreementMember 2025-01-01 2025-12-31 0001460702 srt:ChiefExecutiveOfficerMember AIXC:LeadInvestorAgreementMember 2025-01-01 2025-12-31 0001460702 srt:PresidentMember AIXC:LeadInvestorAgreementMember 2025-01-01 2025-12-31 0001460702 AIXC:MasterServiceAgreementMember 2025-01-01 2025-12-31 0001460702 AIXC:FaradayFutureGlobalPartnersMember 2025-01-01 2025-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:SeniorConvertibleDebentureMember 2022-12-22 2022-12-22 0001460702 AIXC:AlphaCapitalMember AIXC:SeniorConvertibleDebentureMember 2022-12-22 0001460702 AIXC:AlphaCapitalMember AIXC:SeniorConvertibleDebentureMember 2023-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:SeniorConvertibleDebentureMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:SeniorConvertibleDebentureMember 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:ConvertibleDebentureMember 2024-02-27 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:ConvertibleDebentureMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:ConvertibleDebentureMember 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:ConvertibleDebentureMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:ConvertibleDebentureMember 2024-11-20 0001460702 AIXC:YiHuaChenMember AIXC:ConvertibleDebentureMember 2024-04-12 2024-04-12 0001460702 AIXC:YiHuaChenMember AIXC:ConvertibleDebentureMember 2024-04-12 0001460702 AIXC:AlphaCapitalMember AIXC:TwentyTwentyFourChenDebentureMember us-gaap:RelatedPartyMember 2024-11-18 2024-11-18 0001460702 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001460702 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-12-31 0001460702 AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-05 0001460702 2024-04-12 2024-04-12 0001460702 2024-04-12 0001460702 AIXC:SegmentReportingExpenseInformationMember 2025-01-01 2025-12-31 0001460702 AIXC:SegmentReportingExpenseInformationMember 2024-01-01 2024-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-01-01 2026-01-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-01-31 0001460702 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 0001460702 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-02-01 2026-02-28 0001460702 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-02-28 0001460702 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2026-03-01 2026-03-31 0001460702 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-03-01 2026-03-31 0001460702 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-03-31 0001460702 AIXC:AlphaCapitalAnstaltMember us-gaap:SubsequentEventMember 2026-01-01 2026-01-31 0001460702 us-gaap:SubsequentEventMember AIXC:EntrustedInvestmentAgreementMember 2026-01-31 0001460702 us-gaap:SubsequentEventMember AIXC:SecuritiesPurchaseAgreementMember 2026-01-01 2026-01-31 0001460702 us-gaap:SubsequentEventMember 2026-03-20 iso4217:USD shares iso4217:USD shares pure AIXC:Integer AIXC:Segment false FY 0001460702 100

http://fasb.org/us-gaap/2025#DomesticCountryMember

10-K true 2025-12-31 --12-31 2025 false 001-37428 AIxCrypto Holdings, Inc. DE 26-3474527 5857 Owens Avenue Suite 300 Carlsbad CA 92008 (760) 452-8111 Common Stock, par value $0.001 per share AIXC NASDAQ No No No Yes Non-accelerated Filer true false false false false 5581476 0.001 20234993 The Company recognizes the increasing complexity and significance of cybersecurity risks in safeguarding its technology, operations, proprietary systems, and data. The Company’s operations rely on interconnected digital infrastructure, cloud-based systems, and proprietary software platforms, including systems supporting digital asset management and cryptocurrency operations, making cybersecurity an essential component of its risk management framework. The Company has implemented a cybersecurity program designed to identify, assess, mitigate, and respond to cybersecurity risks. This program is informed by recognized industry practices, including the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”). The following disclosure outlines the Company’s cybersecurity risk management strategy and governance, including the Board’s oversight and management’s role. 1. Cybersecurity Risk Management The Company employs a structured cybersecurity risk management program to assess, identify, and manage cybersecurity risks across its information technology environment, including corporate systems and cloud-based platforms. The Company currently operates in part through shared IT infrastructure and personnel, which provides continuity of cybersecurity controls and practices while the Company develops its standalone capabilities. Key elements of the program include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk assessments and periodic evaluation of cybersecurity risks across systems and environments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Threat detection and monitoring, including alert triage and investigation, to identify suspicious activity and potential incidents.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Vulnerability management, including scanning, prioritization, and remediation activities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Access controls and security protections, including multi-factor authentication, encryption protocols, and endpoint security measures where appropriate.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Third-party risk management, including evaluation of vendors and service providers that may access Company data or systems.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cybersecurity risks are evaluated in coordination with management and are considered within the Company’s broader operational and enterprise risk considerations.</td></tr></table> 2. Governance and Oversight <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_zZJWLJfnozQ8">Cybersecurity oversight is a shared responsibility between the Company’s Board of Directors and management. The Vice President provides cybersecurity updates to the full Board as appropriate, including information regarding the Company’s cybersecurity posture, risk environment, incident trends, and mitigation efforts. The Company is in the process of establishing a formal cadence of cybersecurity reporting to the Board as part of its ongoing business transition. In addition to scheduled updates, management’s incident response procedures require that potential material cybersecurity incidents are escalated to senior leadership and the Board promptly, as appropriate. The Company enforces a top-down approach to cybersecurity governance, ensuring accountability and continuous risk monitoring at all levels of the organization. 3. Management’s Role in Cybersecurity <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zQtRXl6V7dKg">Management is responsible for the day-to-day execution of the Company’s cybersecurity program. The Vice President oversees cybersecurity initiatives and supervises cybersecurity personnel and processes. The Company’s cybersecurity incident response governance is supported by an Incident Response Policy that is in the process of being established and will define roles and responsibilities, incident classification, documentation expectations, evidence preservation requirements, and communication protocols. 4. Cybersecurity Strategy and Resilience The Company maintains cybersecurity resilience measures designed to support business continuity and protect critical assets. These measures include monitoring and response capabilities, as well as processes for containment, remediation, and recovery when incidents occur. 5. Material Cybersecurity Incidents <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_znjRWhrBAUQb">During fiscal year 2025, the Company did not experience any material cybersecurity incidents. No cybersecurity incidents required disclosure under Form 8-K Item 1.05 during 2025. 6. Impact of Cyber Incidents Cybersecurity incidents, if material, could adversely affect the Company’s financial condition, results of operations, operational stability, and reputation. Potential impacts may include remediation costs, operational disruptions, litigation or regulatory exposure, and reputational harm. The Company evaluates cybersecurity risks as part of its ongoing risk assessment processes. 7. Board Expertise in Cybersecurity <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zaMxf9EVTEll">The Board’s cybersecurity oversight is informed through management briefings and periodic updates. The Company may enhance Board education on cybersecurity trends and governance practices as appropriate. 8. Use of Third-Party Services <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zTPbgiyX2RLe">The Company uses third-party service providers to support certain technology and security functions. Digital asset custody services are provided by BitGo, a qualified custodian maintaining its own security controls and compliance frameworks. The Company evaluates third-party cybersecurity risks through vendor due diligence processes, including review of security documentation and reports where applicable, and monitors third-party risks on an ongoing basis. Given the nature of the Company’s cryptocurrency-focused operations, the security practices of digital asset custodians and blockchain infrastructure providers are a particular focus of the Company’s third-party risk management process. 9. Regulatory and Legal Compliance Risks The Company is subject to cybersecurity and data privacy requirements, including applicable data privacy laws and SEC disclosure requirements. Failure to comply with applicable requirements could result in financial penalties, legal liabilities, and reputational harm. The Company performs compliance-focused activities as part of its cybersecurity program. 10. Incident Response Plan The Company maintains an incident response policy framework intended to support timely identification, containment, investigation, remediation, and recovery. Incident response procedures include incident severity classification, escalation, documentation, evidence preservation, and communications protocols. 11. Cyber Insurance The Company does not maintain standalone cybersecurity insurance coverage. The Company evaluates risk mitigation and risk transfer options as part of its broader risk management considerations. 12. Historical Cyber Incidents The Company did not record any material cybersecurity incidents during fiscal year 2025. 13. Technology and Infrastructure Risks The Company’s cybersecurity program includes measures intended to protect systems and data, including monitoring, endpoint protections, access controls, and vulnerability management. As cybersecurity threats continue to evolve, the Company may adjust its cybersecurity tools, processes, and controls over time. 14. Data Security and Privacy Policies The Company maintains policies and controls intended to protect sensitive data, including access controls and other security measures designed to safeguard data confidentiality and integrity. 15. Ongoing Cybersecurity Efforts The Company continues to invest in cybersecurity capabilities, including monitoring, vulnerability management, employee awareness training, and improvements to policies and procedures, to address evolving cybersecurity threats. As a company in transition, the Company expects to continue developing its standalone cybersecurity infrastructure and formalizing its governance processes accordingly. Cybersecurity oversight is a shared responsibility between the Company’s Board of Directors and management. Management is responsible for the day-to-day execution of the Company’s cybersecurity program. The Vice President oversees cybersecurity initiatives and supervises cybersecurity personnel and processes. false The Board’s cybersecurity oversight is informed through management briefings and periodic updates. The Company may enhance Board education on cybersecurity trends and governance practices as appropriate. true 7000 We have audited the accompanying balance sheet of AIxCrypto Holdings, Inc. (the “Company”) as of December 31, 2025, and the related statement of operations and comprehensive loss, changes in shareholders’ deficit, and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for year ended December 31, 2025, in accordance with accounting principles generally accepted in the United States of America. HTL International, LLC Houston, Texas WithumSmith+Brown, PC San Francisco, California

19332707

1174608

10250497

1028506

1499219

4600000

360000

343060

2010692

30954770

4684519

314727

2000

10349

325076

2000

31279846

4686519

1259944

1568065

1648945

136234

170243

141878 269175

142236

3329237

2007483

0.001

15000000

601

6256

659040

5716400

0.001

15000000

39943

31183357

0.001

225000000

5160383

736431

69738

65314

136065924

119958897

-140027450

-123061575

27950609

2679036

31279846

4686519

8822300

4204558

184796

1197162

4195000 360000

13202096

5761720

-13202096

-5761720

127297 415810

191068

37707

988500

908943

742018

128795

91943 358279

-3588106

56010

-56997

208852 348305

-2252

1946

-3763779

-391137

-16965875

-6152857

6334

-16965875

-6159191

100000

-100000

-16965875

-6259191

2562867

87604

-19528742

-6346795

-8.11

-17.27

-0.28

-8.11

-17.55

2407817

361587

6256

5716400

736431

65314

119958897

-123061575

2679036

-5655 -5057360 1922702 1923 5055437

269

4500 4257937 4257937 39943 31183357 31183357 497689 497 6795388 6795885 -4500 -4257937 2003561 2004 4255933

-16965875

601

659040

39943

31183357

5160383

69738

136065924

-140027450

27950609

107243

43262

114655565

-116802384

-2103557

482737

14724

3038625

3053349

5102 4562400 4562400 1154 1154000 1154000

66222

3311

731772

735083

45497 2275 901054 903329

12036

-262259 -262259 197456 197456

31998

1600

414380

415980

2843

142

142209

142351

109

128059

-6259191

6256

5716400

736431

65314

119958897

-123061575

2679036

-16965875

-6259191

-100000

-16965875

-6159191

268

128059

-127297

-415810

191068

56010 20000 325635

4195000

360000

617868 113292

988500

-3588106

39968 208852 -615534

-56997

-91943 -358279 348305 37707 12036

-462364

219774

-350246

-445141

1435751

-118669

-6951458

-6327503

1909500

2257400

16500000

2621429

93416

350000

-15881487

-1907400

200000

1475000

7711544

4562400

34200000

3053348

132000

499021

4408500

2000000

415981

3420000

2000000

40991044

9007708

40991044

9007708

18158099

772805

1174608

401803

19332707

1174608

1010500

92838

5522

1154000 903329 735083 -2562867 -87604 -675625 142351 197456 262259 5340491

9315298

<p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zWMZrnBZH6Wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">NOTE 1 — BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES Corporate History Ritter Pharmaceuticals, Inc. (the Company’s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 7 – Discontinued Operations ). In 2022, the Company acquired a <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zMUmhsmnmIrf" title="Voting interests acquired">52.8% interest in NanoSynex, Ltd. (“NanoSynex”). In 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the “NanoSynex Amendment”), which resulted in the Company losing its controlling interest in NanoSynex. In September 2025 the Company consummated a Subscription Agreement (the “Subscription Agreement”) with certain investors including Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (the “Lead Investor” or “Faraday”) pursuant to which the investors purchased $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zg7dZxTyKbO8" title="Proceeds from issuance of common stock">40.7 million (the “Offering”) of the Company’s common stock and shares of a newly created Series B Convertible Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zSjvNZXVixCh" title="Preferred stock, par value">0.001 per share (the “Series B Preferred Stock”) (see Note 15 - Stockholders’ Equity). This offering resulted in $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zBSSBPUW3xD1" title="Net proceeds">37.7 million in net proceeds after $3.0 million in issuance costs were deducted. Up to $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zZ6LfvxHwFk1" title="Net proceeds from the Offerings">6.8 million of the net proceeds from the Offering were used to pay existing debt and fund the Company’s existing business operations, and the balance of the cash proceeds and contributed currency will be used for the execution of the Company’s cryptocurrency treasury strategy. Basis of Presentation The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange Commission (“SEC”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In general, the functional currency of the Company is the U.S. dollar. There were no foreign currency transactions in the years ended December 31, 2025 and 2024, As of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment resulted in a loss of control of a subsidiary that constitutes a business under Accounting Standards Codification (“ASC”) 810. The retained investment in NanoSynex is accounted for prospectively as an equity method investment. Discontinued Operations On July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations for all periods presented herein. On July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a former majority owned subsidiary of the Company, to, among other things, forfeit <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFbabVArulx9" title="Number of shares forfeit">281,000 Series B Preferred Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. Accounting Estimates Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The Company’s estimates relate to the estimated fair value of convertible debt, warrant liabilities, and determination of the allowance for credit losses. Actual results could vary from the estimates that were used. Related Parties and Related Party Transactions A related party is a person who has the ability to exert significant influence over the Company and may include executive officers and directors, including members of their immediate families, shareholders owning more than 10% of the Company’s voting securities, or other entities deemed to be affiliates, as defined in ASC 850, Related Party Disclosures. The Company assesses its related parties and applicable disclosures on a quarterly basis, considering all relevant facts and circumstances. Reverse Stock Split On November 5, 2024, the Company effected a 1-for-50 reverse stock split of its outstanding shares of common stock (the “2024 Reverse Stock Split”). The 2024 Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the 2024 Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the reverse stock split. The number of authorized shares of common stock and the par value per share remains unchanged. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. As of December 31, 2025, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts. Digital Assets The Company accounts for its digital assets in accordance with ASC 350, Intangibles—Goodwill and Other, as amended by ASU 2023-08, Accounting for and Disclosure of Crypto Assets. The Company adopted ASU 2023-08 effective January 1, 2025. Digital assets held by the Company, including Bitcoin, Cardano, Chainlink, Dogecoin, Ethereum, Hyperliquid EVM, Native BNB, Ripple, Solana, Tether (USDT), and Tron, meet the scope criteria of ASU 2023-08 and are recognized as indefinite-lived intangible assets. These assets are initially recorded at cost , including transaction fees, upon obtaining control of the asset, and are measured subsequently at fair value with changes in value recognized in net income or loss. The Company uses a FIFO methodology to assign costs to digital assets for purposes of the digital assets held and realized gains and losses disclosures. Purchases and sales of digital assets that are not revenue arrangements are classified on the statement of cash flows as investing activities. Net loss on digital assets are adjusted in operating activities in the statement of cash flows. General and Administrative Expenses Beginning in December 2024, the Company engaged IR Agency LLC to provide marketing and advertising services to communicate information about the Company to the investment community. During the year ended December 31, 2025, expenses related to the work performed by IR Agency LLC totaled $1.5 million, or roughly 17% of operating expenses for that period. The Company deemed this expense necessary at the time to raise additional funding which would provide liquidity to the Company for business operations . This expense is not anticipated to be recurring in future periods. Software Capitalization The Company accounts for the costs incurred in developing its product offerings under ASC 350-40, Internal-Use Software. In accordance with the guidance in ASC 350-40, the Company will capitalize costs incurred in connection with the development of the Company’s product offerings during the application development stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred in connection with maintenance activities, including training or bug fixes are also expensed as incurred. The Company stops capitalizing qualifying costs once development activities are completed and the project is ready for its intended use. Capitalized software costs will be amortized on a straight-line basis over a 36-month useful life beginning on the date when the product is ready for its intended use. Management will subsequently test the capitalized software costs for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable in accordance with ASC 360. Research and Development Except for acquired in process research and development (IPR&D ), the Company expenses research and development costs as incurred including therapeutics license costs. Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated statements of operations. Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 9 – Warrant Liabilities). Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Inputs that are unobservable.</td></tr> </table> Fair Value of Financial Instruments Cash, prepaid expenses, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Short-term notes receivable are valued subject to a current expected credit loss (“CECL”) model (see Note 6 - Short-Term Notes Receivable). The value of the Company’s warrant liabilities as of December 31, 2025 was determined using the Black-Scholes Model. Significant assumptions used in the valuation include the expected volatility of the Company’s common stock, the contractual term of the warrants, the risk-free interest rate, and an expected dividend yield of zero. Expected volatility is based on a blend of comparable public company data and, as available, the Company’s own historical volatility. The risk-free rate is derived from U.S. Treasury yields with maturities commensurate with the remaining contractual term of the warrants. Fair value measurements associated with the liability-classified warrants represent Level 3 valuations under the fair value hierarchy. The Company from time to time elects the fair value option to account for certain debt liabilities. Electing the fair value option allows the Company to initially and subsequently measure such liabilities at fair value rather than amortized cost and may be applied to debt liabilities that contain conversion or other features that would otherwise require bifurcation and mark to market accounting. Such debt liabilities will initially be measured using valuation techniques appropriate to the terms and expected life of the note. The Company expects to use level 3 input to measure the fair value in subsequent periods. Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant. Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years. See Note 18 - Income Taxes for further information. Recently Adopted Accounting Standards In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740) (“ASU 2023-09”), which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The Company adopted this standard as of December 31, 2025 and included revised disclosures with Note 18 – Income Taxes. The adoption of this standard did not have a material impact on our consolidated financial statements. In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Accounting for and Disclosure of Software Costs (“ASU 2025-06”), which amends certain aspects of the accounting for and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December 31, 2028, with early adoption permitted. The Company adopted this standard as of December 31, 2025, and it did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies interim disclosure requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company. ASU 2025-11 is effective for the Company’s interim financial statements beginning with the first fiscal quarter of the year ended December 31, 2028, with early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is evaluating the disclosure requirements related to the new standard. The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.

Corporate History Ritter Pharmaceuticals, Inc. (the Company’s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 7 – Discontinued Operations ). In 2022, the Company acquired a <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zMUmhsmnmIrf" title="Voting interests acquired">52.8% interest in NanoSynex, Ltd. (“NanoSynex”). In 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the “NanoSynex Amendment”), which resulted in the Company losing its controlling interest in NanoSynex. In September 2025 the Company consummated a Subscription Agreement (the “Subscription Agreement”) with certain investors including Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (the “Lead Investor” or “Faraday”) pursuant to which the investors purchased $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zg7dZxTyKbO8" title="Proceeds from issuance of common stock">40.7 million (the “Offering”) of the Company’s common stock and shares of a newly created Series B Convertible Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zSjvNZXVixCh" title="Preferred stock, par value">0.001 per share (the “Series B Preferred Stock”) (see Note 15 - Stockholders’ Equity). This offering resulted in $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zBSSBPUW3xD1" title="Net proceeds">37.7 million in net proceeds after $3.0 million in issuance costs were deducted. Up to $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zZ6LfvxHwFk1" title="Net proceeds from the Offerings">6.8 million of the net proceeds from the Offering were used to pay existing debt and fund the Company’s existing business operations, and the balance of the cash proceeds and contributed currency will be used for the execution of the Company’s cryptocurrency treasury strategy.

0.528

40700000

0.001

37700000

3000000.0

6800000

Basis of Presentation The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange Commission (“SEC”).

Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In general, the functional currency of the Company is the U.S. dollar. There were no foreign currency transactions in the years ended December 31, 2025 and 2024, As of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment resulted in a loss of control of a subsidiary that constitutes a business under Accounting Standards Codification (“ASC”) 810. The retained investment in NanoSynex is accounted for prospectively as an equity method investment.

Discontinued Operations On July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations for all periods presented herein. On July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a former majority owned subsidiary of the Company, to, among other things, forfeit <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFbabVArulx9" title="Number of shares forfeit">281,000 Series B Preferred Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex.

281000

Accounting Estimates Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The Company’s estimates relate to the estimated fair value of convertible debt, warrant liabilities, and determination of the allowance for credit losses. Actual results could vary from the estimates that were used.

Related Parties and Related Party Transactions A related party is a person who has the ability to exert significant influence over the Company and may include executive officers and directors, including members of their immediate families, shareholders owning more than 10% of the Company’s voting securities, or other entities deemed to be affiliates, as defined in ASC 850, Related Party Disclosures. The Company assesses its related parties and applicable disclosures on a quarterly basis, considering all relevant facts and circumstances. Reverse Stock Split On November 5, 2024, the Company effected a 1-for-50 reverse stock split of its outstanding shares of common stock (the “2024 Reverse Stock Split”). The 2024 Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the 2024 Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the reverse stock split. The number of authorized shares of common stock and the par value per share remains unchanged.

1-for-50

Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. As of December 31, 2025, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.

Digital Assets The Company accounts for its digital assets in accordance with ASC 350, Intangibles—Goodwill and Other, as amended by ASU 2023-08, Accounting for and Disclosure of Crypto Assets. The Company adopted ASU 2023-08 effective January 1, 2025. Digital assets held by the Company, including Bitcoin, Cardano, Chainlink, Dogecoin, Ethereum, Hyperliquid EVM, Native BNB, Ripple, Solana, Tether (USDT), and Tron, meet the scope criteria of ASU 2023-08 and are recognized as indefinite-lived intangible assets. These assets are initially recorded at cost , including transaction fees, upon obtaining control of the asset, and are measured subsequently at fair value with changes in value recognized in net income or loss. The Company uses a FIFO methodology to assign costs to digital assets for purposes of the digital assets held and realized gains and losses disclosures. Purchases and sales of digital assets that are not revenue arrangements are classified on the statement of cash flows as investing activities. Net loss on digital assets are adjusted in operating activities in the statement of cash flows.

General and Administrative Expenses Beginning in December 2024, the Company engaged IR Agency LLC to provide marketing and advertising services to communicate information about the Company to the investment community. During the year ended December 31, 2025, expenses related to the work performed by IR Agency LLC totaled $1.5 million, or roughly 17% of operating expenses for that period. The Company deemed this expense necessary at the time to raise additional funding which would provide liquidity to the Company for business operations . This expense is not anticipated to be recurring in future periods.

1500000

0.17 Software Capitalization The Company accounts for the costs incurred in developing its product offerings under ASC 350-40, Internal-Use Software. In accordance with the guidance in ASC 350-40, the Company will capitalize costs incurred in connection with the development of the Company’s product offerings during the application development stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred in connection with maintenance activities, including training or bug fixes are also expensed as incurred. The Company stops capitalizing qualifying costs once development activities are completed and the project is ready for its intended use. Capitalized software costs will be amortized on a straight-line basis over a 36-month useful life beginning on the date when the product is ready for its intended use. Management will subsequently test the capitalized software costs for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable in accordance with ASC 360.

Research and Development Except for acquired in process research and development (IPR&D ), the Company expenses research and development costs as incurred including therapeutics license costs.

Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated statements of operations. Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 9 – Warrant Liabilities).

Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Inputs that are unobservable.</td></tr> </table>

Fair Value of Financial Instruments Cash, prepaid expenses, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Short-term notes receivable are valued subject to a current expected credit loss (“CECL”) model (see Note 6 - Short-Term Notes Receivable). The value of the Company’s warrant liabilities as of December 31, 2025 was determined using the Black-Scholes Model. Significant assumptions used in the valuation include the expected volatility of the Company’s common stock, the contractual term of the warrants, the risk-free interest rate, and an expected dividend yield of zero. Expected volatility is based on a blend of comparable public company data and, as available, the Company’s own historical volatility. The risk-free rate is derived from U.S. Treasury yields with maturities commensurate with the remaining contractual term of the warrants. Fair value measurements associated with the liability-classified warrants represent Level 3 valuations under the fair value hierarchy. The Company from time to time elects the fair value option to account for certain debt liabilities. Electing the fair value option allows the Company to initially and subsequently measure such liabilities at fair value rather than amortized cost and may be applied to debt liabilities that contain conversion or other features that would otherwise require bifurcation and mark to market accounting. Such debt liabilities will initially be measured using valuation techniques appropriate to the terms and expected life of the note. The Company expects to use level 3 input to measure the fair value in subsequent periods.

Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.

Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years. See Note 18 - Income Taxes for further information.

Recently Adopted Accounting Standards In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740) (“ASU 2023-09”), which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The Company adopted this standard as of December 31, 2025 and included revised disclosures with Note 18 – Income Taxes. The adoption of this standard did not have a material impact on our consolidated financial statements. In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Accounting for and Disclosure of Software Costs (“ASU 2025-06”), which amends certain aspects of the accounting for and disclosure of internal-use software costs. ASU 2025-06 is effective for annual reporting periods beginning with the year ending December 31, 2028, with early adoption permitted. The Company adopted this standard as of December 31, 2025, and it did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Standards Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies interim disclosure requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company. ASU 2025-11 is effective for the Company’s interim financial statements beginning with the first fiscal quarter of the year ended December 31, 2028, with early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is evaluating the disclosure requirements related to the new standard. The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.

NOTE 2 — LIQUIDITY AND GOING CONCERN As of December 31, 2025, the Company had approximately $19.3 million in cash and an accumulated deficit of $140.0 million. For the years ended December 31, 2025 and 2024, the Company used cash of $<span id="xdx_906_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iN_pn5n6_di_c20250101__20251231_zTKhFxy4Km37" title="Restricted cash equivalents">7.0 million and $<span id="xdx_902_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iN_pn5n6_di_c20240101__20241231_zF91whpAnkyj" title="Restricted cash equivalents">6.3 million, respectively, in operations, and generated no revenue in both years while suffering from recurring net loss. During the year ended December 31, 2025, the Company borrowed a total of $3.5 million from nine investors as promissory notes and convertible debt, each due within six months after the date of borrowing. In July 2025, the Company closed a private placement transaction to raise additional funding through the sale of equity, for a net total of $4.2 million. In September 2025, the Company closed a subscription agreement to raise additional funding through the sale of equity for a net total of $37.7 million . While this $37.7 million of cash was received, up to $6.8 million of the net cash proceeds will be used to pay existing debt and fund the Company’s existing research and development operations, and the balance of the cash proceeds will be used for the establishment of the Company’s new cryptocurrency treasury operations, and will therefore not readily be available to fund immediate operations. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ from those reflected in the accompanying financial statements.

19300000

-140000000.0

-7000000.0

-6300000

3500000

4200000

37700000

6800000

NOTE 3 — DIGITAL ASSETS As part of its strategic realignment completed in the fourth quarter of 2025, the Company began acquiring digital assets for investment purposes and for use within its programmable technology infrastructure platform. The Company holds digital assets consisting of cryptocurrencies, stablecoins, and other blockchain-based tokens, as detailed below. Significant Holdings As of December 31, 2025, the Company’s significant digital asset holdings consisted of the following: SCHEDULE OF CRYPTO ASSET HOLDINGS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Units Held</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Cardano ADA (ADA)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--CardanoADAMember_zgYqOshDw8jj" style="width: 12%; text-align: right" title="Crypto asset number of units">238,136</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--CardanoADAMember_zGlxOA5gqFQ1" style="width: 12%; text-align: right" title="Crypto asset cost basis">149,259</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--CardanoADAMember_zkY57s19Wz6e" style="width: 12%; text-align: right" title="Crypto asset fair value">83,610</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Native BNB (BSC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--NativeBNBMember_zDd4RyzZMUH8" style="text-align: right" title="Crypto asset number of units">1,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--NativeBNBMember_zOOGZqM5XQw3" style="text-align: right" title="Crypto asset cost basis">1,517,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--NativeBNBMember_zMoqcoj0OKQa" style="text-align: right" title="Crypto asset fair value">1,251,051</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Bitcoin (BTC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--BitcoinMember_z2y8WeovZt7f" style="text-align: right" title="Crypto asset number of units">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--BitcoinMember_zXGrkW39K3L9" style="text-align: right" title="Crypto asset cost basis">5,489,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--BitcoinMember_zXKbUifwyfa1" style="text-align: right" title="Crypto asset fair value">4,535,208</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dogecoin (DOGE)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--DogecoinMember_zPLBIoWlCjTg" style="text-align: right" title="Crypto asset number of units">2,292,863</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--DogecoinMember_z6MT8M9IRJad" style="text-align: right" title="Crypto asset cost basis">437,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--DogecoinMember_zvGMOu2GPd3" style="text-align: right" title="Crypto asset fair value">282,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ethereum (ETH)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--EthereumMember_zHdtHBbYIPE" style="text-align: right" title="Crypto asset number of units">685</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--EthereumMember_zklNo1nRwNkl" style="text-align: right" title="Crypto asset cost basis">2,569,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--EthereumMember_zzcCarXX2ytk" style="text-align: right" title="Crypto asset fair value">2,033,436</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">ChainLink (LINK)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--ChainLinkMember_zABOX72Z5tW5" style="text-align: right" title="Crypto asset number of units">21,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--ChainLinkMember_zUoPeWh8JChc" style="text-align: right" title="Crypto asset cost basis">374,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--ChainLinkMember_zgRI03zYGMZg" style="text-align: right" title="Crypto asset fair value">267,559</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Solana (SOL)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--SolanaMember_zmROOGIEocj4" style="text-align: right" title="Crypto asset number of units">7,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--SolanaMember_z5PiWj72mjLd" style="text-align: right" title="Crypto asset cost basis">1,322,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--SolanaMember_zM1NlrNOmYk4" style="text-align: right" title="Crypto asset fair value">924,029</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tron (TRX)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--TronMember_zFyd95qPif82" style="text-align: right" title="Crypto asset number of units">590,372</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--TronMember_zH4IvMmHzMhb" style="text-align: right" title="Crypto asset cost basis">181,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--TronMember_zdOc9hJj78fj" style="text-align: right" title="Crypto asset fair value">168,846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">USD Tether (USDT)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--USDTetherMember_zblyiHFcsimi" style="text-align: right" title="Crypto asset number of units">1,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--USDTetherMember_zhEmfVLyaVqh" style="text-align: right" title="Crypto asset cost basis">1,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--USDTetherMember_z9okQOC0LIx7" style="text-align: right" title="Crypto asset fair value">1,801</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Ripple (XRP)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--RippleMember_zRTR75TCpPE4" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset number of units">374,454</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--RippleMember_zuh5kSLcA5lh" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset cost basis">895,922</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--RippleMember_zbK3nhff3shj" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset fair value">702,476</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20251231_zggIPbNccF96" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset cost basis">12,939,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CryptoAssetFairValue_iI_c20251231_zh7bFVOiDn3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset fair value">10,250,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Digital Asset Activity The following table summarizes digital asset activity for the period indicated, including cost basis, fair value at the time of sale, realized and unrealized losses, and the fair value of outstanding digital assets as of December 31, 2025: SCHEDULE OF DIGITAL ASSET ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49C_20250101__20251231_zziGwonl6mi5" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetFairValue_iS_zRKHt9EFNdya" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetPurchase_zUdGgvLFJT7j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 76%">Additions(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 20%; text-align: right">16,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CryptoAssetSale_iN_di_zZ1h214dBFE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Dispositions (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,621,429</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--ChangeInFairValueDigitalAsset_iN_di_z20ZD1uly1Fh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Gains(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,117</td><td style="text-align: left"></td></tr> <tr id="xdx_40F_ecustom--LossOnSalesDigitalAsset_iN_di_zhjDRXn49wEg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Losses(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,601,223</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetPaymentForService_iN_di_zMIXYNNBrRqd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payments made but uncleared</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(39,968</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetFairValue_iE_zpxjIJMwhKu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,250,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto asstes held for investment</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">The Company measures gains and losses by each asset held. These amounts include cumulative realized gains of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--RealizedGainOnDigitalAssets_c20250101__20251231_zDC71GyiJwVh" title="Realized gains">13,117, realized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--RealizedLossOnDigitalAssets_c20250101__20251231_zXZso4RBKei9" title="Realized loss">896,471, and unrealized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_ecustom--UnrealizedLossOnDigitalAssets_c20250101__20251231_zogmdMOasqCi" title="Unrealized loss">2,704,752 during the year ended December 31, 2025</td></tr> </table> The Company measures digital assets at fair value in accordance with ASC 820, Fair Value Measurement. Fair value is determined using quoted prices in active markets for identical assets (Level 1 inputs). The Company utilizes pricing information provided by the principal market, which is based on observable market prices from active trading exchanges.

As of December 31, 2025, the Company’s significant digital asset holdings consisted of the following: SCHEDULE OF CRYPTO ASSET HOLDINGS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Units Held</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Cardano ADA (ADA)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--CardanoADAMember_zgYqOshDw8jj" style="width: 12%; text-align: right" title="Crypto asset number of units">238,136</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--CardanoADAMember_zGlxOA5gqFQ1" style="width: 12%; text-align: right" title="Crypto asset cost basis">149,259</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--CardanoADAMember_zkY57s19Wz6e" style="width: 12%; text-align: right" title="Crypto asset fair value">83,610</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Native BNB (BSC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--NativeBNBMember_zDd4RyzZMUH8" style="text-align: right" title="Crypto asset number of units">1,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--NativeBNBMember_zOOGZqM5XQw3" style="text-align: right" title="Crypto asset cost basis">1,517,819</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--NativeBNBMember_zMoqcoj0OKQa" style="text-align: right" title="Crypto asset fair value">1,251,051</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Bitcoin (BTC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--BitcoinMember_z2y8WeovZt7f" style="text-align: right" title="Crypto asset number of units">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--BitcoinMember_zXGrkW39K3L9" style="text-align: right" title="Crypto asset cost basis">5,489,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--BitcoinMember_zXKbUifwyfa1" style="text-align: right" title="Crypto asset fair value">4,535,208</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dogecoin (DOGE)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--DogecoinMember_zPLBIoWlCjTg" style="text-align: right" title="Crypto asset number of units">2,292,863</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--DogecoinMember_z6MT8M9IRJad" style="text-align: right" title="Crypto asset cost basis">437,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--DogecoinMember_zvGMOu2GPd3" style="text-align: right" title="Crypto asset fair value">282,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ethereum (ETH)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--EthereumMember_zHdtHBbYIPE" style="text-align: right" title="Crypto asset number of units">685</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--EthereumMember_zklNo1nRwNkl" style="text-align: right" title="Crypto asset cost basis">2,569,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--EthereumMember_zzcCarXX2ytk" style="text-align: right" title="Crypto asset fair value">2,033,436</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">ChainLink (LINK)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--ChainLinkMember_zABOX72Z5tW5" style="text-align: right" title="Crypto asset number of units">21,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--ChainLinkMember_zUoPeWh8JChc" style="text-align: right" title="Crypto asset cost basis">374,768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--ChainLinkMember_zgRI03zYGMZg" style="text-align: right" title="Crypto asset fair value">267,559</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Solana (SOL)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--SolanaMember_zmROOGIEocj4" style="text-align: right" title="Crypto asset number of units">7,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--SolanaMember_z5PiWj72mjLd" style="text-align: right" title="Crypto asset cost basis">1,322,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--SolanaMember_zM1NlrNOmYk4" style="text-align: right" title="Crypto asset fair value">924,029</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tron (TRX)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--TronMember_zFyd95qPif82" style="text-align: right" title="Crypto asset number of units">590,372</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--TronMember_zH4IvMmHzMhb" style="text-align: right" title="Crypto asset cost basis">181,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--TronMember_zdOc9hJj78fj" style="text-align: right" title="Crypto asset fair value">168,846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">USD Tether (USDT)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--USDTetherMember_zblyiHFcsimi" style="text-align: right" title="Crypto asset number of units">1,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--USDTetherMember_zhEmfVLyaVqh" style="text-align: right" title="Crypto asset cost basis">1,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--USDTetherMember_z9okQOC0LIx7" style="text-align: right" title="Crypto asset fair value">1,801</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Ripple (XRP)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231__srt--CryptoAssetAxis__custom--RippleMember_zRTR75TCpPE4" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset number of units">374,454</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_c20251231__srt--CryptoAssetAxis__custom--RippleMember_zuh5kSLcA5lh" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset cost basis">895,922</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetFairValue_iI_c20251231__srt--CryptoAssetAxis__custom--RippleMember_zbK3nhff3shj" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset fair value">702,476</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20251231_zggIPbNccF96" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset cost basis">12,939,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CryptoAssetFairValue_iI_c20251231_zh7bFVOiDn3h" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset fair value">10,250,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

238136

149259

83610

1454

1517819

1251051

5489227

4535208

2292863

437027

282481

685

2569277

2033436

21560

374768

267559

7399

1322550

924029

590372

181725

168846

1856

1854

1801

374454

895922

702476

12939428

10250497

The following table summarizes digital asset activity for the period indicated, including cost basis, fair value at the time of sale, realized and unrealized losses, and the fair value of outstanding digital assets as of December 31, 2025: SCHEDULE OF DIGITAL ASSET ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49C_20250101__20251231_zziGwonl6mi5" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetFairValue_iS_zRKHt9EFNdya" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at December 31, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetPurchase_zUdGgvLFJT7j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 76%">Additions(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 20%; text-align: right">16,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CryptoAssetSale_iN_di_zZ1h214dBFE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Dispositions (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,621,429</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--ChangeInFairValueDigitalAsset_iN_di_z20ZD1uly1Fh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Gains(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,117</td><td style="text-align: left"></td></tr> <tr id="xdx_40F_ecustom--LossOnSalesDigitalAsset_iN_di_zhjDRXn49wEg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Losses(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,601,223</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetPaymentForService_iN_di_zMIXYNNBrRqd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payments made but uncleared</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(39,968</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetFairValue_iE_zpxjIJMwhKu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,250,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto asstes held for investment</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">The Company measures gains and losses by each asset held. These amounts include cumulative realized gains of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--RealizedGainOnDigitalAssets_c20250101__20251231_zDC71GyiJwVh" title="Realized gains">13,117, realized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--RealizedLossOnDigitalAssets_c20250101__20251231_zXZso4RBKei9" title="Realized loss">896,471, and unrealized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_ecustom--UnrealizedLossOnDigitalAssets_c20250101__20251231_zogmdMOasqCi" title="Unrealized loss">2,704,752 during the year ended December 31, 2025</td></tr> </table>

16500000

2621429

-13117 3601223

39968

10250497

13117 896471 2704752

NOTE 4 — FAIR VALUE MEASUREMENTS Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2025: SCHEDULE OF FAIR VALUE MEASUREMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z43g9GVrfy7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmmIIy3hysKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze3ZFLNA95T3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231_zQ8Gg9KjJHo1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zu5bTeLZ4sGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zjFQRuMI5bbb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Money Market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iI_ziXYGB8AS992" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Digital Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_iI_zs7hCZmimsEi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zu9oMFLIJcNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zZWNGAdc4JG8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Convertible Debt</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_zODCyk7JoPzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant Liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_z9aYfty6hjba" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXkmQqemZa1c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUN6FDdgm978" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgQTfVvAFQX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20241231_zaGfuEyX5wPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zpCaYjmkhVsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zzalk0cFez24" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Money Market funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">724,732</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">724,732</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_z1VUFBACdxv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">724,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">724,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zbamcfhZUT8" style="vertical-align: bottom; background-color: White"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_zYvNtfxOtMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant Liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">269,175</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">269,175</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesFairValueDisclosure_iI_zBTyyb0XnTsa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2025: SCHEDULE OF FAIR VALUE MEASUREMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z43g9GVrfy7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zmmIIy3hysKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze3ZFLNA95T3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231_zQ8Gg9KjJHo1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zu5bTeLZ4sGi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zjFQRuMI5bbb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Money Market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iI_ziXYGB8AS992" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Digital Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_iI_zs7hCZmimsEi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zu9oMFLIJcNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zZWNGAdc4JG8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Convertible Debt</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_zODCyk7JoPzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant Liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_z9aYfty6hjba" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zXkmQqemZa1c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUN6FDdgm978" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgQTfVvAFQX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20241231_zaGfuEyX5wPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zpCaYjmkhVsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zzalk0cFez24" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Money Market funds</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">724,732</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">724,732</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_z1VUFBACdxv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">724,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">724,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zbamcfhZUT8" style="vertical-align: bottom; background-color: White"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_zYvNtfxOtMJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant Liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">269,175</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">269,175</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LiabilitiesFairValueDisclosure_iI_zBTyyb0XnTsa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

15957179 15957179

10250497

26207676

142236

141878 141878

284114

724732 724732

724732

269175 269175

269175

NOTE 5 — PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following at December 31, 2025 and 2024: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20251231_zbTM7DpjSs2l" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20241231_zyZqkLiRNdsc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--PrepaidConsulting_iI_pp0p0_maPEAOAzdSM_z4rX1qsqC8ga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">461,337</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,241,537</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zLkqRvQJgtMd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">481,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,482</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrepaidLegal_iI_pp0p0_maPEAOAzdSM_ziefwOeeoOsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepaid legal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPEAOAzdSM_zC38nbdVnZH1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,638</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zCW4Yu0gt8C8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,028,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,499,219</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Prepaid expenses and other current assets consisted of the following at December 31, 2025 and 2024: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20251231_zbTM7DpjSs2l" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20241231_zyZqkLiRNdsc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--PrepaidConsulting_iI_pp0p0_maPEAOAzdSM_z4rX1qsqC8ga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">461,337</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,241,537</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zLkqRvQJgtMd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">481,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,482</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrepaidLegal_iI_pp0p0_maPEAOAzdSM_ziefwOeeoOsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepaid legal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPEAOAzdSM_zC38nbdVnZH1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,638</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zCW4Yu0gt8C8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,028,506</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,499,219</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

461337 1241537

481338

226482

84193

1638

31200

1028506

1499219

NOTE 6 —SHORT-TERM NOTES RECEIVABLE Short term notes receivable - consisted of the following at December 31, 2025 and 2024: SCHEDULE OF SHORT-TERM NOTE RECEIVABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20251231_zV4cbSWsuLx3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20241231_zblHXpb92EUe" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_maNALRNzwcc_zdEMLfw5OZt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Short-term note receivable - Marizyme</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,898,060</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,370,692</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_msNALRNzwcc_zHbkScqlDK1f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,555,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(360,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--NotesAndLoansReceivableNetCurrent_iTI_mtNALRNzwcc_zFcHmKK6LNbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Short-term notes receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">343,060</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,010,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the year ended December 31, 2025 and 2024, the Company advanced to Marizyme, Inc., $1,909,500 and $2,257,400, respectively, against which Marizyme delivered demand promissory notes to the Company of like principal amounts (the “Marizyme Notes”). As of December 31, 2025 and 2024 accrued interest related to the Marizyme Notes was $731,160 and $113,292, respectively and interest income of $<span id="xdx_90E_ecustom--AccruedInterestOnShorttermNoteReceivable_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--IncomeOtherMember_zIQuUEajb8y4" title="Accrued interest on short-term note receivable">617,868 and $<span id="xdx_908_ecustom--AccruedInterestOnShorttermNoteReceivable_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--IncomeOtherMember_z8kwfWQdo76l" title="Accrued interest on short-term note receivable">113,292, respectively, was recognized in other income in the consolidated statement of operations. The Marizyme Notes bear at interest the rate of eighteen percent (18%) per annum. Marizyme may pre-pay all or any part of the outstanding principal or interest at any time and from time to time, in whole or in part, without premium or penalty. Under ASC 326-20, known as the current expected credit loss (“CECL”) model, the Company was required to estimate credit losses expected over the life of an exposure (or pool of exposures) based on historical information, current information, and reasonable and supportable forecasts. The Company is unable to use its historical data to estimate losses as it has no relevant loss history to date. To determine the estimate of expected credit losses, the Company used a probability-weighted approach that incorporates multiple settlement scenarios, including recovery of amounts due upon an acquisition of the debtor, and recovery in different liquidation scenarios, and determines the expected recoverable amount of the loan in each scenario. This model requires management to make certain assumptions including the likelihood of each outcome, the estimated value of the debtor’s assets, and the Company’s expected claim and recovery rate on the debtor’s assets in the event of an insolvency or a liquidation proceeding. As of December 31, 2025, the estimate for expected credit losses on the Marizyme Notes is $4,555,000. Given the inherently uncertain nature of the debtor’s financial condition and future outcomes, actual credit losses may differ materially from this estimate. The Company will continue to monitor relevant events and conditions and update its assumptions and allowance as necessary. The Company is also party to a Co-Development Agreement with Marizyme (see Note 14 - Research and License Agreements).

Short term notes receivable - consisted of the following at December 31, 2025 and 2024: SCHEDULE OF SHORT-TERM NOTE RECEIVABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20251231_zV4cbSWsuLx3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20241231_zblHXpb92EUe" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_maNALRNzwcc_zdEMLfw5OZt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Short-term note receivable - Marizyme</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,898,060</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,370,692</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_msNALRNzwcc_zHbkScqlDK1f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,555,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(360,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--NotesAndLoansReceivableNetCurrent_iTI_mtNALRNzwcc_zFcHmKK6LNbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Short-term notes receivable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">343,060</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,010,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4898060

2370692

4555000

360000

343060

2010692

1909500

2257400

731160 113292 617868 113292

0.18

4555000

NOTE 7 — DISCONTINUED OPERATIONS On July 20, 2023, the Company completed the sale of Qualigen, Inc., its formerly wholly-owned subsidiary, to Chembio Diagnostics, Inc. for net cash consideration of $<span id="xdx_909_eus-gaap--ProceedsFromDivestitureOfBusinessesNetOfCashDivested_pn5n6_c20230720__20230720__dei--LegalEntityAxis__custom--ChembioDiagnosticsMember_z5ffChHkXqkd" title="Net cash consideration">5.4 million, of which $4.9 million was received during the year ended December 31, 2023, and $450,000 was being held in escrow until January 20, 2025 to satisfy certain Company indemnification obligations. On June 4, 2024, the escrow account was settled early by mutual agreement of the Company and the buyer resulting in cash proceeds to the Company of $350,000 and a loss on disposal of discontinued operations of $100,000 for the year ended December 31, 2024. There was no activity related to Qualigen, Inc. during the year ended December 31, 2025. There were no assets and liabilities remaining related to Qualigen, Inc. as of December 31, 2025 or December 31, 2024.

5400000

4900000

450000

350000

100000

NOTE 8 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following at December 31, 2025 and 2024: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20251231_zlzf3FeOCXLa" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20241231_zplcCNOi5pac" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzOMI_z7VB3e98KjA7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">License fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">20,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,427</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedCreditCard_iI_pp0p0_maALCzOMI_z2dRtmZYOvr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z9aQPdtWft3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,434</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,324</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzOMI_zpN9agAfitH" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vacation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,492</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzOMI_zCIXsoD17XX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">136,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">170,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accrued expenses and other current liabilities consisted of the following at December 31, 2025 and 2024: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20251231_zlzf3FeOCXLa" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20241231_zplcCNOi5pac" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzOMI_z7VB3e98KjA7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">License fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">20,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,427</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedCreditCard_iI_pp0p0_maALCzOMI_z2dRtmZYOvr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z9aQPdtWft3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,434</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,324</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzOMI_zpN9agAfitH" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vacation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,492</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzOMI_zCIXsoD17XX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">136,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">170,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

20000 14427 800

115434

109324

46492

136234

170243

NOTE 9 – WARRANT LIABILITIES In 2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company. On February 27, 2024, these Series C Warrants were repriced as a result of a down-round provision triggered by a Securities Purchase Agreement with Alpha for the purchase of the February 2024 Debentures described below, from an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240226__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z6i7TfIUacx5" title="Warrant exercise price">36.50 per share to an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zTST32ow4Xs2" title="Warrant exercise price">13.00 per share, with <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240227__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_znrT7i8wHXo7" title="Warrants issued">16,473 additional ratchet Series C Warrants issued, resulting in <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zFjirXdVXAR4" title="Warrants outstanding">25,586 Series C Warrants outstanding on March 31, 2024, which expired on June 26, 2024, resulting in a gain recorded in the amount of $<span id="xdx_901_ecustom--GainLossOnChangeInFairValueOfWarrantLiabilities_c20240626__20240626__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z9GKQVfzJApj" title="Gain on warrants">187,900 . At December 31, 2025 and December 31, 2024 the fair value of these warrants was $0. On November 20, 2024, the Company closed its private placement transaction resulting in the issuance of newly designated Series A-2 Preferred Stock (see Note 15 – Stockholders Equity). As a result of the issuance of a new class of voting securities, the Company evaluated its equity classified warrants’ respective terms, and concluded that warrants for <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zjY0mjpegRS7" title="Warrants to purchase common shares">68,712 common shares with a weighted average exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_z137K4rP7zO1" title="Warrants exercise price">2.00 were required to be reclassified to liabilities, including pre-funded warrants with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zdKv9Bcjn071" title="Warrants exercise price">0.05 per share. The pre-funded warrants are exercisable upon issuance and will remain exercisable until all the pre-funded warrants are exercised in full. At December 31, 2025, pre-funded warrants for <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zwPcsr2Yquc7" title="Warrants to purchase common shares">51,199 common shares remained outstanding. During the years ended December 31, 2025 and 2024 the Company recorded a loss on change in fair value of warrant liabilities of approximately $<span id="xdx_906_ecustom--GainLossOnChangeInFairValueOfWarrantLiabilities_di_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zk1v7ZUwhvF6" title="Fair value of warrant liabilities">127,000 and $<span id="xdx_90D_ecustom--GainLossOnChangeInFairValueOfWarrantLiabilities_di_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zQa1YSlWKts1" title="Gain (loss) on change in fair value of warrant liabilities">22,000, respectively for these warrants. At December 31, 2025 and December 31, 2024, the fair value of these warrants was approximately $142,000 and $269,000, respectively. The following table summarizes the activity in liability classified warrants for the year ended December 31, 2025: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBEd0jsMIWg2" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">68,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQG46OtcliZ8" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zqmqGkkTjDY3" title="Range of Exercise Price, Beginning">0.05 - $<span id="xdx_906_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zoSrYJYWlFni" title="Range of Exercise Price, Beginning">7.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zuBNKbN1eQMa" title="Weighted - Average Remaining Life (Years) Outstanding">4.32</td><td style="width: 1%; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6wCkwTTLMCa" style="text-align: right" title="Number of Shares, Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxdnEhhIbOH2" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceGranted_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhmTGvPmhX77" title="Range of Exercise Price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaFFtga0l0Zf" title="Weighted - Average Remaining Life (Years) Granted">4.16-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpEjMFi0ZxXj" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8oz4vnP0oul" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExcercised_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zob6bltbnC64" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromEquity_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6Vjiu0GY8Ej" style="text-align: right" title="Number of Shares, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedEquityPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zG9A5XKBgoj3" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxKNFMe4UKwa" title="Range of Exercise Price, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity_iN_pid_di_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxYhhTHWIfP5" style="text-align: right" title="Number of Shares, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_znIRC60Rw9Gi" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zC0viekWVd5k" title="Range of Exercise Price, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsEquityWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zT55JeNBuB32" title="Weighted - Average Remaining Life (Years) Reclassified to equity">4—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYkxd14uLbi7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">(1,494</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1OPwztmiK3b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">6.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--RangeOfExpiredPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemoV8gdQlS9" title="Range of Expired Price">6.50 - $<span id="xdx_902_ecustom--RangeOfExpiredPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zSF1D3DRXbnl" title="Range of Expired Price">6.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding –December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZCrAV6iCQVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">67,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdFHIEqmspOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdGWXESKUUXh" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_90E_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBvWZJqG6bQa" title="Range of Exercise Price, Ending">7.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zVZCnPvDCWF3" title="Weighted-Average Remaining Life (Years) Outstanding">3.68</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0zSb9H0b0n7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">67,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYlXH9YIwGDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">1.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCLMH4abAKEb" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztiNOTLX27Qb" title="Range of Exercise Price, Exercisable">7.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zkaICQwowuch" title="Weighted-Average Remaining Life (Years) Exercisable">3.68</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F07_zWPV3G7Rn1W" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">excludes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdBUlJBTlRTIEFDVElWSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zbzWzOEvvOk8" title="Warrants with no expiration">51,199 pre-funded warrants which have no expiration date.</td> </tr></table> The following table summarizes the activity in liability classified warrants for the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDw1j7ExmI65" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">9,113</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhhtzaFKp1ol" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zg8FO2IGMPM8" title="Range of Exercise Price, Beginning">36.50 - $<span id="xdx_90E_ecustom--RangeOfExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zNXcNMgniHZh" title="Range of Exercise Price, Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zmLD9fE13OE2" title="Weighted - Average Remaining Life (Years) Outstanding">0.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zmxWnKRnMp6d" style="text-align: right" title="Number of Shares, Warrants Granted">52,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQ44K3nz3gyd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">8.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceGranted_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhffcavs7iWk" title="Range of Exercise Price, Granted">6.50 - $<span id="xdx_906_ecustom--RangeOfExercisePriceGranted_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zxOvwQc1Fhc9" title="Range of Exercise Price, Granted">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zebxORtJR0Nj" title="Weighted - Average Remaining Life (Years) Granted">4.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCGQjzBFWq8" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJnsCftt2Gjd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExcercised_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zibLRJAyJQNc" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2UxbIx8mLO1" style="text-align: right" title="Number of Shares, Reclassified from equity">71,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedEquityPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8fl3X5bQ1mj" style="text-align: right" title="Weighted Average Exercise Price Per Share, Reclassified from equity">2.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zzk2l4ocq8id" title="Range of Exercise Price, Reclassified from equity">0.05 - $<span id="xdx_906_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zx22cQdYY0l4" title="Range of Exercise Price, Reclassified from equity">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity_iN_pid_di_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zd2gB6p8Kfo3" style="text-align: right" title="Number of Shares, Reclassified to equity">(38,315</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zR27fPaZC8Rb" style="text-align: right" title="Weighted Average Exercise Price Per Share, Reclassified to equity">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zPqwMFh1LDUb" title="Range of Exercise Price, Reclassified to equity">6.50 - $<span id="xdx_90D_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zZ8DYogE0eK7" title="Range of Exercise Price, Reclassified to equity">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsEquityWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zo89o9bw1gN" title="Weighted - Average Remaining Life (Years) Reclassified to equity">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcmngXzgqxy5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">(25,586</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0Z9YqK0Kf3g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">13.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--RangeOfExpiredPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zt16sYeVndm1" title="Range of Expired Price">13.00 - $<span id="xdx_903_ecustom--RangeOfExpiredPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zxgg7tfQcibd" title="Range of Exercise Price, Expired">13.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding –December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEb9mHQKYlva" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">68,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgrLSNNVeHyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">2.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zr9mIEz3gS95" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_906_ecustom--RangeOfExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zAQoDqKRYKVc" title="Range of Exercise Price, Ending">7.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">n/a</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMcLCJTZDZUi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">52,693</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXFbU7qZztz8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">0.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iE_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zr387Bu92AD7" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iE_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zrcGtM5A8Aaf" title="Range of Exercise Price, Exercisable">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">n/a</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2025: SCHEDULE OF FAIR VALUE OF HIERARCHY FOR WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWPcmli8kAeg" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0JsuNjIXPhe"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoKZQIFJvD7g"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20250101__20251231_z0EE2EQ1qZ4"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z7gNBcbCXE8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zS8EcKYSYli6" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_zqGTdsZoCtfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_z3zDGNz4I43h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair value of warrants reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_iN_di_zSFE21TVF2Y" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair value of warrants reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zcp0Wbm3QKEg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss on change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zBVG5Fnvg0c8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRtlkH0dFhqi" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9l3ijJFa8ie"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztp1kAWPr4P2"> </td><td> </td><td> </td> <td colspan="2" id="xdx_499_20240101__20241231_zUgM5HaQaNnb"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zUZlB2xPKkna" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">54,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">54,600</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z8rkRmXeY5kf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Common stock warrant liabilities, Beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">54,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">54,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zz75xEgpQl4e" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,582</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_z870jV0rEgBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_zuLcVXaumGeg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262,259</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_iN_di_zWW0d2wy6cv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197,456</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197,456</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zq6Hk36B9ZAb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gain on change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(415,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(415,810</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zr560mRRa0Gd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z066bNVCoUg6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Common stock warrant liabilities, Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the year ended December 31, 2024, warrants for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrtYpi5X2r1e" title="Warrants to purchase common shares">71,026 common shares with a weighted average exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHKiYRMYuLVe" title="Warrants exercise price">2.14 and a fair value of $262,259 were reclassified from equity to liabilities, and warrants for <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zHpMgivd7Xs5" title="Warrants to purchase common shares">38,315 common shares with a weighted average exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zj1oE2wtuhGe" title="Warrants exercise price">6.50 and a fair value of $197,456 were reclassified from liabilities to equity. There were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2024. The value of the warrant liabilities was based on valuations internally generated Black Scholes valuations. Due to the nominal exercise price of the 2024 Pre-Funded Warrants and indefinite term, the Company calculated an implied value of the 2024 Pre-Funded Warrants based on the underlying common stock price on the valuation date, less the exercise price. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements. The following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2025 and 2024: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zpVWCbfR6Yuk" title="Risk-free interest rate">3.64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_zO9v5ZTW1n86" title="Risk-free interest rate">3.64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrtTJQ08Jj3k" title="Risk-free interest rate">4.24% - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvaOwWxCyNi" title="Risk-free interest rate">4.38</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_zMIHAOF7sby3" title="Risk-free interest rate">4.37</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (peer group)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPiqpcSjwhBf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_zHnc2STnDEa1" title="Expected volatility">130.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zS3FacCqdLj2" title="Risk-free interest rate">117.5% - <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztucgUXrsDnf" title="Risk-free interest rate">133.50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_zvd94JVtEZte" title="Expected volatility">133.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Term of warrants (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2lyTkfknvv8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.68 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zwkjRPEyfhde" title="Term of warrants (in years)">3.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zWW3Z0I0HGk4" title="Warrants outstanding, measurement input">0.4 - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zS8h4vmlDYug" title="Warrants outstanding, measurement input">4.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zKtBSm2azEKf" title="Term of warrants (in years)">4.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zWE8FNFVCXB2" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zjXPHDjmW38d" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zDe2IEbnJ3Fc" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zcsttzMjnWsb" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

36.50

13.00

16473

25586

187900

68712

2.00

0.05

51199

-127000 -22000

142000

269000

The following table summarizes the activity in liability classified warrants for the year ended December 31, 2025: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBEd0jsMIWg2" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">68,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQG46OtcliZ8" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zqmqGkkTjDY3" title="Range of Exercise Price, Beginning">0.05 - $<span id="xdx_906_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zoSrYJYWlFni" title="Range of Exercise Price, Beginning">7.80</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zuBNKbN1eQMa" title="Weighted - Average Remaining Life (Years) Outstanding">4.32</td><td style="width: 1%; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6wCkwTTLMCa" style="text-align: right" title="Number of Shares, Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxdnEhhIbOH2" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceGranted_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhmTGvPmhX77" title="Range of Exercise Price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaFFtga0l0Zf" title="Weighted - Average Remaining Life (Years) Granted">4.16-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zpEjMFi0ZxXj" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8oz4vnP0oul" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExcercised_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zob6bltbnC64" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromEquity_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z6Vjiu0GY8Ej" style="text-align: right" title="Number of Shares, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedEquityPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zG9A5XKBgoj3" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxKNFMe4UKwa" title="Range of Exercise Price, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity_iN_pid_di_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxYhhTHWIfP5" style="text-align: right" title="Number of Shares, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_znIRC60Rw9Gi" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zC0viekWVd5k" title="Range of Exercise Price, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsEquityWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zT55JeNBuB32" title="Weighted - Average Remaining Life (Years) Reclassified to equity">4—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYkxd14uLbi7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">(1,494</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1OPwztmiK3b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">6.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--RangeOfExpiredPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemoV8gdQlS9" title="Range of Expired Price">6.50 - $<span id="xdx_902_ecustom--RangeOfExpiredPrice_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zSF1D3DRXbnl" title="Range of Expired Price">6.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding –December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZCrAV6iCQVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">67,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdFHIEqmspOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdGWXESKUUXh" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_90E_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBvWZJqG6bQa" title="Range of Exercise Price, Ending">7.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zVZCnPvDCWF3" title="Weighted-Average Remaining Life (Years) Outstanding">3.68</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0zSb9H0b0n7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">67,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYlXH9YIwGDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">1.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCLMH4abAKEb" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_90E_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_ztiNOTLX27Qb" title="Range of Exercise Price, Exercisable">7.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zkaICQwowuch" title="Weighted-Average Remaining Life (Years) Exercisable">3.68</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F07_zWPV3G7Rn1W" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">excludes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdBUlJBTlRTIEFDVElWSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zbzWzOEvvOk8" title="Warrants with no expiration">51,199 pre-funded warrants which have no expiration date.</td> </tr></table> The following table summarizes the activity in liability classified warrants for the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDw1j7ExmI65" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">9,113</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhhtzaFKp1ol" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zg8FO2IGMPM8" title="Range of Exercise Price, Beginning">36.50 - $<span id="xdx_90E_ecustom--RangeOfExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zNXcNMgniHZh" title="Range of Exercise Price, Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zmLD9fE13OE2" title="Weighted - Average Remaining Life (Years) Outstanding">0.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zmxWnKRnMp6d" style="text-align: right" title="Number of Shares, Warrants Granted">52,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQ44K3nz3gyd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">8.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceGranted_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zhffcavs7iWk" title="Range of Exercise Price, Granted">6.50 - $<span id="xdx_906_ecustom--RangeOfExercisePriceGranted_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zxOvwQc1Fhc9" title="Range of Exercise Price, Granted">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zebxORtJR0Nj" title="Weighted - Average Remaining Life (Years) Granted">4.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zCGQjzBFWq8" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJnsCftt2Gjd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExcercised_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zibLRJAyJQNc" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2UxbIx8mLO1" style="text-align: right" title="Number of Shares, Reclassified from equity">71,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedEquityPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z8fl3X5bQ1mj" style="text-align: right" title="Weighted Average Exercise Price Per Share, Reclassified from equity">2.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zzk2l4ocq8id" title="Range of Exercise Price, Reclassified from equity">0.05 - $<span id="xdx_906_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zx22cQdYY0l4" title="Range of Exercise Price, Reclassified from equity">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity_iN_pid_di_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zd2gB6p8Kfo3" style="text-align: right" title="Number of Shares, Reclassified to equity">(38,315</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zR27fPaZC8Rb" style="text-align: right" title="Weighted Average Exercise Price Per Share, Reclassified to equity">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zPqwMFh1LDUb" title="Range of Exercise Price, Reclassified to equity">6.50 - $<span id="xdx_90D_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zZ8DYogE0eK7" title="Range of Exercise Price, Reclassified to equity">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsEquityWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zo89o9bw1gN" title="Weighted - Average Remaining Life (Years) Reclassified to equity">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcmngXzgqxy5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">(25,586</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z0Z9YqK0Kf3g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">13.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--RangeOfExpiredPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zt16sYeVndm1" title="Range of Expired Price">13.00 - $<span id="xdx_903_ecustom--RangeOfExpiredPrice_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zxgg7tfQcibd" title="Range of Exercise Price, Expired">13.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding –December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEb9mHQKYlva" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">68,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgrLSNNVeHyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">2.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zr9mIEz3gS95" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_906_ecustom--RangeOfExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zAQoDqKRYKVc" title="Range of Exercise Price, Ending">7.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">n/a</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMcLCJTZDZUi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">52,693</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXFbU7qZztz8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">0.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExercisableVested_iE_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zr387Bu92AD7" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iE_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zrcGtM5A8Aaf" title="Range of Exercise Price, Exercisable">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">n/a</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

68712

2.00 0.05 7.80 P4Y3M25D P4Y1M28D P4Y

-1494

6.50 6.50 6.50

67218

1.90 0.05 7.80 P3Y8M4D 67218 1.90 0.05 7.80 P3Y8M4D

51199

9113

36.50 36.50 36.50 P0Y5M26D

52474

8.54 6.50 13.00 P4Y1M28D 71026 2.14 0.05 7.80 38315 7 6.50 6.50 P4Y

-25586

13.00 13.00 13.00

68712

2.00 0.05 7.80 52693 0.23 0.05 6.50

The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2025: SCHEDULE OF FAIR VALUE OF HIERARCHY FOR WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWPcmli8kAeg" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0JsuNjIXPhe"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoKZQIFJvD7g"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20250101__20251231_z0EE2EQ1qZ4"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z7gNBcbCXE8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zS8EcKYSYli6" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_zqGTdsZoCtfg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_z3zDGNz4I43h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair value of warrants reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_iN_di_zSFE21TVF2Y" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair value of warrants reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zcp0Wbm3QKEg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss on change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zBVG5Fnvg0c8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRtlkH0dFhqi" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9l3ijJFa8ie"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztp1kAWPr4P2"> </td><td> </td><td> </td> <td colspan="2" id="xdx_499_20240101__20241231_zUgM5HaQaNnb"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zUZlB2xPKkna" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">54,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">54,600</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z8rkRmXeY5kf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Common stock warrant liabilities, Beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">54,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">54,600</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zz75xEgpQl4e" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,582</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_z870jV0rEgBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_zuLcVXaumGeg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262,259</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_iN_di_zWW0d2wy6cv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197,456</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197,456</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zq6Hk36B9ZAb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Gain on change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(415,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(415,810</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zr560mRRa0Gd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z066bNVCoUg6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Common stock warrant liabilities, Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

269175

-127297

141878

54600

565582

262259

197456

-415810

269175

71026

2.14

262259

38315

6.50

197456

The following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2025 and 2024: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zpVWCbfR6Yuk" title="Risk-free interest rate">3.64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_zO9v5ZTW1n86" title="Risk-free interest rate">3.64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrtTJQ08Jj3k" title="Risk-free interest rate">4.24% - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvaOwWxCyNi" title="Risk-free interest rate">4.38</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_zMIHAOF7sby3" title="Risk-free interest rate">4.37</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (peer group)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPiqpcSjwhBf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_zHnc2STnDEa1" title="Expected volatility">130.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zS3FacCqdLj2" title="Risk-free interest rate">117.5% - <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztucgUXrsDnf" title="Risk-free interest rate">133.50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_zvd94JVtEZte" title="Expected volatility">133.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Term of warrants (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2lyTkfknvv8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.68 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zwkjRPEyfhde" title="Term of warrants (in years)">3.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zWW3Z0I0HGk4" title="Warrants outstanding, measurement input">0.4 - <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zS8h4vmlDYug" title="Warrants outstanding, measurement input">4.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zKtBSm2azEKf" title="Term of warrants (in years)">4.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zWE8FNFVCXB2" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zjXPHDjmW38d" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zDe2IEbnJ3Fc" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zcsttzMjnWsb" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

3.64

4.24

4.38

4.37

130.0

130.00

117.5

133.50

133.5

P3Y8M4D

P0Y4M24D

P4Y8M12D

P4Y2M12D

0.00

NOTE 10 — CONVERTIBLE DEBT 2022 Convertible Debenture (Related party) On December 22, 2022, the Company issued to Alpha an <span id="xdx_903_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_ziMvEvmmN04h" title="Senior convertible debenture rate">8% Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_908_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z2Z0jRCPm1ba" title="Principal amount">3,300,000 (the “2022 Debenture”) for a purchase price of $<span id="xdx_907_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zT8qpX63iBr" title="Purchase price">3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the “2022 Securities Purchase Agreement”). The 2022 Debenture carried a maturity date of <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z0H4vASlS8Cg" title="Maturity date">December 22, 2025 and was convertible, at any time, at Alpha’s option, into shares of the Company’s common stock (the “Conversion Shares”), at a price initially equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zVXQ2Dbw3HDb" title="Conversion price">66.00 per share, subject to adjustment as described in the 2022 Debenture. On July 13, 2023, the Company obtained stockholder approval, for purposes of complying with Nasdaq Listing Rule 5635(d), to allow for the issuance to Alpha of more than <span id="xdx_904_ecustom--PercentageOfStockIssuedAndOutstanding_pid_dp_uPure_c20230713__20230713__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zKDU7wwV6aE2" title="Issued and outstanding shares percentage">20% of our issued and outstanding shares of common stock pursuant to the terms and conditions of the 2022 Debenture, and the common stock purchase warrant dated December 22, 2022 (the “2022 Warrant”) issued by us to Alpha. Commencing June 1, 2023, the Company was required to redeem $<span id="xdx_90E_eus-gaap--RepaymentsOfLongTermDebtAndCapitalSecurities_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zkauxhZ243Ed" title="Redeemable debt">110,000 monthly, plus accrued and unpaid interest in cash, or, subject to the Equity Conditions (as defined in the 2022 Debenture) having been satisfied or waived, in shares of our common stock, based on a conversion price equal to the lesser of (i) the then-effective conversion price of the 2022 Debenture and (ii) <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z211dyz1Sh7a" title="Conversion rate">85% of the average of the VWAPs (as defined in the 2022 Debenture) for the five consecutive trading days ending on the trading day immediately before the applicable monthly redemption date. The 2022 Debenture accrued interest at the rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231201__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z27jxRRM7K78" title="Debenture accrues interest rate">8% per annum beginning on December 1, 2023, and was payable on a monthly or quarterly basis in cash or, subject to the Equity Conditions having been satisfied or waived, shares or a combination thereof at our option. In December 2022, pursuant to the terms of the 2022 Securities Purchase Agreement, we entered into a registration rights agreement with Alpha (the “Registration Rights Agreement”), pursuant to which we agreed to file one or more registration statements, as necessary, and to the extent permissible, to register under the Securities Act the resale of the remaining shares (underlying the 2022 Debenture and the 2022 Warrant) not otherwise registered under the Company’s registration statement on Form S-3 (File No. 333-266430). We filed a resale registration statement on Form S-3 pursuant to the requirements of the Registration Rights Agreement on December 2022 (File Number 333-269088), which registration statement was declared effective by the SEC on January 5, 2023. On September 1, 2023, we filed a Post-Effective Amendment No. 1 to Form S-3 on Form S-1 (File No. 333-269088), which Post-Effective Amendment was declared effective by the SEC on September 7, 2023. On May 1, 2024, we filed a Post-Effective Amendment No. 2 to Form S-1 on Form S-3 (File No. 333-269088), which Post-Effective Amendment was declared effective by the SEC on May 2, 2024. The Company evaluated the 2022 Debenture and the 2022 Warrant and determined that the 2022 Warrant is a freestanding financial instrument. Initially, the 2022 Warrant is not considered indexed to the Company’s own stock, because the settlement amount would not equal the difference between the fair value of a fixed number of the Company’s equity shares and a fixed strike price and all of the adjustment features in Section 3(b) of the Alpha Warrant are not down round provisions, as defined in ASU 2017-11. Accordingly, the 2022 Warrant was classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings. In accordance with ASC 470-50, the Company determined that the modified terms of the 2022 Debenture were substantially different when compared to the original terms that existed prior to the SPA Amendment, and thus the event was required to be accounted for as a debt extinguishment. Accordingly, the Company derecognized the net carrying value of the original Debenture, and recorded the new debt instrument at its fair value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgBZWnv28Qx7" title="Debt instrument fair value">1.4 million, and recorded a $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z13Q5Rt2P7U9" title="Loss on extinguishment">0.6 million loss on debt extinguishment. The difference between the remaining 2022 Debenture principal and its fair value on December 5, 2023 was recorded as a debt discount, which was amortized to interest expense over the expected term of the Debenture using the effective interest method, in accordance with ASC 835-30. On February 27, 2024, in connection with the issuance of an additional warrant to Alpha with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zbtMpXAtjvkb" title="Warrants exercise price">13.00 per share, and pursuant to certain antidilution provisions in the 2022 Debenture, the Conversion Price of the 2022 Debenture was reduced from $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zq9nEyA41Lv8" title="Conversion price per share">36.50 per share to $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zW7omuuTn5O4" title="Conversion price per share">13.00 per share. During the year ended December 31, 2024, the Company issued a total of <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z8T7gMvgNdBg" title="Shares of common stock conversion">45,496 shares of common stock to Alpha in lieu of cash for monthly redemption payments totaling $<span id="xdx_902_ecustom--DebtRedemptionAmountInCommonStock_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zsDDYTFW2q6a" title="Redemption amounts in common stock">660,000 due on the 2022 Debenture at a weighted average conversion price of $<span id="xdx_906_ecustom--WeightedAverageConversionPricePerShare_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z55ntKdSTAx7" title="Weighted average conversion price per share">14.51 per share, resulting in a net loss on debt extinguishment of approximately $<span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zeeGqkWei15b" title="Loss on extinguishment">209,000 in other expenses on the consolidated statements of operations. No redemption payments were paid in cash during the year ended December 31, 2024. Interest expense on the 2022 Debenture was approximately $<span id="xdx_901_eus-gaap--InterestExpense_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zB0AcRY39ilj" title="Interest expense">162,000 for the year ended December 31, 2024, of which approximately $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zKQT4lIfyoSa" title="Amortization of debt discount">120,000 was attributable to discount amortization), which is reported in other expenses in the consolidated statement of operations. In June and July 2024, Alpha voluntarily converted the aggregate remaining principal of the 2022 Debenture of $<span id="xdx_90F_ecustom--GainLossOnVoluntaryConversionOfConvertibleDebtIntoCommonStock_c20240601__20240630__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zcEt8Kjvxhfa" title="Voluntary conversion of convertible debt"><span id="xdx_90F_ecustom--GainLossOnVoluntaryConversionOfConvertibleDebtIntoCommonStock_c20240701__20240731__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z7wEw1BSoAE9" title="Voluntary conversion of convertible debt">758,922, extinguishing the Company’s obligations in full with respect to the 2022 Debenture and suite of bifurcated embedded derivative features. As a result of such voluntary conversions, the Company issued a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240601__20240630__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zINxI2TGvRG6" title="Number of shares issued"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240701__20240731__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zYpYkBTAdMS8" title="Number of shares issued">58,378 shares of common stock at a weighted average conversion price of $<span id="xdx_909_ecustom--WeightedAverageConversionPricePerShare_pid_c20240601__20240630__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_zDbbfQOBn8O5" title="Weighted average conversion price per share"><span id="xdx_90F_ecustom--WeightedAverageConversionPricePerShare_pid_c20240701__20240731__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember_z365fGf0RlL2" title="Weighted average conversion price per share">13.00. The Company recorded a gain on voluntary conversions of approximately $<span id="xdx_90F_ecustom--GainLossOnVoluntaryConversionOfConvertibleDebtIntoCommonStock_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoSeniorConvertibleDebentureMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zpbnv7uxCKN1" title="Voluntary conversion of convertible debt">85,000 during the year ended December 31, 2024. As of December 31, 2024, there were no amounts outstanding under the 2022 Debenture. 2024 Alpha Debenture (Related party) On February 27, 2024, pursuant to a Securities Purchase Agreement executed with Alpha on February 27, 2024 (the “2024 Securities Purchase Agreement”) we issued to Alpha an <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1ZEQEFFecv3" title="Interest rate">8% Convertible Debenture (the “2024 Alpha Debenture”) with a principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJUe8yTXYeC9" title="Principal amount">550,000, for a gross purchase price of $<span id="xdx_901_eus-gaap--RepaymentsOfDebt_c20240227__20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zpHljsKsnYua" title="Cash purchase price payment">500,000 less expenses. The 2024 Alpha Debenture carried a maturity date of December 31, 2024 and was convertible, at any time, and from time to time, at Alpha’s option, into shares of common stock of the Company, at a conversion price initially equal to $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGW62KQuRDLb" title="Share price per share">30.56 per share, subject to adjustment as described in the 2024 Alpha Debenture. Upon the closing of the public offering on September 6, 2024 per the terms of the antidilution provisions in the 2022 Debenture, the conversion price of the 2024 Alpha Debenture was reduced from $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240905__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zcaoEAN416y4" title="Conversion price per share">30.56 to $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zS3lKQkkdZUg" title="Conversion price per share">6.50 per share. The 2024 Alpha Debenture accrued interest on its outstanding principal balance at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zm8L2armIY9c" title="Interest rate">8% per annum, payable at maturity. In connection with this issuance, we also issued to Alpha a noncompensatory equity classified <span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_uPure_c20240227__20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhrFeCQ6hwll" title="Debt term">5-year common stock purchase warrant (the “2024 Alpha Warrant”) to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOvkyRNYoJmi" title="Purchase of warrants for shares">18,001 shares of our common stock at an exercise price initially equal to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhlVxtxR6Dk1" title="Warrant exercise price">13.00 per share (see Note 15 - Stockholders Equity). Pursuant to the 2024 Securities Purchase Agreement, we also granted to Alpha an option (the “Option”), exercisable until July 1, 2024, to purchase from us an additional <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zchN2F5pRCyg">8% Convertible Debentures, of like tenor, with a face amount of up to $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__srt--RangeAxis__srt--MaximumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zi22yonam17h" title="Face amount">1.1 million (and with a proportional number of accompanying common stock warrants of like tenor, up to a total of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__srt--RangeAxis__srt--MaximumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zUH93blI3nS" title="Purchase of warrants for shares">36,001 additional warrants), for a purchase price of $<span id="xdx_909_eus-gaap--PaymentsForRepurchaseOfWarrants_pn5n6_c20240227__20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__srt--RangeAxis__srt--MaximumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDVDikhWnkml" title="Purchase price of warrants">1.0 million. The Company evaluated the terms of the 2024 Securities Purchase Agreement and determined that the 2024 Alpha Warrant and the Option issued to Alpha are each considered freestanding financial instruments. The 2024 Alpha Warrant was further determined to initially (i) be indexed to the Company’s own stock, and (ii) meet all of the additional criteria for permanent equity classification. As the Option required the Company to issue convertible debt with multiple cash settlement alternatives, the Option was classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings. The net proceeds from the issuance of the 2024 Alpha Debenture were allocated first to the liability-classified Option and the bifurcated embedded features in the 2024 Alpha Debenture (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting difference, if any, allocated to the loan host instrument and the equity-classified warrant on a relative fair value basis. The fair value of the Option was estimated to be $<span id="xdx_90A_eus-gaap--EquityFairValueDisclosure_iI_pn5n6_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuwr4SGlCX19" title="Fair value of option">0.8 million at issuance, and the suite of bifurcated embedded derivative features was $<span id="xdx_906_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_pn4n6_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zLIEZjb69Dfg" title="Fair value of embedded derivative features">0.08 million. As the fair value of the liability-classified instruments and features exceeded the net proceeds received, the Company recognized a loss on issuance of convertible debt of $<span id="xdx_90E_eus-gaap--DebtConversionOriginalDebtAmount1_pn5n6_c20240227__20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zkNklpGXr73j" title="Issuance of convertible debt">0.4 million, presented in other expenses in the consolidated statements of operations. As a result, the Company recorded a debt discount at the maximum amount equal to the principal of $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_c20240227__20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWUjunbPUq0k" title="Debt discount">550,000, which was amortized as additional interest expense over the expected term of the 2024 Alpha Debenture. On September 9, 2024 we issued <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240909__20240909__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztXKFDmOYDih" title="Shares of common stock conversion">7,842 shares of common stock upon Alpha’s partial voluntary conversion of the 2024 Alpha Debenture at a conversion price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240909__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDYlCv0XvMr7" title="Conversion price">6.50 per share for a total of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20240909__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIuLzx0VbXO8" title="Principal amount">50,979 in principal. The Company recognized a loss on partial voluntary conversion of approximately $<span id="xdx_900_ecustom--VoluntaryConversionOfConvertibleDebt_iI_c20240909__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlrbMLTW6vNf" title="Loss on voluntary conversion">29,000. During the year ended December 31, 2024, interest expense on the 2024 Alpha Debenture was approximately $486,000, of which approximately $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember_zZzLaiDJ0A7a" title="Amortization of debt discount">473,000 was attributable to discount amortization), which is reported in other expenses in the consolidated statements of operations. On November 20, 2024, in connection with the closing of the Company’s private placement transaction and issuance of Series A-2 Preferred Stock, the Company used $<span id="xdx_902_eus-gaap--ProceedsFromRepaymentsOfDebt_c20241120__20241120__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourAlphaDebentureMember_za5WjtTZirB2" title="Proceeds to repay the outstanding principal and accrued interest">530,839 of the proceeds to repay the outstanding principal and accrued interest on the Alpha Debenture, in full settlement of the obligation. The Company recognized a debt extinguishment loss of $68,000 on the settlement date, representing the difference between (i) the cash reacquisition price, and (ii) the net carrying value of the debt, inclusive of unamortized discounts and issuance costs and the fair value of the associated suite of bifurcated derivative liabilities on the settlement date. As of December 31, 2024, there were no amounts outstanding under the 2024 Alpha Debenture. 2024 Chen Debenture (Related party) In April 2024, Alpha assigned the Option to Yi Hua Chen (“Chen”) and Chen exercised the option in full, in exchange for $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240401__20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__srt--RangeAxis__srt--MaximumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zx4BDYdszLu9" title="Debt conversion">1,000,000, less expenses, we issued to Chen an <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0UY4Ryqn0oi" title="Interest rate">8% Convertible Debenture (the “2024 Chen Debenture”) with a principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__srt--RangeAxis__srt--MaximumMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zf9daYpwxRg8" title="Principal amount">1,100,000. The 2024 Chen Debenture carried a maturity date of December 31, 2024 and was convertible, at any time, and from time to time, at Chen’s option, into shares of common stock of the Company at a conversion price initially equal to $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDnLso17TMqi">30.56 per share, subject to adjustment as described in the 2024 Chen Debenture. Upon the closing of the public offering on September 6, 2024 per the terms of the antidilution provision, the conversion price of the 2024 Chen Debenture was reduced from $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240905__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z7Pdw0bZXSA5" title="Conversion price per share">30.56 to $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zZbn52VDpLdl" title="Conversion price per share">6.50 per share. The 2024 Chen Debenture accrues interest on its outstanding principal balance at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zqOx9w8hiWp4">8% per annum, payable at maturity. In connection with this issuance, we also issued to Chen a <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_uPure_c20240401__20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zM9jWPcezOf7">5-year liability classified common stock purchase warrant (the “2024 Chen Warrant”) to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zUzvkvhAFY26" title="Class of warrant">36,001 shares of our common stock at an exercise price initially equal to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember_zQXes6Q1aRle">13.00 per share (see Note 9 - Warrant Liabilities). The Company evaluated the terms of the 2024 Chen Debenture and the 2024 Chen Warrant and determined that the 2024 Chen Warrant was considered a freestanding financial instrument. The 2024 Chen Warrant was further determined to be indexed to the Company’s own stock. However, the 2024 Chen Warrant failed to meet the additional criteria for permanent equity classification due to a lack of authorized shares available to settle the instrument, as the Company was required to obtain shareholder approval to issue all shares underlying the 2024 Securities Purchase Agreement to comply with the rules of Nasdaq. The Company has adopted a sequencing approach under ASC 815-40, Derivatives and Hedging - Contracts in Entity’s Own Equity to determine the classification of its contracts at issuance and at each subsequent reporting date, whereby shares are allocated based on the earliest issuance date of potentially dilutive instruments, with the earliest issuance date receiving the first allocation of shares. In the event of identical issuance dates, shares are then allocated beginning with instruments with the latest maturity date first. Pursuant to this sequencing approach, as of April 27, 2024, we determined that the authorized shares were sufficient to settle the 2024 Alpha Warrant and was therefore classified in equity. The Company determined the remaining shares were not sufficient to settle the 2024 Chen Warrant and therefore classified as a liability at fair value, with subsequent changes in fair value recognized in earnings, until such shareholder approval was obtained on October 25, 2024 (see Note 9 - Warrant Liabilities). The net proceeds from the issuance of the 2024 Chen Debenture, inclusive of the fair value of the settled Option on April 12, 2024 of $<span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20240412__20240412__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCherF1WPUu6" title="Proceeds from issuance of debt">0.7 million, was first allocated to the liability-classified 2024 Chen Warrant and the bifurcated embedded features in the 2024 Chen Debenture, with the resulting difference, if any, allocated to the loan host instrument. As a result, the fair value of the 2024 Chen Warrant at issuance of $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20240412__20240412__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVPgCkx4p0vc" title="Fair value of warrant">0.6 million at issuance and the suite of bifurcated embedded derivative features of $<span id="xdx_906_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_pn4n6_c20240412__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlpk7CJb80Xk" title="Fair value of embedded derivative features">0.03 million comprised the initial debt discount, which was amortized to interest expense over the expected term of the 2024 Chen Debenture using the effective interest method, in accordance with ASC 835-30. During the year ended December 31, 2024, interest expense on the 2024 Chen Debenture was approximately $<span id="xdx_903_eus-gaap--InterestExpense_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zTUXxNOPhAwg" title="Interest expense">78,000, of which approximately $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zqNdLH2Fl0Jg" title="Amortization of debt discount">23,000 was attributable to discount amortization), which is reported in other expenses in the consolidated statements of operations. In November 2024, in connection with the closing of the Company’s private placement transaction and issuance of Series A-2 Preferred Stock, the Company and Chen executed an Exchange Agreement (the “Exchange Agreement”), agreeing to convert all outstanding principal and accrued interest on the 2024 Chen Debenture totaling approximately $<span id="xdx_905_eus-gaap--DebtConversionOriginalDebtAmount1_c20241120__20241120__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zm7erDrdHSAf" title="Debt conversion amount">1,154,000, in exchange for <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20241120__20241120__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSvMnjIbWjSi" title="Shares of common stock conversion">1,154 shares of newly designated Series A-2 Preferred Stock, in full settlement of the Company’s obligations with respect to the Chen Debenture. As of December 31, 2025 and December 31, 2024, there were no amounts outstanding under the 2024 Chen Debenture. 2025 Convertible Note On April 28, 2025, the Company entered into a Secured Convertible Note (the “2025 Convertible Note”) with Alpha Capital Anstalt (“Alpha”, or “Holder”), pursuant to which the Company issued to Alpha a non-interest-bearing note with a principal of $264,000, and an original issue discount (“OID”) of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250428__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zMOMFnhteK02" title="Original issue discount">20%, or $44,000, in exchange for $220,000 cash, less $20,000 in expenses. The Note is convertible at any time at Alpha’s option, into shares of the Company’s common stock at a price equal to $3.80 per share, subject to certain adjustments. The Convertible Note bears no interest, and the principal will be due on January 28, 2026 (the “Maturity Date”). The Company determined the 2025 Convertible Note does not contain a substantial premium and therefore the Company elected to account for the Convertible Note under the fair value option in accordance with ASC 825-10-15-4. The Company determined the fair value of the Convertible Note was $<span id="xdx_90D_eus-gaap--ConvertiblePreferredStockConvertedToOtherSecurities_c20250428__20250428__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zRxFBiQbXzRj" title="Fair value of convertible securities">311,943 at issuance. The difference between the $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250428__20250428__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zi5btsFYDxni" title="Proceeds from issuance of convertible note">220,000 proceeds received and fair value was recorded as a loss upon issuance in the amount of $91,943. Issuance costs incurred in connection with the transaction were expensed immediately. On June 4, 2025 the Company paid down $132,000 in principal at the request of Alpha. As of December 31, 2025 the Company reassessed the fair value of the 2025 Convertible Note at $<span id="xdx_903_ecustom--ChangeInFairValueOfConvertibleNote_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_z1AvpxnSc9Sb" title="Change in fair value of convertible note">142,236, with a gain on the change in fair value of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zHJ9fT2S0x3d" title="Gain loss on extinguishment of debt">37,707 recorded in the year ended December 31, 2025.

0.08

3300000

3000000

2025-12-22

66.00

0.20

110000

0.85

0.08

1400000

600000

13.00

36.50

13.00

45496

660000 14.51

209000

162000

120000

758922 758922

58378

13.00 13.00 85000

0.08

550000

500000

30.56

6.50

0.08

P5Y

18001

13.00

0.08

1100000

36001

1000000.0

800000

80000.00

400000

550000

7842

6.50

50979

29000

486000

473000

530839

68000

1000000

0.08

1100000

30.56

6.50

0.08

P5Y

36001

13.00

700000

600000

30000.00

78000

23000

1154000

1154

264000

0.20

44000

220000

20000

3.80

311943

220000

91943

132000

142236

37707

NOTE 11 — PROMISSORY NOTES During the year ended December 31, 2025, the Company issued short term notes payable totaling $4.4 million for total net proceeds of $3.4 million. Over the course of the year the Company repaid all notes for a total of $4.4 million, with the additional $1.0 million paid as a premium to some of the lenders and was recorded under interest expenses. There were no outstanding promissory notes outstanding as of December 31, 2025 or 2024.

4400000

3400000

4400000

1000000.0

NOTE 12 — EARNINGS (LOSS) PER SHARE Basic loss per share (“EPS”) is computed by dividing net loss including deemed dividends by the weighted-average number of common shares outstanding plus unexercised pre-funded warrants. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from preferred stock, convertible debt, stock options and warrants. SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20251231_zBVDQj8zLA85" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zBWbu5uSotS2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfitLoss_ztTeaQvmIGw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net loss attributable to shareholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(19,528,742</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(6,346,795</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zLGp8CWv85qk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic weighted-average common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,407,817</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">361,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zElagEbKh3b3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zpOLNzcNDDm5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,407,817</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">361,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zD8VrR7NAHpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2025 and 2024 because their effect would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231_z5yoJW8lQAs9" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zW50769eZx73" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4D3bHbgyRk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,870</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsSP8YNeB677" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of common stock subject to outstanding warrants (excluding pre-funded warrants)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,026</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zJHAxRXZMxE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of common stock subject to outstanding preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,051,425</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,437,363</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zqSf6QKWNUR7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Shares of common stock subject to outstanding convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,143</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zKCgJ1VQOu0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">18,628,514</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,529,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Basic loss per share (“EPS”) is computed by dividing net loss including deemed dividends by the weighted-average number of common shares outstanding plus unexercised pre-funded warrants. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from preferred stock, convertible debt, stock options and warrants. SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20251231_zBVDQj8zLA85" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zBWbu5uSotS2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfitLoss_ztTeaQvmIGw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net loss attributable to shareholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(19,528,742</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(6,346,795</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zLGp8CWv85qk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic weighted-average common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,407,817</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">361,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zElagEbKh3b3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zpOLNzcNDDm5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,407,817</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">361,587</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-19528742

-6346795

2407817

361587

2407817

361587

<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zD8VrR7NAHpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2025 and 2024 because their effect would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231_z5yoJW8lQAs9" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zW50769eZx73" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z4D3bHbgyRk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,870</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsSP8YNeB677" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of common stock subject to outstanding warrants (excluding pre-funded warrants)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,026</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zJHAxRXZMxE4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of common stock subject to outstanding preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,051,425</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,437,363</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtMember_zqSf6QKWNUR7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Shares of common stock subject to outstanding convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,143</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zKCgJ1VQOu0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total common stock equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">18,628,514</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,529,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1570

1870

528376

90026

18051425

3437363

47143

18628514

3529259

NOTE 13 — COMMITMENTS AND CONTINGENCIES Litigation and Other Legal Proceedings On January 29, 2025, the Company was named as a defendant in an action brought by LifeSci Capital LLC (“LifeSci”) in the U.S. District Court for the Southern District of New York. The complaint alleges that the Company failed to pay $503,483 in connection with offerings of the Company’s common stock that occurred during the tail period of the agreement, pursuant to an engagement under which the Company retained LifeSci to serve as its placement agent and financial advisor. The Company filed its answer on March 17, 2025, denying the material allegations in the complaint and asserting various affirmative defenses. On October 9, 2025 the matter was settled out of court and the Company agreed to pay Lifesci $75,000 to settle the outstanding claim, which was paid.

503483

75000

NOTE 14 — RESEARCH AND LICENSE AGREEMENTS UCL Business Limited In January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound is now being developed at the Company under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required a $<span id="xdx_90F_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zYaN6Clszxe4" title="Reimbursement of patent">150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $160,000), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty sublicensing consideration paid to the Company. For the years ended December 31, 2025 and 2024 there were license costs of $20,000 and $2,000, respectively, related to this agreement which are included in research and development expenses in the consolidated statements of operations and other comprehensive loss. QN-302 Phase 1 Study In June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (“TD2”) whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company may enter into statements of work with TD2 for the performance of specific services under this Master Clinical Research Services Agreement. In June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) whereby MLM agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply, testing, validation, data management, and storage services. From time to time, the Company may enter into work orders with MLM for the performance of specific services under this Master Laboratory Services Agreement. In June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (“Clinigen”) whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company may enter into statements of work with Clinigen for the performance of specific services under this Master Services Agreement. In July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services for the conduct of the QN-302 Phase 1 study. Given our financial situation, the company slowed the development of the QN-302 Phase 1 Study beginning in the second quarter of 2024. University of Louisville Research Foundation In March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with University of Louisville Research Foundation, Inc. (“ULRF”) for development of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $<span id="xdx_909_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zhm92Uh3K4bj" title="Reimbursement of research expenses">693,000 for this program. This agreement was amended in February 2021, March 2022 and August 2023, with the current term of this agreement expired in December 2023 and the aggregate amount that the Company would reimburse ULRF for sponsored research expenses increased to approximately $<span id="xdx_904_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zwm35rInSTk8" title="Research expenses">2.9 million. <span id="xdx_90E_ecustom--AgreementTermPaymentDescription_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zigaaat11Gi2" title="Agreement term payment, description">In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $<span id="xdx_907_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zix5Ip9o6bRj" title="Milestone payment">50,000 to $<span id="xdx_906_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXmbxqwuOh55" title="Milestone payment">5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $<span id="xdx_90F_ecustom--MilestonePayment_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zraZgcsEvYaf" title="Milestone payment">50,000 for first dosing in a Phase 1 clinical trial, $<span id="xdx_906_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_z0uG7Y3PgRp3" title="Milestone payment">100,000 for first dosing in a Phase 2 clinical trial, $<span id="xdx_900_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zFpd2NgQs212" title="Milestone payment">150,000 for first dosing in a Phase 3 clinical trial, $<span id="xdx_90F_ecustom--CumulativeSalesOne_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWVRhGMmScyl" title="Cumulative sales">300,000 for regulatory marketing approval and $<span id="xdx_900_ecustom--CumulativeSales_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zTjEPumWlGFf" title="Cumulative sales">5,000,000 upon achieving a cumulative $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zU8OsyWrSaJc" title="Revenue">500,000,000 of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_90A_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zemmGGB6mhT9" title="Upfront license fee">20,000 to $<span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z88OQYel4cHi" title="Upfront license fee">100,000) for such year. There were <span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQVRFobNdNTc" title="Research and development expenses"><span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zdRbRsmYLoh1" title="Research and development expenses">no sponsored research expenses related to these agreements for the years ended December 31, 2025 and 2024. License costs were approximately $<span id="xdx_905_ecustom--LicenseCost_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_za5YdupMQnR6" title="License costs">0 and $<span id="xdx_902_ecustom--LicenseCost_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z1mJK3vWDmW9" title="License costs">68,000 related to these agreements for the years ended December 31, 2025 and 2024, respectively and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. Between June 2018 and April 2022, the Company entered into license and sponsored research agreements with ULRF for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. <span id="xdx_90E_ecustom--AgreementTermPaymentDescription_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zlg0j6gb7Lb" title="License and sponsored research agreement terms">Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLUPQ7HgjwHc" title="Proceeds from convertible debt">50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $<span id="xdx_905_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGCnM6iVoi2d" title="Reimbursement of research expenses">805,000 and prior patent costs of up to $<span id="xdx_90D_ecustom--PatentCosts_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zUswKePMxGZd" title="Patent costs">200,000. In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z74oEUe3QIY4" title="Milestone payment">100,000 to $<span id="xdx_90B_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zx52dIRiiJA1" title="Milestone payment">5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $<span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z46nwVKa9uX3" title="Milestone payment">100,000 for first dosing in a Phase 1 clinical trial, $<span id="xdx_900_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zL7PAHrCVixb" title="Milestone payment">200,000 for first dosing in a Phase 2 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zwgvdZD7Uodk" title="Milestone payment">350,000 for first dosing in a Phase 3 clinical trial, $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zoZo9b6RO9q3" title="Marketing approval expenses">500,000 for regulatory marketing approval and $<span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3IS1M7tZNS2" title="Cumulative sales">5,000,000 upon achieving a cumulative $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zOdYS2WKo3Lg" title="Revenue">500,000,000 of Licensed Product sales. The Company also agreed to pay another $<span id="xdx_90E_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zcKBwAfoQUJl" title="Regulatory marketing approval, expenses">500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_908_ecustom--ShortfallPayments_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zFDPEHw8ITJ2" title="Shortfall payments">10,000 to $<span id="xdx_905_ecustom--ShortfallPayments_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z4WIVfCinh62" title="Shortfall payments">50,000) for such year. The sponsored research agreement for QN-247 expired in August 2022 and there were <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zwUECEt39xl4" title="Research and development expenses"><span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zQlCMFrXIPlj" title="Research and development expenses">no sponsored research expenses related to these agreements for the years ended December 31, 2025 and 2024. License costs related to these agreements for the years ended December 31, 2025 and 2024 were approximately $0 and 1,000, respectively, and are included in research and development expenses in the consolidated statements of operations and other comprehensive loss. All agreements with the ULRF were terminated in August 2024. Marizyme On April 11, 2024, we entered into a Co-Development Agreement with Marizyme. Under the Co-Development Agreement (as amended), <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_c20240411__20240411__us-gaap--TypeOfArrangementAxis__custom--CoDevelopmentAgreementMember_zyUx0fOcZTVh" title="Marizyme agreement terms">we agreed to pay Marizyme funding payments and an exclusivity fee of $200,000. The Exclusivity Fee of $200,000 and a funding payment of $500,000 was paid to Marizyme on April 12, 2024, and is included in research and development expenses in the consolidated statements of operations and other comprehensive loss. The Exclusivity Fee entitled us to an exclusivity period until May 31, 2024 for purposes of proposing and outlining a broader strategic relationship with Marizyme with regard to Marizyme’s DuraGraft business. The funding payments are designed to provide financial support for commercialization of Marizyme’s DuraGraft™ vascular conduit solution, which is indicated for adult patients undergoing coronary artery bypass grafting surgeries and is intended for the flushing and storage of the saphenous vein grafts used in coronary artery bypass grafting surgery. In return for the funding payments we will receive quarterly a 33% payment in the nature of royalties on any Net Sales (as defined with a meaning tantamount to gross profit on net sales) of DuraGraft, capped at double the amount of the funding payments provided. No such payments-in-the-nature-of-royalties would accrue until after DuraGraft has been launched in the United States and a cumulative total of $500,000 of DuraGraft Net Sales have been made in the United States. As of the year ended December 31, 2025, these conditions have not been met and no royalty payments are due. 150000 160000 20000 2000 693000 2900000 In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. 50000 5000000 50000 100000 150000 300000 5000000

500000000

20000 100000

0 68000 Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $805,000 and prior patent costs of up to $200,000. In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical trial, $350,000 for first dosing in a Phase 3 clinical trial, $500,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company also agreed to pay another $500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $10,000 to $50,000) for such year.

50000

805000 200000 100000 5000000 100000 200000 350000 500000 5000000

500000000

500000 10000 50000

0 1000

we agreed to pay Marizyme funding payments and an exclusivity fee of $200,000. The Exclusivity Fee of $200,000 and a funding payment of $500,000 was paid to Marizyme on April 12, 2024, and is included in research and development expenses in the consolidated statements of operations and other comprehensive loss. The Exclusivity Fee entitled us to an exclusivity period until May 31, 2024 for purposes of proposing and outlining a broader strategic relationship with Marizyme with regard to Marizyme’s DuraGraft business. The funding payments are designed to provide financial support for commercialization of Marizyme’s DuraGraft™ vascular conduit solution, which is indicated for adult patients undergoing coronary artery bypass grafting surgeries and is intended for the flushing and storage of the saphenous vein grafts used in coronary artery bypass grafting surgery. In return for the funding payments we will receive quarterly a 33% payment in the nature of royalties on any Net Sales (as defined with a meaning tantamount to gross profit on net sales) of DuraGraft, capped at double the amount of the funding payments provided. No such payments-in-the-nature-of-royalties would accrue until after DuraGraft has been launched in the United States and a cumulative total of $500,000 of DuraGraft Net Sales have been made in the United States. As of the year ended December 31, 2025, these conditions have not been met and no royalty payments are due.

200000

500000

NOTE 15 — STOCKHOLDERS’ EQUITY As of December 31, 2025 and 2024, the Company had two classes of authorized capital stock: common stock and preferred stock. Common Stock Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions. At December 31, 2025, the Company has reserved 19,350,388 shares of authorized but unissued common stock for possible future issuance as follows: SCHEDULE OF RESERVED SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49E_20251231_zOpA3C8T3yml" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3y3S6PatG0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">13,544</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zH7hXa5a4EJd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of Series A-2 preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">267,364</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_z0i7BCrKtTsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of Series B preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,784,061</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--ConvertibleDebtMember_z0zae8epRJ41" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8a7N5deZ9G1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercise of stock warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,226,648</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zfZ5ss3RaWE8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,350,388</td><td style="text-align: left"> </td></tr> </table> Faraday Subscription Agreement As described in Note 1 – Organization and Summary of Significant Accounting Policies and Estimates, on September 29, 2025, the Company consummated the Subscription Agreement with certain investors, including Faraday pursuant to which the Company issued and sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zi6xdbXAVx1g" title="Number of shares issued and sold">337,432 shares of the Company’s common stock and issued <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalFirmMember_zrWwfSAK8q06" title="Number of shares issued and sold">100,000 to the Company’s legal firm . The purchase price of the common stock was $2.246 per share for an aggregate $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_zxDvyB3HzKCj" title="Value of shares sold">0.8 million. Additionally, in connection with the closing of the Subscription Agreement, the Company issued <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvisorMember_zJ8tuOw1YPB" title="Number of shares issued and sold">60,257 shares of common stock as compensation to its advisor which has been accounted for under ASC 718 Compensation—Stock Compensation (See Note 1 – Organization and Summary of Significant Accounting Policies and Estimates). The grant date fair value of these shares of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_zsughFLU1Mm4" title="Grant date fair value of shares">0.3 million, is included in General and Administrative Expenses on the Company’s Consolidated Statement of Operations and Comprehensive Loss. Further, in connection with the closing of the Subscription Agreement, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_zGG7U9jCEbM6" title="Warrants issued">1,087,266 warrants were issued to the placement agent, (the “Placement Agent Warrants”). The Placement Agent Warrants were immediately exercisable and have an initial exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_zw1f9A1xK3y5" title="Exercise price">2.47 per share. At December 31, 2025, 1,087,266 Placement Agent Warrants remain outstanding. 2024 Common Stock Purchase Agreement On November 19, 2024, the Company entered into a Common Stock Purchase Agreement (the “Common Stock Purchase Agreement”) with Horberg Enterprises LP (the “Investor”), pursuant to which the Company in its sole discretion has the right, but not the obligation, to issue and sell to the Investor up to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20241119__20241119__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDjHW6cMYfYf" title="Value of shares available for sale">10.0 million of the Company’s common stock, from time to time beginning on the Commencement Date, as discussed below, subject to certain limitations and conditions detailed in the Common Stock Purchase Agreement. The Company is not obligated to sell any shares to the Investor under the Common Stock Purchase Agreement; sales and timing of any sales of the Company’s common stock are solely at the Company’s election. In accordance with the terms of the Common Stock Purchase Agreement, the Commencement Date is subject to certain conditions, including the effectiveness of a registration statement on Form S-1 or a similar prospectus permitting the Investor to offer and resell the shares of common stock acquired under the Common Stock Purchase Agreement. No upfront fees were paid to the Investor at the execution of the arrangement. As of December 31, 2025, no registration statement had been filed and thus the Commencement Date permitting the sale of shares under the Common Stock Purchase Agreement had not yet occurred. The Company evaluated the Common Stock Purchase Agreement under ASC 815-40 Derivatives and Hedging-Contracts on an Entity’s Own Equity as it represents the right to require the Investor to purchase shares of Common Stock in the future, similar to a put option. The Company concluded the Common Stock Purchase Agreement represents a freestanding derivative instrument that does not qualify for equity classification and therefore requires fair value accounting. The Company analyzed the terms of the contract and concluded the derivative instrument had no value at inception, as of December 31, 2025, or as of December 31, 2024. Preferred Stock There are a total of 15,000,000 shares of Preferred Stock authorized , of which <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zMC3n59zpgb6" title="Preferred stock, shares designated">10,000 shares are designated as Series A-2 Preferred Stock, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA3ConvertiblePreferredStockMember_zBss1Rkiv1dc" title="Preferred stock, shares designated">10,000 shares are designed as Series A-3 Preferred Stock, and to <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zEwmKht6inu2" title="Preferred stock, shares designated">500,000 shares are designated as Series B Preferred Stock. As described in Note 1 – Organization and Summary of Significant Accounting Policies and Estimates, on September 29, 2025, the Company consummated the Subscription Agreement pursuant to which the Company issued <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zWJAv60ih50e" title="Number of shares issued and sold">39,943 shares of the newly designated Series B Preferred Stock, for $1,000 per share, for aggregate gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250929__20250929__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zo5hAEHH8Kv8" title="Gross proceeds from issuance of shares">39.9 million, before deducting placement agent fees and other offering expenses. This offering triggered a down-round provision of the Series A-2 Convertible Preferred Stock and Series A-3 Convertible Preferred Stock, as described further below, which resulted in a lower conversion price. As a result, the Company recorded a $2.0 million deemed dividend in the amount equal to the change in fair value of the abovementioned series of convertible preferred stock before and after the anti-dilution adjustment. On July 28, 2025, in a private placement transaction, the Company sold and issued to certain institutional and accredited investors <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250728__20250728__us-gaap--AwardTypeAxis__custom--SeriesA3ConvertiblePreferredStockMember_zYs8sJsflgA" title="Number of shares issued and sold">4,500 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share, (the “Series A-3 Preferred Stock”), at a purchase price of $1,000 per share, for aggregate gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250728__20250728__us-gaap--AwardTypeAxis__custom--SeriesA3ConvertiblePreferredStockMember_zQBVyVaVDzhe" title="Gross proceeds from issuance of shares">4.5 million before deducting placement agent fees and offering expenses of $0.2 million, resulting in net proceeds of $4.3 million. This offering triggered a down-round provision of the Series A-2 Convertible Preferred stock, as described further below, which resulted in a lower conversion price. As a result, the Company recorded a $0.6 million deemed dividend in the amount equal to the change in fair value of the aforementioned series of convertible preferred stock before and after the anti-dilution adjustment. On November 20, 2024 in a private placement transaction, the Company sold and issued to certain institutional and accredited investors <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241120__20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zw3kIbyjJOgf" title="Number of shares issued and sold">5,102 shares of the newly designated Series A-2 Convertible Preferred Stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_z3eXcysKUG43" title="Preferred stock, par value">0.001 per share (the “Series A-2 Preferred Stock” and together with the Series A-3 Preferred Stock, the “Series A Preferred Stock”), at a purchase price of $1,000 per share, for an aggregate purchase price of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20241120__20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zDyY9rUvtXke" title="Gross proceeds from issuance of shares">5.1 million. The Company also entered into an Exchange Agreement with Yi Hua Chen on November 18, 2024, pursuant to which it issued <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pp0p0_c20241118__20241118__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_zCBpfXEYlPvh" title="Shares issued upon debt exchange">1,154 shares of Series A-2 Preferred Stock in full settlement of the outstanding balance of the 2024 Chen Debenture of approximately $<span id="xdx_903_eus-gaap--DebtConversionOriginalDebtAmount1_pn4n6_c20241118__20241118__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_z0MP2hI8RnCg" title="Debt amount exchanged">1.15 million. At December 31, 2024 the Company had <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zPWAijt7pPQ1" title="Preferred stock, shares outstanding">6,256 shares of Series A-2 preferred stock outstanding, which were convertible into <span id="xdx_90E_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zMH40E3Xw0Ba" title="Common shares issuable upon conversion">1,718,681 shares of common stock at a Conversion Price of $3.64. During the year ended December 31, 2025, <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zsAmTMjqjt0c" title="Preferred stock, shares conversion">5,656 shares of Series A-2 Convertible Preferred stock and <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA3ConvertiblePreferredStockMember_zBrFQ9tR30ak" title="Preferred stock converted">4,500 shares of Series A-3 Convertible Preferred Stock were converted into <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2AndA3ConvertiblePreferredStockMember_zlI0ceZBWZ8g" title="Common stock issued upon conversion">3,926,263 shares of common stock at a Conversion Price ranging from $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2AndA3ConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zO7yKrqoqE81" title="Conversion price">3.64 to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2AndA3ConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zuxN1xQCLiIl" title="Conversion price">2.246. At December 31, 2025, the Company’s outstanding preferred stock consists of the following: SCHEDULE OF OUTSTANDING PREFERRED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Authorized Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Conversion Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Equivalent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Series A-2</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_z6HBvvruegof" style="width: 11%; text-align: right" title="Preferred stock, shares authorized">10,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_z5B7NalPe1jh" style="width: 11%; text-align: right" title="Preferred stock, shares outstanding">601</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zzKFYMkcnpKd" style="width: 11%; text-align: right" title="Preferred stock, conversion price">2.246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zPNmszHr3Daj" style="width: 11%; text-align: right" title="Preferred stock, common stock equivalent">267,364</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zOyLVTX2Qlc8" style="text-align: right" title="Preferred stock, shares authorized">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_z5USV7le3u8a" style="text-align: right" title="Preferred stock, shares outstanding">39,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zgYMEqkfNE7c" style="text-align: right" title="Preferred stock, conversion price">2.246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zjrOGeLeoRhe" style="text-align: right" title="Preferred stock, common stock equivalent">17,784,061</td><td style="text-align: left"> </td></tr> </table> The shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Conversion Rights – Each share of Preferred Stock is convertible at any time, at the option of the holder, into a number of shares of common stock equal to $1,000 (the “Stated Value”), divided by a conversion price initially equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zqALEIRRtrZ5" title="Conversion price, per share">3.64 for each share of Series A-2 Preferred Stock, $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA3ConvertiblePreferredStockMember_zJUKvGTlfHuk" title="Conversion price, per share">2.80 for each share of Series A-3 Preferred stock and $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zsvsC5leHOdj" title="Conversion price, per share">2.246 for each share of Series B Preferred Stock (the “Conversion Shares”), subject to adjustment for any stock splits, stock dividends and similar events (the “Conversion Price”). The Conversion Prices of the Series A Preferred Stock are also subject to down-round adjustments if the Company at any time while the Series A Preferred Stock is outstanding issues common stock or common stock equivalents at a lower effective price per share than the then-effective Conversion Price, in all cases subject to a floor price of $1.82 and $1.40 for the Series A-2 Preferred Stocka and the Series A-3 Preferred Stock, respectively. Conversion of the Series A Preferred Stock will be prohibited if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 4.99% (or 9.99% at the option of the holder) of the total number of shares of the Company’s common stock issued and outstanding. Liquidation Preference – Upon any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, the holders of Series A Preferred Stock shall be entitled to an amount equal to the Stated Value for each share of Series A-2 Preferred Stock before any distribution or payment shall be made to the holders of common stock. Upon any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, the holders of Series B Preferred Stock shall be entitled to an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon before any distribution or payment shall be made to the holders of common stock. Voting Rights – The holders of Series A Preferred Stock are entitled to vote, together as a single class with the common stock, on all matters presented to the common stockholders for a vote. Each share of Preferred Stock is entitled to a number of votes equal to the number of shares into which such share of Preferred Stock would be convertible, as of the record date for determination of stockholders entitled to vote as to such matter, if the conversion price was equal to the “Minimum Price” (as defined in Nasdaq Listing Rule 5635(d)) as of the original issue date of the Series A Preferred Stock, taking into account for such purposes the beneficial ownership limitation as then in effect. The holders of Series B Preferred stock will vote together with common stock on an as-converted basis. Dividends – The holders of Series A Preferred Stock and Series B Preferred Stock are entitled to receive dividends, if and when such dividends are paid to holders of common stock, in the same form and at the same time on an as-converted to common stock basis. Protective Provisions – At all times while the Series A Preferred Stock and Series B Preferred Stock are outstanding, without the consent of the holders of at least 67% of the Stated Value of each series of the then-outstanding Series A Preferred Stock and holders of at least 75% of the Stated Value of the then-outstanding Series B Preferred Stock, (the “Required Consent”), the Company is prohibited from amending its charter documents in any manner that adversely affects the rights of the Series A Preferred Stock and Series B Preferred Stock, repurchase junior securities of the Company, pay cash dividends or distributions on junior securities of the Company, or enter into a material transactions with an affiliate of the Company (unless it is at arm’s length and expressly approved by a majority of the disinterested directors). Without the Required Consent of the Series B Preferred Stock, the Company is prohibited from entering into, creating, assuming or guaranteeing any new indebtedness or liens of any kind. In addition, as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series B Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series B Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of the Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing. Upon any subsequent issuance by the Company or any of its subsidiaries of common stock or common stock equivalents for cash consideration, indebtedness or a combination of units thereof (a “Subsequent Financing”), holders of Series B Preferred Stock may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series B Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. Additionally, if in such Subsequent Financing there are any contractual provisions or side letters that provide terms more favorable to the investors than the terms previously provided to holders of the Series B Preferred Stock, holders of the Series B Preferred Stock shall become a part of the transaction documents, at their option. Stock Options and Warrants Stock Options The Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting period. In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2025 and 2024, there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z5ODLZuZBcyl" title="Options outstanding">1,570 and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zyPMyr1IHIUl" title="Options outstanding">1,870 outstanding stock options, respectively, under the 2020 Plan and on such dates there were <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zaYJyA4YlK8i" title="Shares reserved for future issuance">13,544 and <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zfLvjrF21sI3" title="Shares reserved for future issuance">13,244 shares reserved under the 2020 Plan, respectively, for future grant. The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December 31, 2025, and changes during the twelve-months then ended: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjMsC1hCbvuc" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">1,870</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZfF2bOLHLCe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, outstanding, beginning">1,948.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zjijGoaODWy8" title="Range of exercise price, options outstanding, beginning">256.80 — $<span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zNhBmwlC962e" title="Range of exercise price, options outstanding, beginning">2,565.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaQqUZUUeQ84" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning Balance">5.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4m2GdajHVt7" style="text-align: right" title="Number of shares, options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zdbjuQNuVPkg" style="text-align: right" title="Weighted Average Exercise Price, options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zay6F9gWIXZb" style="text-align: right" title="Number of shares, options expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFqRmjiMrfna" style="text-align: right" title="Weighted Average Exercise Price, options expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIn3wZNMMAT6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options forfeited">(300</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z62UQWnDopw8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, options forfeited">1,527.27</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMMqTGZsIsj5" title="Range of exercise price, options forfeited">256.80 — $<span id="xdx_902_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zRBxrgdjgqBj" title="Range of exercise price, options forfeited">2,565.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31 , 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zdWNB2TUNLAf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options outstanding, ending">1,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zT0CV4dP2tt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">2,028.88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhQ6da7CYWZ7" title="Range of exercise price, options outstanding, ending">256.80 — $<span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zO7bYdotAobk" title="Range of exercise price, options outstanding, ending">2,485.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zEjaxDz187jl" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending Balance">4.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLyyzIU7fXc2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">1,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zUk5KaZRkage" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, options exercisable (vested)">2,028.88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zedsFp2LFSo3" title="Range of exercise price, options exercisable (vested)">256.80 — $<span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zTDTldJvFaW3" title="Range of exercise price, options exercisable (vested)">2,485.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zykClaz4Yq69" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">4.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRmL7zUdFWH7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zi2PaGTq1cR" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zX4N6ZioZaQ" title="Range of exercise price, options non-exercisable (non-vested)">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December 31, 2024, and changes during the twelve months then ended: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted–</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Weighted–</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Range of</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Remaining</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Life (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7AkDk5yQdZi" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">7,978</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjwwTqdrwQej" style="width: 12%; text-align: right" title="Weighted average exercise price, beginning">1,760.26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zypkmyeNYCae" title="Range of exercise price, options outstanding, beginning">256.80 — $<span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zXb0qa0F9uzc" title="Range of exercise price, options outstanding, beginning">2,565.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1AONZzaRJ97" title="Weighted average remaining life (Years)">7.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNCi0gVLtwB" style="text-align: right" title="Number of shares, options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNFAMGOUhsX4" style="text-align: right" title="Weighted average exercise price, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zOHISPgbl52b" style="text-align: right" title="Number of shares, options expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zguR0yPvaM89" style="text-align: right" title="Weighted average exercise price, expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zQ87xseZwwSh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options forfeited">(6,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z6PvmzRBQjfj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">1,703.64</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmxLDXak73el" title="Range of exercise price, options forfeited">256.80 — $<span id="xdx_904_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zYliAnKMigG8" title="Range of exercise price, options forfeited">2,565.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaXTeES7ZLZa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options outstanding, ending">1,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zEPFv7FfvE84" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending">1,948.41</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zUQng2WXJPzl" title="Range of exercise price, options outstanding, ending">256.80 — $<span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zCOGveJDI6b" title="Range of exercise price, options outstanding, ending">2,565.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbOjJs7aUAo1" title="Weighted average remaining life (Years)">5.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkJrmYEk4Zdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zoqvWgq0yKrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options exercisable (vested)">2,085.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z9JdrCoR3Flk" title="Range of exercise price, options exercisable (vested)">256.80 — $<span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEGCLmPvvlp6" title="Range of exercise price, options exercisable (vested)">2,565.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIrh6CDceF55" title="Weighted average remaining life (Years), exercisable (vested)">5.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z16zRHCVd28l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">156</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znTAGeynS7Rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">442.02</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zYeF86pRHLXl" title="Range of exercise price, options non-exercisable (non-vested)">256.80 — $<span id="xdx_90C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKRvm7lySKpl" title="Range of exercise price, options non-exercisable (non-vested)">620.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpBzBh7OTWc8" title="Weighted average remaining life (Years), Non-exercisable (non-vested)">7.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There were $269 and $128,059 of compensation costs related to outstanding options for the years ended December 31, 2025 and 2024, respectively. In the year ended December 31, 2025, $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zDTuCXs1KB37" title="Compensation cost">269 was classified under general and administrative expense and <span id="xdx_906_eus-gaap--ShareBasedCompensation_dn_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zD63hIx8706f" title="Compensation cost">none was recorded under research and development expense. In the year ended December 31, 2024, $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zvAeLp2ygPWd" title="Compensation cost">103,378 was classified under general and administrative expense and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zy9wg4DQWcni" title="Compensation cost">24,681 was recorded under research and development expense. As of December 31, 2025, there was <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIWwH6aJAhE2" title="Unrecognized compensation cost related to unvested stock-based compensation arrangements">no unrecognized compensation cost related to unvested stock-based compensation arrangements. The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a ten-year period. A forfeiture is recognized as incurred if the option holder does not exercise after 90 days following termination of service. No stock options were granted or exercised during the years ended December 31, 2025 and 2024. Fair Value of Equity Awards The Company utilizes the Black-Scholes option pricing model to value awards under its equity plans. Key valuation assumptions include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected dividend yield. The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected stock-price volatility. The Company’s expected volatility is derived from the average historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term, because the Company does not have sufficient stock price history over the expected term.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</td></tr> </table> Equity Classified Compensatory Warrants As part of the May 2020 reverse recapitalization transaction, the Company issued equity classified compensatory common stock warrants to an advisor and its designees. In addition, various service providers hold equity classified compensatory common stock warrants issued in 2017 and earlier (originally exercisable to purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock). These are to be differentiated from the Series C Warrants described in Note 9- Warrant Liabilities. As of December 31, 2025, warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXSJYOxzovdg" title="Warrants to purchase common stock">160 shares of the Company’s common stock remain outstanding. On February 27, 2024, as a result of a down-round provision triggered by a Securities Purchase Agreement with Alpha for the purchase of the February 2024 Debenture, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240227__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlOiLrTfxi1k" title="Purchase of warrants">1,353 warrants were repriced from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8Rrbz2jQTmi" title="Class of warrant or right, exercise price per share">36.50 per share exercise price to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240226__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOUFiWyMs4v4" title="Class of warrant or right, exercise">13.50 per share exercise price. The increase in fair value of $9,737 for the modification of these warrants was charged to general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. On September 6, 2024 as a result of a down-round provision triggered by shares sold in the public offering, these <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z98CJIsOBHeg" title="Purchase of warrants">1,353 warrants were repriced again from $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEgs3eOAKTe4" title="Class of warrant or right, exercise price per share">13.50 per share exercise price to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHTPrsqBYntf" title="Class of warrant or right, exercise">6.50 per share exercise price. These warrants were reclassified to warrant liabilities during the year ended December 31, 2024 and expired during the year ended December 31, 2025 (See Note 9 – Warrant Liabilities) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_do_c20250101__20251231_zDaGLjlPwBic" title="Number of shares, warrants granted"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_do_c20240101__20241231_zb3CvcbETjOb" title="Number of shares, warrants granted">No new compensatory warrants were issued during the years ended December 31, 2025 or 2024. <p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z56cdIx7GOQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2025: SCHEDULE OF COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted–Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpk6l7L0Fnt2" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQP2Dh23qXCa" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zLiwQ2GfeyIc" title="Range of exercise price - beginning">1,270.25 — $<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zYQN5k4FrEj9" title="Range of exercise price - beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zjXjnppQoEUb" title="Weighted Average Remaining Life (Years) - outstanding">0.69</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKEKvO0G5EI2" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmzGdLvHGoWc" style="text-align: right" title="Weighted average exercise price per share warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zgxYfB5MZixb" style="text-align: right" title="Number of Shares, Warrants Expired">(349</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQYYqetVGezg" style="text-align: right" title="Weighted average exercise price per share warrants expired">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePriceExpired_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zeNfNhtnqi29" title="Range of exercise price, expired">1,270.25 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExpired_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z7rPkGp1cfE4" title="Range of exercise price, expired">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdD2mFg5kYWe" style="text-align: right" title="Number of Shares, Warrants Reclassified to liabilities">(1,353</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvBgoQUhoxd" style="text-align: right" title="Weighted average exercise price per share warrants reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zjKH2FMGp2F4" title="Range of exercise price, reclassified to liabilities">6.50 — $<span id="xdx_906_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zinrttgZrJD1" title="Range of exercise price, reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Forfeited</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9kXYcEcg6Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zy4EofMAVcx8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share warrants forfeited">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zBUBGYWKrKq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zeMzfDdKmaal" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zWnnOSMSwlo7" title="Range of exercise price - ending">1,270.25— $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zvbR525ZTHMk" title="Range of exercise price - ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqPwX23rfRfg" title="Weighted Average Remaining Life (Years) - outstanding">0.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zgHBwArE4aG5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zPHNXflyUxll" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zY2c33tAEHN6" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zJWCjD4tRZXa" title="Range of exercise price, exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdWzQ0Gb9i8b" title="Weighted Average Remaining Life (Years) Exercisable">0.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJtcyrAqJEni" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrlxy2YuTVr" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zeEDKBsA4sxi" title="Range of Exercise Price, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted–Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMSgLVgKf01h" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">2,381</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zkOp9fwhrsre" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">534.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">$<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zNQo9i7GasX9" title="Range of exercise price - beginning">66.00 — $<span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zohEhv0AhdNj" title="Range of Exercise Price, Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyCZtVUvPQxj" title="Weighted Average Remaining Life (Years) - outstanding">1.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zPWoRg2ORAo4" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zkqgEZBJsJel" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7a6fKzGEez2" style="text-align: right" title="Number of Shares, Warrants Expired">(519</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5Ldoi2NlSci" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Expired">1,033.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90C_ecustom--RangeOfExercisePriceExpired_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zXGs0BrIB693" title="Range of Exercise Price, Expired">1,033.15 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zGE5IXXrsWIi" title="Range of Exercise Price, Expired">1,033.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zK8qBpU503y4" style="text-align: right" title="Number of Shares, Warrants Reclassified to liabilities">(1,353</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvC1PgXZckVk" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_909_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zzheyEAqXQFl" title="Range of exercise price, reclassified to liabilities">6.50 — $<span id="xdx_900_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zOlE3rWgRcT" title="Range of Exercise Price, Reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRGoC2Nzsohb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRDBvN0KXq5j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxofwW1bXFKi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">509</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6m4A6Cy8L4d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_900_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zUYjK8eLSd3b" title="Range of exercise price - ending">1,270.25 — $<span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zngYCzr5N8Pj" title="Range of Exercise Price, Ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAoQDZeoRtZg" title="Weighted Average Remaining Life (Years) - outstanding">0.69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAM3ymlgppid" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">509</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zeKzIaHb29mk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z6vFwp2Lv1Wl" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zMfwlpUmFiSl" title="Range of Exercise Price, Exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zXwBPbtDt5C8" title="Weighted Average Remaining Life (Years) Exercisable">0.69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfTh8Odkv8Pg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4PE3hI2XPXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zhfvPI3U3Mqh" title="Range of Exercise Price, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There were noncompensation costs related to outstanding warrants for the year ended December 31, 2025 and approximately $12,000 for the year ended December 31, 2024. As of December 31, 2025 and 2024, there was <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zlAHfYG83Kj4" title="Unrecognized compensation cost"><span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zYMvqrvikPBl" title="Unrecognized compensation cost">no unrecognized compensation cost related to nonvested warrants. Noncompensatory Equity Classified Warrants On December 22, 2022, in conjunction with the issuance of a debenture to Alpha (see Note 10 – Convertible Debt), the Company issued to Alpha a warrant to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zZK9W9zP4JUj" title="Warrant to purchase shares">50,000 shares of the Company’s common stock. The exercise price of this warrant was initially $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zRBHzivLWiLc" title="Exercise price of warrant">82.50, and may be exercised in whole or in part, on or after June 22, 2023 and at any time before June 22, 2028. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to the related Securities Purchase Agreement, with Alpha. This Amendment reduced the Exercise Price of the December 22, 2022 warrant from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zJnO2eTPtWSf" title="Exercise price of warrant">82.50 per share to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zHj0g8TBatW" title="Exercise price of warrant">36.50 per share. The Amendment also revised certain provisions of the warrant which resulted in reclassification of the warrant from liabilities to equity during the year ended December 31, 2023. During the year ended December 31, 2024 this warrant was partially exercised for <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zeTUnoAL3Kac" title="Warrant exercised">31,998 shares, and as of December 31, 2025 warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_znFnHECovyPj" title="Warrant to purchase shares of common stock">18,002 shares of the Company’s common stock remain outstanding. On February 27, 2024 the Company entered into a new Securities Purchase Agreement with Alpha for the purchase of the February 2024 Debenture (see Note 10 – Convertible Debt). This Securities Purchase Agreement resulted in the reduction of the exercise price of the December 22, 2022 warrant and the May 2020 warrant from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zSFwtmfmxtJ5" title="Exercise price of warrant">36.50 per share to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_ziqbrKQiPAQl" title="Exercise price of warrant">13.00 per share. The company recognized a deemed dividend of $60,017, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the consolidated statements of changes in stockholders’ equity. In addition, on February 27, 2024, the Company issued to Alpha a warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zca8JlMlJKJg" title="Warrant to purchase shares of common stock">18,001 shares of the Company’s common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zQ0mLrmoPIRg" title="Exercise price of warrant">13.00 per share, which may be exercised in whole or in part, at any time before February 27, 2029. On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zWwPRcQxKitf" title="Exercise price of warrant">13.00 per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zTgtVaNwCgbf" title="Exercise price of warrant">6.50 per share exercise price. The company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the consolidated statements of changes in stockholders’ equity. On April 12, 2024, in connection with the issuance of a convertible debenture to Chen (see Note 10 – Convertible Debt), the Company issued a liability classified warrant to Chen to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_zMva5zqJOyPe" title="Warrant to purchase shares">36,001 shares of common stock, exercisable until February 27, 2029. On September 6, 2024, as a result of a down-round provision triggered by shares sold in a public offering, the warrant was repriced from an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zQrFhfgNt2R1" title="Exercise price of warrant">13.00 per share to an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zXD7ut6hCnMj" title="Exercise price of warrant">6.50 per share. The warrant was initially liability classified due to an insufficient number of authorized shares to settle the warrant prior to the receipt of shareholder approval, which was subsequently obtained on October 25, 2024. As of that date, the Company determined that shareholder approval resulted in equity classification for the warrant and accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants. On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z5cGyf022Ze8" title="Exercise price of warrant">13.00 per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zpW9tyVmC7va" title="Exercise price of warrant">6.50 per share exercise price. The company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital. As a result of a partial voluntary conversion of the 2024 Alpha Debenture on September 9, 2024, the Company no longer had sufficient shares to settle the 2024 Alpha Warrant in full until shareholder approval was obtained, and a portion (2,314 warrant shares with a fair value of $14,997) was reclassified to liabilities (see Note 9 – Warrant Liabilities). Shareholder approval was subsequently obtained on October 25, 2024, and as of that date, the Company determined that shareholder approval resulted in equity classification for the warrant again and, accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants. On September 6, 2024, upon the closing of a public offering, the Company issued pre-funded warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240906__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z7FufEkSlNv4" title="Warrant to purchase shares of common stock">239,456 common shares at a price of $6.45 per share with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zu197X8UgRXj" title="Warrant exercise price">0.05 per share (the “pre-funded warrants”). The pre-funded warrants are exercisable upon issuance and will remain exercisable until all the pre-funded warrants are exercised in full. Pre-funded warrants for <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zXgaMr4ehZu" title="Warrants exercised">188,257 common shares were exercised during the year ended December 31, 2024. At December 31, 2025 pre-funded warrants for 51,199 common shares remained outstanding. On September 6, 2024, upon the closing of a public offering, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240906__20240906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqcNDpXJE3Ij" title="Number of warrants issued">16,019 warrants were issued to the placement agent. These warrants were not exercisable until March 5, 2025 and expire on September 6, 2029. On November 20, 2024, the Company closed its private placement transaction resulting in the issuance of newly designated Series A-2 Preferred Stock. As a result of the issuance of a new class of voting securities, the Company evaluated its equity classified compensatory warrants’ respective terms, and concluded that compensatory warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241120__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5WOP9ndGFwi" title="Warrants reclassified to liabilities">1,353 common shares with a weighted average exercise price of $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20241120__20241120__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zV9gkWurlZ1e" title="Weighted average exercise price per share warrants reclassified to liabilities">6.50 and a fair value of $<span id="xdx_900_ecustom--FairValueOfWarrantsReclassifiedToLiabilitiesFromEquity_c20241120__20241120__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIu42QzUgaM1" title="Fair value of warrants reclassified to liabilities from equity">904 were required to be reclassified to liabilities as of November 20, 2024. On April 28, 2025 as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note (see Note 10 - Convertible Debt), warrants for <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250428__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zdnoLKaZErKf" title="Warrant to purchase shares">54,002 common shares were repriced from $6.50 per share exercise price to $5.82 per share exercise price. The company recognized a deemed dividend of $1,586, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the consolidated statements of changes in stockholders’ equity. As discussed above, on September 29, 2025, <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250929__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zlUgvVkZ99gj" title="Warrant to purchase shares of common stock">1,087,266 Placement Agent Warrants were issued. The Placement Agent Warrants were immediately exercisable and have an initial exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250929__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_z2ZuK7gx39hh" title="Exercise price">2.47 per share. At December 31, 2025, 1,087,266 Placement Agent Warrants remain outstanding. <p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zJzlmiDwWP24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2025: SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zIsQc1N1nUi1" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">72,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHHPM1l5sMb4" style="width: 12%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">6.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zgOSrtSKe2b3" title="Range of exercise price">6.50 — $<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zFJ0aFChnoq4" title="Range of exercise price">6.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAXqTFLkWcSa" title="Weighted average remaining life (Years) exercisable">3.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHmDrgmMNAdl" style="text-align: right" title="Number of shares, warrants outstanding granted">1,087,266</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBRxgV5ns9De" style="text-align: right" title="Weighted average exercise price, warrants granted">2.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zq05PJopcln8" title="Range of exercise price warrant, granted">2.47 — $<span id="xdx_908_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zmVgBRIWPOFi" title="Range of exercise price warrant, granted">2.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragGrantedRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcupYIGsxIJk" title="Weighted average remaining life (Years), warrants, granted">5.00</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgDy7gUD95f4" style="text-align: right" title="Number of shares, warrants outstanding prefunded investor warrants issued">239,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlpFU6E9VTUg" style="text-align: right" title="Weighted average exercise price, warrants prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z9rLZCvWZtp9" title="Range of exercise price, granted prefunded prefunded investor warrants issued">0.05 — $<span id="xdx_904_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zymxquDp8U1k" title="Range of exercise price, granted prefunded prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercised_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4lkHi2AAZPf" style="text-align: right" title="Number of shares, warrants outstanding prefunded investor warrants exercised">(188,257</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJjt8bZSl3Kd" style="text-align: right" title="Weighted average exercise price, warrants prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfHzgUMxMG8d" title="Range of exercise price, granted prefunded prefunded investor warrants exercised">0.05 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zAqe8GlJZK5f" title="Range of exercise price, granted prefunded prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zqJs9gvpJVxc" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfO2wCl85G7b" style="text-align: right" title="Weighted average exercise price, warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsqWGGZhnX83" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_ziRXxkeMLEz7" style="text-align: right" title="Number of shares, warrants outstanding reclassified to liabilities">(69,672</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNeiuRnYFIu6" style="text-align: right" title="Weighted average exercise price, warrants reclassified to liabilities">2.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z09NeVeBv3k4" title="Range of exercise price, reclassified to liabilities">0.05 — $<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zgZVOp9OZsMj" title="Range of exercise price, reclassified to liabilities">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified from liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFPD4VzfvIPl" style="text-align: right" title="Number of shares, warrants outstanding reclassified from liabilities">38,315</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbtZ8gtUFD8j" style="text-align: right" title="Weighted average exercise price, warrants reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zYX7VtQg6Ls" title="Range of exercise price, reclassified from liabilities">6.50 — $<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zzwgs0WekdQc" title="Range of exercise price, reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOQvQnNzcXFi" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zz9wydJBerYl" style="text-align: right" title="Weighted average exercise price, warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9r6tw3fVz5i" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTa92960ko5c" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuSebTBlDG3h" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zLdFdreSsJu5" title="Range of Exercise Price, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQEfclb3H7D7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">1,159,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJ2fNZ960Vzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">2.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zDJUDO1lueJ1" title="Range of exercise price">2.47 — $<span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zbeDuhsk4plc" title="Range of exercise price">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdletDHHPiW2" title="Weighted average remaining life (Years) exercisable">4.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbcg8487u5y6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,159,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zavLLuVgKNf1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zktdfnTGgx1a" title="Range of exercise price, exercisable">2.47 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z2fBY36Ttjz8" title="Range of exercise price, exercisable">6.50 </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAPZYV9ieUug" title="Weighted average remaining life (Years) exercisable">4.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuENdPCVui4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQ92YLHk4Z91" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLsg4COHeOYi" title="Range of exercise price, Non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMpuO8gLvHH1" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">50,141</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zklROlSTQCe7" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zHGGUukEARfa" title="Range of exercise price">36.50 — $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zQCehCTC84ug" title="Range of Exercise Price, Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbi96xZaUxj7" title="Weighted Average Remaining Life (Years) - outstanding">4.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvmnHeYq44N2" style="text-align: right" title="Number of Shares, Warrants, Granted">34,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNevOkapqJ05" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Granted">7.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zwcpPmlYmZ5a" title="Range of exercise price, granted">6.50 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zKKSJJRwIrw6" title="Range of Exercise Price, Granted">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragGrantedRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmQ30mWsdSea" title="Weighted Average Remaining Life (Years) - outstanding, Granted">4.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zIJICsKSpbx4" style="text-align: right" title="Number of Shares, Warrants, Prefunded investor warrants issued">239,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzeKneKObxHb" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zRUwrfAXG27b" title="Range of exercise price, granted prefunded prefunded investor warrants issued">0.05 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zr4R9TOpuDB" title="Range of Exercise Price, Prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercised_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zX88MI0OrWY" style="text-align: right" title="Number of Shares, Warrants, Prefunded investor warrants exercised">(188,257</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlETvw6JFF19" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zC5TxEgF0oS1" title="Range of exercise price, granted prefunded prefunded investor warrants exercised">0.05 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zRazm6UFc7y6" title="Range of Exercise Price, Prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTdLuX0m7urj" style="text-align: right" title="Number of Shares, Warrants Exercised">(31,998</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z1ElasoQyVq7" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Exercised">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zvGDDh4lTSjl" title="Range of Exercise Price, Exercised">13.00 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zbGrVhS99Z8" title="Range of Exercise Price, Exercised">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgaul0qV6qnl" style="text-align: right" title="Number of Shares, Warrants, Reclassified to liabilities">(69,672</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUqZZtr2JjR1" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Reclassified to liabilities">2.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4wAzV0xDNj3" title="Range of exercise price, reclassified to liabilities">0.05 — $<span id="xdx_903_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z9sVrJvTUtFc" title="Range of Exercise Price, Reclassified to liabilities">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified from liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzgif4SpjqB6" style="text-align: right" title="Number of Shares, Warrants, Reclassified from liabilities">38,315</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5TMbSOqRmXb" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z79uoi314Pdf" title="Range of exercise price, reclassified from liabilities">6.50 — $<span id="xdx_908_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_znrnAdZ3ahi" title="Range of Exercise Price, Reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFDUkzbrkrJj" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCxrkrSuEiCd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9fK9o6zG1Q4" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zme1ZuXx8NYe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvBxdQHX45Pg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zCIDIv16rvU6" title="Range of Exercise Price, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGw5miEbWEFj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">72,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL2mjnb5SDo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z77iIWWS3Vk8" title="Range of exercise price">6.50 — $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zrelPhRwXbe8" title="Range of Exercise Price, Ending">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zeAjmJMxr9Xd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">72,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zYQsxyZjlVWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Exercisable">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zIFGCTcqXJua" title="Range of exercise price, exercisable">6.50 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zXOr4RicetC3" title="Range of Exercise Price, Exercisable">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvmygaYd5ing" title="Weighted Average Remaining Life (Years) - Exercisable">3.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUgD86U7GuR5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGzil46doEsb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdTZ1gMEvX8e" title="Range of Exercise Price, Non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

19350388

SCHEDULE OF RESERVED SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49E_20251231_zOpA3C8T3yml" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3y3S6PatG0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">13,544</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zH7hXa5a4EJd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of Series A-2 preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">267,364</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_z0i7BCrKtTsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of Series B preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,784,061</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--ConvertibleDebtMember_z0zae8epRJ41" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8a7N5deZ9G1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercise of stock warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,226,648</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zfZ5ss3RaWE8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,350,388</td><td style="text-align: left"> </td></tr> </table>

13544

267364

17784061

58771

1226648

19350388

337432

100000

2.246

800000

60257

300000

1087266

2.47

1087266

10000000.0

15000000

10000

500000

39943

1000

39900000

4500

0.001

1000

4500000

200000

4300000

5102

0.001

1000

5100000

1154

1150000

6256

1718681

3.64

5656

4500

3926263

3.64

2.246

SCHEDULE OF OUTSTANDING PREFERRED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Authorized Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Conversion Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Equivalent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Series A-2</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_z6HBvvruegof" style="width: 11%; text-align: right" title="Preferred stock, shares authorized">10,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_z5B7NalPe1jh" style="width: 11%; text-align: right" title="Preferred stock, shares outstanding">601</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zzKFYMkcnpKd" style="width: 11%; text-align: right" title="Preferred stock, conversion price">2.246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zPNmszHr3Daj" style="width: 11%; text-align: right" title="Preferred stock, common stock equivalent">267,364</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zOyLVTX2Qlc8" style="text-align: right" title="Preferred stock, shares authorized">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_z5USV7le3u8a" style="text-align: right" title="Preferred stock, shares outstanding">39,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zgYMEqkfNE7c" style="text-align: right" title="Preferred stock, conversion price">2.246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zjrOGeLeoRhe" style="text-align: right" title="Preferred stock, common stock equivalent">17,784,061</td><td style="text-align: left"> </td></tr> </table>

10000

601

2.246

267364

500000

39943

2.246

17784061

1000

3.64

2.80

2.246

1.82 1.40

1.00

1570

1870

13544

13244

The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December 31, 2025, and changes during the twelve-months then ended: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjMsC1hCbvuc" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">1,870</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZfF2bOLHLCe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, outstanding, beginning">1,948.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zjijGoaODWy8" title="Range of exercise price, options outstanding, beginning">256.80 — $<span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zNhBmwlC962e" title="Range of exercise price, options outstanding, beginning">2,565.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaQqUZUUeQ84" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning Balance">5.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4m2GdajHVt7" style="text-align: right" title="Number of shares, options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zdbjuQNuVPkg" style="text-align: right" title="Weighted Average Exercise Price, options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zay6F9gWIXZb" style="text-align: right" title="Number of shares, options expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zFqRmjiMrfna" style="text-align: right" title="Weighted Average Exercise Price, options expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIn3wZNMMAT6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options forfeited">(300</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z62UQWnDopw8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, options forfeited">1,527.27</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMMqTGZsIsj5" title="Range of exercise price, options forfeited">256.80 — $<span id="xdx_902_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zRBxrgdjgqBj" title="Range of exercise price, options forfeited">2,565.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31 , 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zdWNB2TUNLAf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options outstanding, ending">1,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zT0CV4dP2tt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">2,028.88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zhQ6da7CYWZ7" title="Range of exercise price, options outstanding, ending">256.80 — $<span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zO7bYdotAobk" title="Range of exercise price, options outstanding, ending">2,485.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zEjaxDz187jl" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending Balance">4.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLyyzIU7fXc2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">1,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zUk5KaZRkage" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, options exercisable (vested)">2,028.88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zedsFp2LFSo3" title="Range of exercise price, options exercisable (vested)">256.80 — $<span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zTDTldJvFaW3" title="Range of exercise price, options exercisable (vested)">2,485.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zykClaz4Yq69" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">4.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zRmL7zUdFWH7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zi2PaGTq1cR" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zX4N6ZioZaQ" title="Range of exercise price, options non-exercisable (non-vested)">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December 31, 2024, and changes during the twelve months then ended: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted–</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Weighted–</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Range of</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Average</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Remaining</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Life (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z7AkDk5yQdZi" style="width: 12%; text-align: right" title="Number of shares, options outstanding, beginning">7,978</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjwwTqdrwQej" style="width: 12%; text-align: right" title="Weighted average exercise price, beginning">1,760.26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zypkmyeNYCae" title="Range of exercise price, options outstanding, beginning">256.80 — $<span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zXb0qa0F9uzc" title="Range of exercise price, options outstanding, beginning">2,565.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1AONZzaRJ97" title="Weighted average remaining life (Years)">7.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNCi0gVLtwB" style="text-align: right" title="Number of shares, options granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNFAMGOUhsX4" style="text-align: right" title="Weighted average exercise price, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zOHISPgbl52b" style="text-align: right" title="Number of shares, options expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zguR0yPvaM89" style="text-align: right" title="Weighted average exercise price, expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zQ87xseZwwSh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options forfeited">(6,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z6PvmzRBQjfj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">1,703.64</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmxLDXak73el" title="Range of exercise price, options forfeited">256.80 — $<span id="xdx_904_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeForfeitedOptionsWeightedAverageExercisePrice1_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zYliAnKMigG8" title="Range of exercise price, options forfeited">2,565.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaXTeES7ZLZa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options outstanding, ending">1,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zEPFv7FfvE84" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending">1,948.41</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zUQng2WXJPzl" title="Range of exercise price, options outstanding, ending">256.80 — $<span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zCOGveJDI6b" title="Range of exercise price, options outstanding, ending">2,565.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbOjJs7aUAo1" title="Weighted average remaining life (Years)">5.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Exercisable (vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkJrmYEk4Zdj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">1,714</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zoqvWgq0yKrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options exercisable (vested)">2,085.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z9JdrCoR3Flk" title="Range of exercise price, options exercisable (vested)">256.80 — $<span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEGCLmPvvlp6" title="Range of exercise price, options exercisable (vested)">2,565.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIrh6CDceF55" title="Weighted average remaining life (Years), exercisable (vested)">5.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z16zRHCVd28l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">156</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znTAGeynS7Rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">442.02</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zYeF86pRHLXl" title="Range of exercise price, options non-exercisable (non-vested)">256.80 — $<span id="xdx_90C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNonExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKRvm7lySKpl" title="Range of exercise price, options non-exercisable (non-vested)">620.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpBzBh7OTWc8" title="Weighted average remaining life (Years), Non-exercisable (non-vested)">7.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1870

1948.41

256.80

2565.00

P5Y11M4D

300

1527.27

256.80 2565.00

1570

2028.88

256.80

2485.00

P4Y10M9D

1570

2028.88

256.80

2485.00

P4Y10M9D

7978

1760.26

256.80

2565.00

P7Y21D

6108

1703.64

256.80 2565.00

1870

1948.41

256.80

2565.00

P5Y11M4D

1714

2085.52

256.80

2565.00

P5Y9M21D

156

442.02

256.80 620.00 P7Y2M26D

269

128059

269

103378

24681

160

1353

36.50

13.50

9737

1353

13.50

6.50

<p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z56cdIx7GOQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2025: SCHEDULE OF COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted–Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zpk6l7L0Fnt2" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQP2Dh23qXCa" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zLiwQ2GfeyIc" title="Range of exercise price - beginning">1,270.25 — $<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zYQN5k4FrEj9" title="Range of exercise price - beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zjXjnppQoEUb" title="Weighted Average Remaining Life (Years) - outstanding">0.69</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKEKvO0G5EI2" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmzGdLvHGoWc" style="text-align: right" title="Weighted average exercise price per share warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zgxYfB5MZixb" style="text-align: right" title="Number of Shares, Warrants Expired">(349</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQYYqetVGezg" style="text-align: right" title="Weighted average exercise price per share warrants expired">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePriceExpired_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zeNfNhtnqi29" title="Range of exercise price, expired">1,270.25 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExpired_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z7rPkGp1cfE4" title="Range of exercise price, expired">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdD2mFg5kYWe" style="text-align: right" title="Number of Shares, Warrants Reclassified to liabilities">(1,353</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvBgoQUhoxd" style="text-align: right" title="Weighted average exercise price per share warrants reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zjKH2FMGp2F4" title="Range of exercise price, reclassified to liabilities">6.50 — $<span id="xdx_906_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zinrttgZrJD1" title="Range of exercise price, reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Forfeited</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9kXYcEcg6Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zy4EofMAVcx8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share warrants forfeited">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zBUBGYWKrKq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zeMzfDdKmaal" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zWnnOSMSwlo7" title="Range of exercise price - ending">1,270.25— $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zvbR525ZTHMk" title="Range of exercise price - ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqPwX23rfRfg" title="Weighted Average Remaining Life (Years) - outstanding">0.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zgHBwArE4aG5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zPHNXflyUxll" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zY2c33tAEHN6" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zJWCjD4tRZXa" title="Range of exercise price, exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdWzQ0Gb9i8b" title="Weighted Average Remaining Life (Years) Exercisable">0.81</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJtcyrAqJEni" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrlxy2YuTVr" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zeEDKBsA4sxi" title="Range of Exercise Price, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted–Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMSgLVgKf01h" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">2,381</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zkOp9fwhrsre" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">534.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">$<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zNQo9i7GasX9" title="Range of exercise price - beginning">66.00 — $<span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zohEhv0AhdNj" title="Range of Exercise Price, Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyCZtVUvPQxj" title="Weighted Average Remaining Life (Years) - outstanding">1.25</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zPWoRg2ORAo4" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zkqgEZBJsJel" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7a6fKzGEez2" style="text-align: right" title="Number of Shares, Warrants Expired">(519</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5Ldoi2NlSci" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Expired">1,033.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90C_ecustom--RangeOfExercisePriceExpired_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zXGs0BrIB693" title="Range of Exercise Price, Expired">1,033.15 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zGE5IXXrsWIi" title="Range of Exercise Price, Expired">1,033.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zK8qBpU503y4" style="text-align: right" title="Number of Shares, Warrants Reclassified to liabilities">(1,353</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvC1PgXZckVk" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_909_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zzheyEAqXQFl" title="Range of exercise price, reclassified to liabilities">6.50 — $<span id="xdx_900_ecustom--RangeOfExercisesPriceExercisableReclassifiedToLiabilities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zOlE3rWgRcT" title="Range of Exercise Price, Reclassified to liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRGoC2Nzsohb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRDBvN0KXq5j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxofwW1bXFKi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">509</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6m4A6Cy8L4d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_900_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zUYjK8eLSd3b" title="Range of exercise price - ending">1,270.25 — $<span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zngYCzr5N8Pj" title="Range of Exercise Price, Ending">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAoQDZeoRtZg" title="Weighted Average Remaining Life (Years) - outstanding">0.69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAM3ymlgppid" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">509</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zeKzIaHb29mk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z6vFwp2Lv1Wl" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zMfwlpUmFiSl" title="Range of Exercise Price, Exercisable">1,270.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zXwBPbtDt5C8" title="Weighted Average Remaining Life (Years) Exercisable">0.69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfTh8Odkv8Pg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4PE3hI2XPXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zhfvPI3U3Mqh" title="Range of Exercise Price, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

509

1270.25 1270.25 1270.25 P0Y8M8D

349

1270.25 1270.25 1270.25 -1353 6.50 6.50 6.50

160

1270.25 1270.25 1270.25 P0Y9M21D 160 1270.25 1270.25 1270.25 P0Y9M21D

2381

534.44 66.00 1270.25 P1Y3M

519

1033.15 1033.15 1033.15 -1353 6.50 6.50 6.50

509

1270.25 1270.25 1270.25 P0Y8M8D 509 1270.25 1270.25 1270.25 P0Y8M8D

12000

50000

82.50

36.50

31998

18002

36.50

13.00

60017

18001

13.00

6.50

27587

36001

13.00

6.50

13.00

6.50

27587

2314

14997

239456

6.45

0.05

188257

51199

16019

1353

6.50 904

54002

6.50

5.82

1586

1087266

2.47

1087266

<p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zJzlmiDwWP24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2025: SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zIsQc1N1nUi1" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">72,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHHPM1l5sMb4" style="width: 12%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">6.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zgOSrtSKe2b3" title="Range of exercise price">6.50 — $<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zFJ0aFChnoq4" title="Range of exercise price">6.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAXqTFLkWcSa" title="Weighted average remaining life (Years) exercisable">3.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHmDrgmMNAdl" style="text-align: right" title="Number of shares, warrants outstanding granted">1,087,266</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBRxgV5ns9De" style="text-align: right" title="Weighted average exercise price, warrants granted">2.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zq05PJopcln8" title="Range of exercise price warrant, granted">2.47 — $<span id="xdx_908_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zmVgBRIWPOFi" title="Range of exercise price warrant, granted">2.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragGrantedRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcupYIGsxIJk" title="Weighted average remaining life (Years), warrants, granted">5.00</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgDy7gUD95f4" style="text-align: right" title="Number of shares, warrants outstanding prefunded investor warrants issued">239,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlpFU6E9VTUg" style="text-align: right" title="Weighted average exercise price, warrants prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z9rLZCvWZtp9" title="Range of exercise price, granted prefunded prefunded investor warrants issued">0.05 — $<span id="xdx_904_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zymxquDp8U1k" title="Range of exercise price, granted prefunded prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercised_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z4lkHi2AAZPf" style="text-align: right" title="Number of shares, warrants outstanding prefunded investor warrants exercised">(188,257</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJjt8bZSl3Kd" style="text-align: right" title="Weighted average exercise price, warrants prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfHzgUMxMG8d" title="Range of exercise price, granted prefunded prefunded investor warrants exercised">0.05 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zAqe8GlJZK5f" title="Range of exercise price, granted prefunded prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zqJs9gvpJVxc" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfO2wCl85G7b" style="text-align: right" title="Weighted average exercise price, warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zsqWGGZhnX83" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_ziRXxkeMLEz7" style="text-align: right" title="Number of shares, warrants outstanding reclassified to liabilities">(69,672</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNeiuRnYFIu6" style="text-align: right" title="Weighted average exercise price, warrants reclassified to liabilities">2.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z09NeVeBv3k4" title="Range of exercise price, reclassified to liabilities">0.05 — $<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zgZVOp9OZsMj" title="Range of exercise price, reclassified to liabilities">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified from liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFPD4VzfvIPl" style="text-align: right" title="Number of shares, warrants outstanding reclassified from liabilities">38,315</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbtZ8gtUFD8j" style="text-align: right" title="Weighted average exercise price, warrants reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zYX7VtQg6Ls" title="Range of exercise price, reclassified from liabilities">6.50 — $<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zzwgs0WekdQc" title="Range of exercise price, reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOQvQnNzcXFi" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zz9wydJBerYl" style="text-align: right" title="Weighted average exercise price, warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9r6tw3fVz5i" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTa92960ko5c" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuSebTBlDG3h" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zLdFdreSsJu5" title="Range of Exercise Price, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total outstanding – December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQEfclb3H7D7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">1,159,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJ2fNZ960Vzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">2.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zDJUDO1lueJ1" title="Range of exercise price">2.47 — $<span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zbeDuhsk4plc" title="Range of exercise price">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdletDHHPiW2" title="Weighted average remaining life (Years) exercisable">4.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbcg8487u5y6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,159,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zavLLuVgKNf1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zktdfnTGgx1a" title="Range of exercise price, exercisable">2.47 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z2fBY36Ttjz8" title="Range of exercise price, exercisable">6.50 </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAPZYV9ieUug" title="Weighted average remaining life (Years) exercisable">4.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTuENdPCVui4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQ92YLHk4Z91" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLsg4COHeOYi" title="Range of exercise price, Non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%">Total outstanding – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMpuO8gLvHH1" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">50,141</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zklROlSTQCe7" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zHGGUukEARfa" title="Range of exercise price">36.50 — $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zQCehCTC84ug" title="Range of Exercise Price, Beginning">36.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbi96xZaUxj7" title="Weighted Average Remaining Life (Years) - outstanding">4.47</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvmnHeYq44N2" style="text-align: right" title="Number of Shares, Warrants, Granted">34,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNevOkapqJ05" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Granted">7.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zwcpPmlYmZ5a" title="Range of exercise price, granted">6.50 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zKKSJJRwIrw6" title="Range of Exercise Price, Granted">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragGrantedRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmQ30mWsdSea" title="Weighted Average Remaining Life (Years) - outstanding, Granted">4.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssued_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zIJICsKSpbx4" style="text-align: right" title="Number of Shares, Warrants, Prefunded investor warrants issued">239,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzeKneKObxHb" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zRUwrfAXG27b" title="Range of exercise price, granted prefunded prefunded investor warrants issued">0.05 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsIssued_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zr4R9TOpuDB" title="Range of Exercise Price, Prefunded investor warrants issued">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Pre-funded investor warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercised_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zX88MI0OrWY" style="text-align: right" title="Number of Shares, Warrants, Prefunded investor warrants exercised">(188,257</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zlETvw6JFF19" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zC5TxEgF0oS1" title="Range of exercise price, granted prefunded prefunded investor warrants exercised">0.05 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceExercisablePrefundedInvestorWarrantsExercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zRazm6UFc7y6" title="Range of Exercise Price, Prefunded investor warrants exercised">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTdLuX0m7urj" style="text-align: right" title="Number of Shares, Warrants Exercised">(31,998</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z1ElasoQyVq7" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Exercised">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zvGDDh4lTSjl" title="Range of Exercise Price, Exercised">13.00 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zbGrVhS99Z8" title="Range of Exercise Price, Exercised">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reclassified to liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgaul0qV6qnl" style="text-align: right" title="Number of Shares, Warrants, Reclassified to liabilities">(69,672</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUqZZtr2JjR1" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Reclassified to liabilities">2.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4wAzV0xDNj3" title="Range of exercise price, reclassified to liabilities">0.05 — $<span id="xdx_903_ecustom--RangeOfExercisePriceExercisableReclassifiedToLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z9sVrJvTUtFc" title="Range of Exercise Price, Reclassified to liabilities">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified from liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilities_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zzgif4SpjqB6" style="text-align: right" title="Number of Shares, Warrants, Reclassified from liabilities">38,315</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromLiabilitiesInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z5TMbSOqRmXb" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z79uoi314Pdf" title="Range of exercise price, reclassified from liabilities">6.50 — $<span id="xdx_908_ecustom--RangeOfExercisePriceExercisableReclassifiedFromLiabilities_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_znrnAdZ3ahi" title="Range of Exercise Price, Reclassified from liabilities">6.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFDUkzbrkrJj" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zCxrkrSuEiCd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z9fK9o6zG1Q4" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zme1ZuXx8NYe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvBxdQHX45Pg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zCIDIv16rvU6" title="Range of Exercise Price, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding – December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGw5miEbWEFj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">72,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL2mjnb5SDo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z77iIWWS3Vk8" title="Range of exercise price">6.50 — $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zrelPhRwXbe8" title="Range of Exercise Price, Ending">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zeAjmJMxr9Xd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">72,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zYQsxyZjlVWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Exercisable">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zIFGCTcqXJua" title="Range of exercise price, exercisable">6.50 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zXOr4RicetC3" title="Range of Exercise Price, Exercisable">6.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvmygaYd5ing" title="Weighted Average Remaining Life (Years) - Exercisable">3.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUgD86U7GuR5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGzil46doEsb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants, Non-Exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdTZ1gMEvX8e" title="Range of Exercise Price, Non-exercisable">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

72004

6.50 6.50 6.50 P3Y11M26D

1087266

2.47 2.47 2.47 P5Y 239456 0.05 0.05 0.05 -188257 0.05 0.05 0.05 -69672 2.06 0.05 7.80 38315 6.50 6.50 6.50

1159270

2.72 2.47 6.50 P4Y7M20D 1159270 2.72 2.47 6.50 P4Y7M20D

50141

36.50 36.50 36.50 P4Y5M19D

34019

7.11 6.50 7.80 P4Y1M28D 239456 0.05 0.05 0.05 -188257 0.05 0.05 0.05

31998

13.00 13.00 13.00 -69672 2.06 0.05 7.80 38315 6.50 6.50 6.50

72004

6.50 6.50 6.50 72004 6.50 6.50 6.50 P3Y11M26D

NOTE 16 — RELATED PARTY TRANSACTIONS Lead Investor Agreement In connection with the Subscription Agreement, the Company and Faraday Future Intelligent Electric Inc. entered into a Lead Investor Agreement. Pursuant to this agreement, Faraday committed to invest a minimum of $30 million in a Private Placement. The material terms of the Lead Investor Agreement include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Treasury Reserve & Crypto Custody: The Company will adopt a Treasury Reserve Policy establishing cryptocurrencies as its primary ongoing treasury reserve asset.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Executive Appointments: Concurrent with the closing, Faraday appointed Jiawei Wang as Co-Chief Executive Officer and Koti Meka as Chief Financial Officer. The Faraday-appointed Co-CEO is solely responsible for all non-legacy business operations and has been granted sole access to all crypto-related accounts of the Company, subject to delegation.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Board Restructuring: The Board size was initially reduced to five members, with Faraday appointing two initial directors to fill vacancies. Following stockholder approval, the Board will expand to seven members, granting Faraday the right to appoint up to two additional directors. Faraday retains the right to proportional board representation so long as it maintains at least 5% beneficial ownership of the Company’s Common Stock.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Transitional Governance Controls: Prior to receiving stockholder approval, the Faraday-appointed Co-CEO will manage all new business affairs and holds the exclusive authority to approve and execute new agreements on behalf of the Company. Legacy business affairs continue to be managed by the current CEO.</td></tr> </table> Actual proceeds from the Lead Investor Agreement from Faraday as well as several members of Faraday’s executive management team amounted to $<span id="xdx_909_ecustom--ProceedsFromInvestor_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LeadInvestorAgreementMember__srt--TitleOfIndividualAxis__us-gaap--ExecutiveCommitteeMember_zaDGkLJjuQN5" title="Proceeds from investor">34.2 million. As part of the Lead Investor Agreement, YT Jia, the Co Chief Executive Officer of Faraday, contributed $<span id="xdx_903_ecustom--ProceedsFromInvestor_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LeadInvestorAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zPxWI8aM6khd" title="Proceeds from investor">4,000,000. As part of the Lead Investor Agreement, Jerry Wang, the President of Faraday, contributed $<span id="xdx_900_ecustom--ProceedsFromInvestor_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LeadInvestorAgreementMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zn66ugYC49N2" title="Proceeds from investor">200,000. Master Service Agreement On September 30, 2025 the Company entered into a Transition Services Agreement with Faraday to provide support and management services. During the year ended December 31, 2025 approximately $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember_ziUtIT2wJxce" title="Transition services charged">1.0 million was charged to the Company under the Transition Services Agreement, which was outstanding as of year end. This balance was classified under Related Party Payable on the consolidated balance sheet Related Party Accrued Expenses In 2025 the Company entered into verbal agreements with several members of management and consultants, including Faraday Future Global Partners (a company that shares several board members with Faraday), the Chief Executive Officer of Faraday, several board members of Faraday, members of the audit committee of the Company, the Chief Executive Officer of the Company, and the Chief Financial Officer of Faraday, to provide management consulting services. These agreements were finalized in 2026, and were made retroactive to November 1, 2025. The agreements includes services beginning in the year ended December 31, 2025 in the total amount of approximately $639,000. This amount is outstanding as of December 31, 2025 and is classified under Related Party Payable on the consolidated balance sheet. Convertible Debt On December 22, 2022, the Company issued to Alpha, an <span id="xdx_90D_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zPosZEaIDKGa" title="Interest rate">8% Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_906_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zQC7bqb4HZR1" title="Aggregate principal amount">3,300,000 for a purchase price of $<span id="xdx_900_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zCdBLRcYkm6c" title="Purchase price">3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. As of December 31, 2023, the remaining principal balance was $<span id="xdx_901_eus-gaap--SecuredDebt_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z4bL6Ge9Owng" title="Principal amount">1,418,922. During the year ended December 31, 2024, the remaining principal balance of this Debenture was converted into <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z4HGJ5nEjUEa" title="Debt conversion shares issued">103,876 shares of common stock of the Company, at a weighted average price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zjA9Ot6kQ8je" title="Conversion price">13.66 per share. On February 27, 2024, the Company issued to Alpha, an <span id="xdx_90D_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20240227__20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_z6Bb8W9ZtI5h" title="Senior convertible debenture rate">8% Convertible Debenture in the principal amount of $<span id="xdx_901_eus-gaap--SecuredDebt_iI_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_z8vgx6eB4eI8" title="Principal amount">550,000 for a purchase price of $<span id="xdx_90B_ecustom--PurchasePrice_iI_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_znIo0kXFBXLf" title="Purchase Price">500,000 less expenses pursuant to the terms of a Securities Purchase Agreement dated February 26, 2024. During the year ended December 31, 2024, a principal amount of $<span id="xdx_90B_eus-gaap--SecuredDebt_iI_c20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zrmpSdo2cDFb" title="Principal amount">50,979 of this Debenture was converted into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk1pbtwbsOse" title="Debt conversion shares issued">7,846 shares of common stock of the Company, at a weighted average price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zX9X6L10U861" title="Conversion price">6.50 per share. On November 20, 2024 the Company paid to Alpha in cash the remaining principal amount of $<span id="xdx_902_eus-gaap--SecuredDebt_iI_c20241120__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zEP6xMuP41Ei" title="Principal amount">499,021 plus outstanding accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20241120__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zre7TV9T2gd8" title="Outstanding accrued interest">31,818. On April 12, 2024, the Company issued to Chen an <span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20240412__20240412__srt--TitleOfIndividualAxis__custom--YiHuaChenMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_ziS8IKO9gc7g" title="Senior convertible debenture rate">8% Convertible Debenture with a principal amount of $<span id="xdx_908_eus-gaap--SecuredDebt_iI_c20240412__srt--TitleOfIndividualAxis__custom--YiHuaChenMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_z68tHNhfxCt9" title="Principal amount">1,100,000 for a purchase price of $<span id="xdx_900_ecustom--PurchasePrice_iI_c20240412__srt--TitleOfIndividualAxis__custom--YiHuaChenMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebentureMember_zoZY6f08zSPl" title="Purchase Price">1,000,000 less expenses pursuant to the terms of a Securities Purchase Agreement dated February 26, 2024. The Company entered into an Exchange Agreement with Yi Hua Chen on November 18, 2024, pursuant to which it issued <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20241118__20241118__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3u3snm4Uhaa" title="Shares of common stock conversion">1,154 shares of Series A-2 Preferred Stock in full settlement of the outstanding balance of the 2024 Chen Debenture of approximately $<span id="xdx_903_eus-gaap--DebtConversionOriginalDebtAmount1_pn4n6_c20241118__20241118__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourChenDebentureMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zNgT0LBmejql" title="Debt conversion amount">1.15 million (see Note 15 — Stockholders’ Equity). Note that as a result of equity issuances that occurred during the year ended December 31, 2024, Alpha went from being a material shareholder to a non-material shareholder. Any transactions with Alpha that occurred after these issuances were not considered to be related party transactions. See Note 10 – Convertible Debt for additional information concerning convertible debt – related party transactions. Warrants On May 22, 2020, as a commitment fee, the Company issued warrants to Alpha for the purchase of common stock. As of December 31, 2024, 141 of these warrants remained outstanding and exercisable, and were able to be exercised in whole or in part, at any time before May 22, 2025. These warrants expired, and as of December 31, 2025, none of these warrants remain outstanding and exercisable. During years ended December 31, 2025 and 2024 there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpVjRg1vmiYc" title="Number of warrant exercised"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3AC1kHOttNg" title="Number of warrant exercised">no exercises of this warrant. This warrant was equity classified as of December 31, 2023 and was reclassified to warrant liabilities during the year ended December 31, 2024 (see Note 9 - Warrant Liabilities). On December 22, 2022, in conjunction with the issuance of a debenture to Alpha, the Company issued to Alpha a warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z4af9UV6Iifk" title="Warrant to purchase shares">50,000 shares of the Company’s common stock. This warrant may be exercised by Alpha, in whole or in part, on or after June 22, 2023 and at any time before June 22, 2028, subject to certain terms and conditions described in the warrant. During the year ended December 31, 2024, Alpha partially exercised this warrant to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zrpRcPGpOJTe" title="Warrant exercised">31,998 shares respectively, of the Company’s common stock at a weighted average exercise price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zW2pwuSoiuLh" title="Weighted average exercise price">13.00, for total cumulative proceeds to the Company of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zrzoSUOWFH3d" title="Cumulative proceeds from issuance of warrants">416,000. During the year ended December 31, 2025, there were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20251231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zDADuR4kG0Td" title="Warrant exercised">no exercises of this warrant. This warrant is included in equity on the Company’s consolidated balance sheets (see Note 15 – Stockholders’ Equity ). On February 27, 2024, in conjunction with the issuance of a debenture to Alpha, the Company issued to Alpha, a warrant to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240227__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zR8mlw6Pyz5a" title="Warrant to purchase shares of common stock">18,001 shares of the Company’s common stock , exercisable in whole or in part, until February 27, 2029, subject to certain terms and conditions described in the warrant. This warrant is presented on the balance sheet as an equity classified warrant. On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zccEDbeHq8gj" title="Exercise price of warrant">13.00 per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zImSHXUZFQK1" title="Exercise price of warrant">6.50 per share exercise price. The company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the consolidated statements of changes in stockholders’ equity. On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note, the warrant was repriced from an exercise price of $6.50 per share to an exercise price of $5.82 per share. No further down-round provisions were triggered by the July 28, 2025 private placement transaction or the Subscription Agreement as these warrants were at their contractual floor. As a result of a partial voluntary conversion of the 2024 Alpha Debenture on September 9, 2024, the Company no longer had sufficient shares to settle the 2024 Alpha Warrant in full until shareholder approval was obtained, and a portion (2,314 warrant shares with a fair value of $14,997) was reclassified to liabilities (see Note 9 – Warrant Liabilities). Shareholder approval was subsequently obtained on October 25, 2024, and as of that date, the Company determined that shareholder approval resulted in equity classification for the warrant again and, accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants. During the year ended December 31, 2025, there were no exercises of this warrant. This warrant is included in equity on the Company’s consolidated balance sheets (see Note 15 – Stockholders’ Equity). As of December 31, 2025, the exercise price of all of the above warrants issued to Alpha was $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z2f3CesS6eD6" title="Exercise price of warrant">6.50. On April 12, 2024, in connection with the issuance of a debenture to Chen (see Note 10 – Convertible Debt), the Company issued a liability classified warrant to Chen to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_zPQkzmsB4zhk" title="Warrant to purchase shares">36,001 shares of common stock, exercisable until February 27, 2029. On September 6, 2024, as a result of a down-round provision triggered by shares sold in a public offering, the warrant was repriced from an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zwwHkaWGnVn3" title="Exercise price of warrant">13.00 per share to an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z3eCjLlLfPVj" title="Exercise price of warrant">6.50 per share. The warrant was initially liability classified due to an insufficient number of authorized shares to settle the warrant prior to the receipt of shareholder approval, which was subsequently obtained on October 25, 2024. As of that date, the Company determined that shareholder approval resulted in equity classification for the warrant and accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants (see Note 15 – Stockholders’ Equity). The fair value of this warrant was $565,582 on the issuance date and $185,531 on the date of reclassification to equity. During the year ended December 31, 2024, the Company recorded a gain on change in fair value of warrant liabilities of $380,051 for this warrant. On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note, the warrant was repriced from an exercise price of $6.50 per share to an exercise price of $5.82 per share. No further down-round provisions were triggered by the July 28, 2025 private placement transaction or the Subscription Agreement as these warrants were at their contractual floor.

30000000

34200000 4000000 200000

1000000.0

639000

0.08

3300000

3000000

1418922

103876

13.66

0.08

550000

500000

50979

7846

6.50

499021

31818

0.08

1100000

1000000

1154

1150000

50000

31998

13.00

416000

18001

13.00

6.50

27587

6.50

5.82

2314

14997

6.50

36001

13.00

6.50

565582 185531 380051

6.50

5.82

NOTE 17 — SEGMENT INFORMATION The Company operates as a single operating and reportable segment. This determination is consistent with the manner in which the Company’s Chief Operating Decision Maker (“CODM”) evaluates performance, allocates resources, and reviews financial results. The CODM consists of the Company’s two Co-Chief Executive Officers and its Chief Financial Officer. The CODM reviews consolidated financial information and does not receive discrete financial information for separate business components. Prior to the Offering (see Note 1 – Organization and Summary of Significant Accounting Policies and Estimates), the CODM consisted of the sole Chief Executive Officer. In accordance with ASC 280, Segment Reporting, the Company has concluded that it has one operating and reportable segment because its financial results are reviewed on a consolidated basis and no component meets the definition of a separate operating segment. The Company’s operations primarily consist of the development and commercialization of AI-enabled technology products and services, including AI-based trading tools, digital-asset tokenization and embedded AI services, and AI-powered cryptocurrency portfolio management solutions. Prior to the Offering, the Company was an early-stage clinical therapeutics company focused on developing treatments for adult and pediatric cancer. The CODM evaluates performance and allocates resources based on consolidated net income (loss). The CODM reviews the Company’s significant segment expenses, which are its consolidated operating expenses, including research and development, general and administrative, and interest and other expenses, broken out as follows: SCHEDULE OF SEGMENT INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20250101__20251231__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zMXJd3g0LQO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zJ26jlXJ2xn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For The Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zK6OhiEpGaQa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">EXPENSES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEz3SZ_zGiR0oqYwcs4" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,822,300</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,204,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEz3SZ_zSf8DsYZjbXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,197,162</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--CreditLossExpenseShorttermNoteReceivable_i01_maOEz3SZ_zqw36tDDMcac" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Credit loss expense - short-term note receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,195,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">360,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtOEz3SZ_zvgioPovXjQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,202,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,761,720</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iN_di_zRxAiabSDTg1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total other expense, net(1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,763,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">497,471</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_znLakGiH5j3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,965,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,259,191</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td style="text-align: justify">Includes total total non-operating expenses, provision for income taxes, and loss from discontinued operations.</td> </tr></table> The CODM evaluates the Company’s financial position based on the consolidated balance sheet and does not review segment-level asset information. Accordingly, no separate segment asset disclosures are presented.

SCHEDULE OF SEGMENT INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20250101__20251231__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zMXJd3g0LQO9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zJ26jlXJ2xn6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For The Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zK6OhiEpGaQa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">EXPENSES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEz3SZ_zGiR0oqYwcs4" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,822,300</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,204,558</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEz3SZ_zSf8DsYZjbXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,197,162</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--CreditLossExpenseShorttermNoteReceivable_i01_maOEz3SZ_zqw36tDDMcac" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Credit loss expense - short-term note receivable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,195,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">360,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtOEz3SZ_zvgioPovXjQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,202,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,761,720</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iN_di_zRxAiabSDTg1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total other expense, net(1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,763,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">497,471</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_znLakGiH5j3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"> Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,965,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,259,191</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"></td><td style="text-align: justify">Includes total total non-operating expenses, provision for income taxes, and loss from discontinued operations.</td> </tr></table>

8822300

4204558

184796

1197162

4195000 360000

13202096

5761720

-3763779

-497471

-16965875

-6259191

NOTE 18 — INCOME TAXES The following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the periods presented: SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250101__20251231_zKHsoh8Ie494" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20241231_zZUKjWFJNYZ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzD3F_znGIexzbY9ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">(16,965,875</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">(6,152,857</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzD3F_zSta22vcGsX6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzD3F_z4hbKtD9rYWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,965,875</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,152,857</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Beginning in 2025 annual reporting, we adopted ASU 2023-09 prospectively. A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zTF22bXmG37g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Percent</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zq4TyxlhG6z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. Federal Statutory Tax Rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maET_c20250101__20251231_zuj8DcLjHTIb" style="width: 14%; text-align: right" title="Statutory federal income tax rate, Amount">(3,562,676</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zuf6Lcg6qRw" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal income tax effect*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maET_c20250101__20251231_fKg_____zpD15pykNh0g" style="text-align: right" title="State taxes, net of federal tax benefit, Amount">(828,843</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.89</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_z2tOTXL6MALc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign Tax Effects</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maET_c20250101__20251231_z3zDhnKpYMo3" style="text-align: right" title="Foreign Tax Effects, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zxoODqwl9Avk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL expiration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Foreign Tax Effects"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_zg4JA2ycuTyi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of Changes in Tax Laws or Rates Enacted in the Current Period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maET_c20250101__20251231_zce1ltJ2yLV1" style="text-align: right" title="Effect of Changes in Tax Laws or Rates Enacted in the Current Period, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_z9sbG4J1Gdua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Effect of Cross-Border Tax Laws</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maET_c20250101__20251231_zW9943S754K8" style="text-align: right" title="Effect of Cross-Border Tax Laws, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zwrGHwx75es9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msABC_zTAJEO9hZVm7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msET_c20250101__20251231_zieLALJK1aIb" style="text-align: right" title="Research and development tax credits, Amount">8,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.05</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_zWYaftxjFZpc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in FV of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_zLQJ12ZwNs6e" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zdNfCf1Vrpo2" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of divestiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_z21HZrayb23f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in Valuation Allowances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maET_c20250101__20251231_zU2Njrms1co1" style="text-align: right" title="Change in valuation allowance, Amount">589,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Nontaxable or Nondeductible Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zgvJsoLjo6r9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepletion_maET_c20250101__20251231_znnCSUPnWFYb" style="text-align: right" title="Non-deductible expenses, Amount">120,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.71</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_zfftQFa32k5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maET_c20250101__20251231_zGC7lY8eFqVk" style="text-align: right" title="Stock compensation, Amount">108,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.64</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingencies_pid_dp_uPure_maABC_zP3xP7BsGg05" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in Unrecognized Tax Benefits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationTaxContingencies_maET_c20250101__20251231_zboYjsjSvdVh" style="text-align: right" title="Changes in Unrecognized Tax Benefits, Amount">(254,408</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfAttributeForfeiture_pid_dp_uPure_maABC_zbgz8i8Yq9b1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Tax impact of section 382 attribute forfeiture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationTaxImpactOfAttributeForfeiture_maET_c20250101__20251231_zHceIf2Jwvj1" style="text-align: right" title="Tax impact of section 382 attribute forfeiture, Amount">3,820,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-22.52</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_zmqxke5gaNX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">True-up</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncomeTaxReconciliationTrueUp_maET_c20250101__20251231_zml0N4vRe9ej" style="border-bottom: Black 1pt solid; text-align: right" title="True-up, Amount">(521</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zhLIvikYQMR4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtET_c20250101__20251231_z9VvIXvZzMV4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income taxes provision (benefit), Amount">0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr> </table> The following table presents required disclosures prior to the adoption of ASU 2023-09 and displays the reconciliation between statutory federal income taxes and the total income tax provision (benefit): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231_zL9PvsQx3fP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zvaqn8DJ8VI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_ztfHLneeYLP" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zR9dd1l1YQyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zhu61YplJ31" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NOL expiration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_z5Qgp1xLUjUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.87</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_zHGf3oTk5X01" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in FV of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.42</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_zedrACmvzA6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax impact of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-4.18</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zos70Uq1Tot4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of divestiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfAttributeForfeiture_pid_dp_uPure_maABC_z371uGLQyXe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax impact of section 382 attribute forfeiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-202.84</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_zrfegrzihf47" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-53.37</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z5z8x5ms4NHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>True-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.87</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zVvKrmIz8kma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">238.69</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_z3dHdxCYzKg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.10</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> The provision for income taxes includes the following: SCHEDULE OF PROVISION FOR INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20251231_zd4uwLyYxX57" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zrT4BhjSqoBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_z2npaZM25n37" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">US Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zk90AkaXn3Hk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">US State</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">6,334</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_ziXcDKXD8Ek1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">US Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_maITEBzWbu_zLZCLtuQ18i7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total current provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zzldQcKo7LQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">US Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(589,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,069,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zptnMNitJ5yi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">US State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(315,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,617,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zRTf4O4C0pxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">US Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zJ4RivMAcGxl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total deferred benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(904,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,686,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_z0MhmAC8oFci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">904,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,686,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtITEBzWbu_zJ32aN4bllR4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,334</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The components of deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zN48keMarRSg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zmNC17E1UyQc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhZ9zSBiTsi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets</td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz2zg_z1srKTQONZml" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,234,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_maDTAGz2zg_zXugxPqRkFee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGz2zg_z4vki7I2iWqh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz2zg_zPkph2IE4MG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_i01I_maDTAGz2zg_z689ucsYvjt8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unrealized loss on digital assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">757,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGz2zg_zOYEHzbxWJg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Provision for losses on notes receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz2zg_znl4OFnsnaac" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Research and development expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">703,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">963,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz2zg_zl3cMUsVgDt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,006,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_i01TI_maDTANzf8i_zXM2oUe2a75f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Net deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,006,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzf8i_zBK3Yexpb7V" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,006,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,102,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzf8i_zRQK1q3iWRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During 2025 and 2024, the aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows: SCHEDULE OF UNRECOGNIZED TAX BENEFITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zPhGwbYMn1f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20241231_zytcziPaPSVc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefits_iS_zIE4kTCcLfRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Gross unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">279,105</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zeS0e9NBnxl4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increases (decreases) related to current year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,285</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsPeriodIncreaseDecrease_zWwg8fTZwUIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increases (decreases) related to prior year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(279,105</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">270,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ExpirationOfUnrecognizedTaxBenefits_zk9RlIAOUr7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expiration of unrecognized tax benefits</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefits_iE_zVe3VluDume2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross unrecognized tax benefits at the end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table below provides the updated requirements of ASU 2023-09 for cash paid for income taxes, net of refunds. SCHEDULE OF INCOME TAX NET OF REFUNDS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20251231_zpYh541v5iEb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zhCCyaVpjzm2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for income taxes, net of refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNzdTh_zb6jGNNHbtgh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxPaidStateAndLocalAfterRefundReceived_maITPNzdTh_z6Tnb85bvIXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%">State</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">6,334</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNzdTh_zPjfEIlWimtk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxesPaid_iT_mtITPNzdTh_zK93haHZL3R1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash paid for income taxes, net of refunds</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,334</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Based on the available objective evidence, including the Company’s history of cumulative losses, management believes it is likely that the Company’s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2025, and December 31, 2024. Due to the full valuation allowance already in place on the Company’s U.S. federal and state net deferred tax assets, the Company does not anticipate significant changes in the Company’s effective tax rate. Changes to US tax law enacted on July 4, 2025, allow for immediate expensing of domestic research and experimentation costs, accelerated depreciation on eligible capital expenditures, and other tax law changes impacting 2025 with certain changes effective in 2026. These changes are reflected in our results for the year ended December 31, 2025, and did not have a material impact on the Company’s effective tax rate in 2025. At December 31, 2025, the Company has U.S. federal and state net operating loss carryforwards of approximately $4,602,000 and $3,831,000, respectively, which are available to offset future taxable income. U.S. federal net operating loss carryforwards can be carried forward indefinitely. State net operating loss carryovers begin to expire in 2044. The Company’s net operating loss and tax credit carryforwards may be subject to an annual limitation under sections 382 and 383 of the Internal Revenue Code of 1986 (the “Code”), and similar state provisions if the Company experienced one or more ownership changes, which would limit the amount of net operating loss and tax credit carryforwards that may be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by section 382, results from equity shifts that increase ownership of certain stockholders or public groups in the stock of the corporation of more than 50% over a three-year period. As a result of the September 2025 subscription agreement, a section 382 ownership change has occurred. After the consummation of the agreement, the Qualigen business has been substantially reduced resulting in any pre-ownership change net operating loss and tax credit carryforwards becoming fully limited under section 382. The pre-ownership change net operating losses and tax credit carryforward DTAs are considered worthless and have been written-off the deferred tax table presented above. The Company has not completed an Internal Revenue Code Section 382 analysis. The Company files income tax returns in the U.S. federal jurisdiction and in California. The Company’s U.S. federal income tax returns remain subject to examination by the Internal Revenue Service. The Company’s California income tax returns remain subject to examination by the California Franchise Tax Board. The companies tax returns for calendar year 2022 and forward are subject to examination by the U.S. federal and state tax authorities. Generally accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company’s financial statements and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company adopted these provisions effective April 1, 2009. The Company had unrecognized tax benefits of $0 as of December 31, 2025. Due to the existence of the valuation allowance, future changes in unrecognized tax benefits would have no effect on the Company’s effective tax rate. The Company does not foresee any material changes over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2025, the Company has not accrued any interest or penalties related to uncertain tax positions.

The following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the periods presented: SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250101__20251231_zKHsoh8Ie494" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20241231_zZUKjWFJNYZ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzD3F_znGIexzbY9ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">(16,965,875</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">(6,152,857</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzD3F_zSta22vcGsX6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzD3F_z4hbKtD9rYWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,965,875</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,152,857</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Beginning in 2025 annual reporting, we adopted ASU 2023-09 prospectively. A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zTF22bXmG37g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Percent</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zq4TyxlhG6z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. Federal Statutory Tax Rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maET_c20250101__20251231_zuj8DcLjHTIb" style="width: 14%; text-align: right" title="Statutory federal income tax rate, Amount">(3,562,676</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zuf6Lcg6qRw" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal income tax effect*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maET_c20250101__20251231_fKg_____zpD15pykNh0g" style="text-align: right" title="State taxes, net of federal tax benefit, Amount">(828,843</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.89</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_z2tOTXL6MALc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign Tax Effects</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maET_c20250101__20251231_z3zDhnKpYMo3" style="text-align: right" title="Foreign Tax Effects, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zxoODqwl9Avk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL expiration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Foreign Tax Effects"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_zg4JA2ycuTyi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of Changes in Tax Laws or Rates Enacted in the Current Period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maET_c20250101__20251231_zce1ltJ2yLV1" style="text-align: right" title="Effect of Changes in Tax Laws or Rates Enacted in the Current Period, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_z9sbG4J1Gdua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Effect of Cross-Border Tax Laws</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maET_c20250101__20251231_zW9943S754K8" style="text-align: right" title="Effect of Cross-Border Tax Laws, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zwrGHwx75es9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msABC_zTAJEO9hZVm7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msET_c20250101__20251231_zieLALJK1aIb" style="text-align: right" title="Research and development tax credits, Amount">8,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.05</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_zWYaftxjFZpc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in FV of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_zLQJ12ZwNs6e" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zdNfCf1Vrpo2" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of divestiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_z21HZrayb23f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in Valuation Allowances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maET_c20250101__20251231_zU2Njrms1co1" style="text-align: right" title="Change in valuation allowance, Amount">589,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Nontaxable or Nondeductible Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zgvJsoLjo6r9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepletion_maET_c20250101__20251231_znnCSUPnWFYb" style="text-align: right" title="Non-deductible expenses, Amount">120,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.71</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_zfftQFa32k5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maET_c20250101__20251231_zGC7lY8eFqVk" style="text-align: right" title="Stock compensation, Amount">108,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.64</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingencies_pid_dp_uPure_maABC_zP3xP7BsGg05" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in Unrecognized Tax Benefits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationTaxContingencies_maET_c20250101__20251231_zboYjsjSvdVh" style="text-align: right" title="Changes in Unrecognized Tax Benefits, Amount">(254,408</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfAttributeForfeiture_pid_dp_uPure_maABC_zbgz8i8Yq9b1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Tax impact of section 382 attribute forfeiture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationTaxImpactOfAttributeForfeiture_maET_c20250101__20251231_zHceIf2Jwvj1" style="text-align: right" title="Tax impact of section 382 attribute forfeiture, Amount">3,820,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-22.52</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_zmqxke5gaNX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">True-up</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncomeTaxReconciliationTrueUp_maET_c20250101__20251231_zml0N4vRe9ej" style="border-bottom: Black 1pt solid; text-align: right" title="True-up, Amount">(521</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zhLIvikYQMR4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtET_c20250101__20251231_z9VvIXvZzMV4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income taxes provision (benefit), Amount">0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr> </table> The following table presents required disclosures prior to the adoption of ASU 2023-09 and displays the reconciliation between statutory federal income taxes and the total income tax provision (benefit): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231_zL9PvsQx3fP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zvaqn8DJ8VI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_ztfHLneeYLP" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zR9dd1l1YQyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zhu61YplJ31" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NOL expiration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_z5Qgp1xLUjUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.87</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_zHGf3oTk5X01" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in FV of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.42</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_zedrACmvzA6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax impact of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-4.18</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zos70Uq1Tot4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of divestiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfAttributeForfeiture_pid_dp_uPure_maABC_z371uGLQyXe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax impact of section 382 attribute forfeiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-202.84</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_zrfegrzihf47" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-53.37</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z5z8x5ms4NHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>True-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.87</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zVvKrmIz8kma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">238.69</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_z3dHdxCYzKg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.10</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

-16965875

-6152857

-16965875

-6152857

Beginning in 2025 annual reporting, we adopted ASU 2023-09 prospectively. A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Amount</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zTF22bXmG37g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Percent</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zq4TyxlhG6z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">U.S. Federal Statutory Tax Rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maET_c20250101__20251231_zuj8DcLjHTIb" style="width: 14%; text-align: right" title="Statutory federal income tax rate, Amount">(3,562,676</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zuf6Lcg6qRw" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal income tax effect*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maET_c20250101__20251231_fKg_____zpD15pykNh0g" style="text-align: right" title="State taxes, net of federal tax benefit, Amount">(828,843</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.89</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_z2tOTXL6MALc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign Tax Effects</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maET_c20250101__20251231_z3zDhnKpYMo3" style="text-align: right" title="Foreign Tax Effects, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zxoODqwl9Avk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL expiration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Foreign Tax Effects"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_zg4JA2ycuTyi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of Changes in Tax Laws or Rates Enacted in the Current Period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maET_c20250101__20251231_zce1ltJ2yLV1" style="text-align: right" title="Effect of Changes in Tax Laws or Rates Enacted in the Current Period, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_z9sbG4J1Gdua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Effect of Cross-Border Tax Laws</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maET_c20250101__20251231_zW9943S754K8" style="text-align: right" title="Effect of Cross-Border Tax Laws, Amount">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zwrGHwx75es9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax Credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msABC_zTAJEO9hZVm7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msET_c20250101__20251231_zieLALJK1aIb" style="text-align: right" title="Research and development tax credits, Amount">8,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.05</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_zWYaftxjFZpc" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in FV of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_zLQJ12ZwNs6e" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zdNfCf1Vrpo2" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of divestiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_z21HZrayb23f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in Valuation Allowances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maET_c20250101__20251231_zU2Njrms1co1" style="text-align: right" title="Change in valuation allowance, Amount">589,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.47</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left">Nontaxable or Nondeductible Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zgvJsoLjo6r9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseDepletion_maET_c20250101__20251231_znnCSUPnWFYb" style="text-align: right" title="Non-deductible expenses, Amount">120,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.71</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_zfftQFa32k5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maET_c20250101__20251231_zGC7lY8eFqVk" style="text-align: right" title="Stock compensation, Amount">108,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.64</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingencies_pid_dp_uPure_maABC_zP3xP7BsGg05" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in Unrecognized Tax Benefits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationTaxContingencies_maET_c20250101__20251231_zboYjsjSvdVh" style="text-align: right" title="Changes in Unrecognized Tax Benefits, Amount">(254,408</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfAttributeForfeiture_pid_dp_uPure_maABC_zbgz8i8Yq9b1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Tax impact of section 382 attribute forfeiture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationTaxImpactOfAttributeForfeiture_maET_c20250101__20251231_zHceIf2Jwvj1" style="text-align: right" title="Tax impact of section 382 attribute forfeiture, Amount">3,820,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-22.52</td><td style="text-align: left">%</td></tr> <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_zmqxke5gaNX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">True-up</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--IncomeTaxReconciliationTrueUp_maET_c20250101__20251231_zml0N4vRe9ej" style="border-bottom: Black 1pt solid; text-align: right" title="True-up, Amount">(521</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zhLIvikYQMR4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtET_c20250101__20251231_z9VvIXvZzMV4" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Income taxes provision (benefit), Amount">0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr> </table> The following table presents required disclosures prior to the adoption of ASU 2023-09 and displays the reconciliation between statutory federal income taxes and the total income tax provision (benefit): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231_zL9PvsQx3fP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zvaqn8DJ8VI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_ztfHLneeYLP" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zR9dd1l1YQyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zhu61YplJ31" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NOL expiration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_z5Qgp1xLUjUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-3.87</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_zHGf3oTk5X01" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in FV of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.42</td><td style="text-align: left">%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_zedrACmvzA6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax impact of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-4.18</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zos70Uq1Tot4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Tax impact of divestiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfAttributeForfeiture_pid_dp_uPure_maABC_z371uGLQyXe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tax impact of section 382 attribute forfeiture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-202.84</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_zrfegrzihf47" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-53.37</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z5z8x5ms4NHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>True-up</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-2.87</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zVvKrmIz8kma" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">238.69</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_z3dHdxCYzKg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income taxes provision (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.10</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

-3562676

0.2100

-828843

0.0489

-8285

0.0005

589175

-0.0347

120826

-0.0071

108017

-0.0064

-254408

0.0150

3820144 -0.2252 -521 0.0000

0.0000

0.2100

0.0590

0.0002

0.0000

0.0387

0.0142

-0.0418 0.0000 -2.0284

-0.5337

-0.0287

2.3869

-0.0010

SCHEDULE OF PROVISION FOR INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20251231_zd4uwLyYxX57" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zrT4BhjSqoBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_z2npaZM25n37" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">US Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zk90AkaXn3Hk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">US State</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">6,334</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBz1MC_ziXcDKXD8Ek1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">US Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_maITEBzWbu_zLZCLtuQ18i7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total current provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zzldQcKo7LQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">US Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(589,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,069,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zptnMNitJ5yi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">US State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(315,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,617,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzCKf_zRTf4O4C0pxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">US Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_zJ4RivMAcGxl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total deferred benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(904,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,686,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_z0MhmAC8oFci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">904,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,686,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtITEBzWbu_zJ32aN4bllR4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,334</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The components of deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zN48keMarRSg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zmNC17E1UyQc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhZ9zSBiTsi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets</td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz2zg_z1srKTQONZml" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,234,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_maDTAGz2zg_zXugxPqRkFee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGz2zg_z4vki7I2iWqh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz2zg_zPkph2IE4MG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_i01I_maDTAGz2zg_z689ucsYvjt8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unrealized loss on digital assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">757,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGz2zg_zOYEHzbxWJg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Provision for losses on notes receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz2zg_znl4OFnsnaac" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Research and development expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">703,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">963,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz2zg_zl3cMUsVgDt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,006,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_i01TI_maDTANzf8i_zXM2oUe2a75f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Net deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,006,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzf8i_zBK3Yexpb7V" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,006,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,102,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzf8i_zRQK1q3iWRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During 2025 and 2024, the aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows: SCHEDULE OF UNRECOGNIZED TAX BENEFITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zPhGwbYMn1f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20241231_zytcziPaPSVc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefits_iS_zIE4kTCcLfRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Gross unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">279,105</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zeS0e9NBnxl4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increases (decreases) related to current year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,285</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsPeriodIncreaseDecrease_zWwg8fTZwUIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increases (decreases) related to prior year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(279,105</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">270,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ExpirationOfUnrecognizedTaxBenefits_zk9RlIAOUr7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expiration of unrecognized tax benefits</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefits_iE_zVe3VluDume2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross unrecognized tax benefits at the end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6334

-589000

6069000

-315000

8617000

-904000

14686000

-904000

14686000

-0

6334

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_zN48keMarRSg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zmNC17E1UyQc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhZ9zSBiTsi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets</td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic"> </td> <td style="font-weight: bold; font-style: italic; text-align: left"> </td><td style="font-weight: bold; font-style: italic; text-align: right"> </td><td style="font-weight: bold; font-style: italic; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz2zg_z1srKTQONZml" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,234,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_maDTAGz2zg_zXugxPqRkFee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGz2zg_z4vki7I2iWqh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz2zg_zPkph2IE4MG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_i01I_maDTAGz2zg_z689ucsYvjt8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unrealized loss on digital assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">757,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGz2zg_zOYEHzbxWJg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Provision for losses on notes receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,275,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz2zg_znl4OFnsnaac" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Research and development expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">703,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">963,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz2zg_zl3cMUsVgDt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,006,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_i01TI_maDTANzf8i_zXM2oUe2a75f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Net deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,006,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzf8i_zBK3Yexpb7V" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,006,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,102,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzf8i_zRQK1q3iWRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During 2025 and 2024, the aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows: SCHEDULE OF UNRECOGNIZED TAX BENEFITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zPhGwbYMn1f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20241231_zytcziPaPSVc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefits_iS_zIE4kTCcLfRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Gross unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">279,105</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zeS0e9NBnxl4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increases (decreases) related to current year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,285</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsPeriodIncreaseDecrease_zWwg8fTZwUIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increases (decreases) related to prior year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(279,105</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">270,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ExpirationOfUnrecognizedTaxBenefits_zk9RlIAOUr7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expiration of unrecognized tax benefits</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefits_iE_zVe3VluDume2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross unrecognized tax benefits at the end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1234000

1626000

254000

13000

37000

145000

757000

1275000

101000

703000

963000

4006000

3102000

4006000

3102000

4006000

3102000

SCHEDULE OF UNRECOGNIZED TAX BENEFITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20251231_zPhGwbYMn1f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20241231_zytcziPaPSVc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefits_iS_zIE4kTCcLfRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Gross unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">279,105</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zeS0e9NBnxl4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increases (decreases) related to current year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,285</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsPeriodIncreaseDecrease_zWwg8fTZwUIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increases (decreases) related to prior year positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(279,105</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">270,820</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ExpirationOfUnrecognizedTaxBenefits_zk9RlIAOUr7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expiration of unrecognized tax benefits</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefits_iE_zVe3VluDume2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross unrecognized tax benefits at the end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

279105

8285

-279105

270820

279105

SCHEDULE OF INCOME TAX NET OF REFUNDS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20251231_zpYh541v5iEb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zhCCyaVpjzm2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for income taxes, net of refunds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNzdTh_zb6jGNNHbtgh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxPaidStateAndLocalAfterRefundReceived_maITPNzdTh_z6Tnb85bvIXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%">State</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">6,334</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNzdTh_zPjfEIlWimtk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxesPaid_iT_mtITPNzdTh_zK93haHZL3R1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total cash paid for income taxes, net of refunds</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,334</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Based on the available objective evidence, including the Company’s history of cumulative losses, management believes it is likely that the Company’s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2025, and December 31, 2024. Due to the full valuation allowance already in place on the Company’s U.S. federal and state net deferred tax assets, the Company does not anticipate significant changes in the Company’s effective tax rate. Changes to US tax law enacted on July 4, 2025, allow for immediate expensing of domestic research and experimentation costs, accelerated depreciation on eligible capital expenditures, and other tax law changes impacting 2025 with certain changes effective in 2026. These changes are reflected in our results for the year ended December 31, 2025, and did not have a material impact on the Company’s effective tax rate in 2025. At December 31, 2025, the Company has U.S. federal and state net operating loss carryforwards of approximately $4,602,000 and $3,831,000, respectively, which are available to offset future taxable income. U.S. federal net operating loss carryforwards can be carried forward indefinitely. State net operating loss carryovers begin to expire in 2044. The Company’s net operating loss and tax credit carryforwards may be subject to an annual limitation under sections 382 and 383 of the Internal Revenue Code of 1986 (the “Code”), and similar state provisions if the Company experienced one or more ownership changes, which would limit the amount of net operating loss and tax credit carryforwards that may be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by section 382, results from equity shifts that increase ownership of certain stockholders or public groups in the stock of the corporation of more than 50% over a three-year period. As a result of the September 2025 subscription agreement, a section 382 ownership change has occurred. After the consummation of the agreement, the Qualigen business has been substantially reduced resulting in any pre-ownership change net operating loss and tax credit carryforwards becoming fully limited under section 382. The pre-ownership change net operating losses and tax credit carryforward DTAs are considered worthless and have been written-off the deferred tax table presented above. The Company has not completed an Internal Revenue Code Section 382 analysis. The Company files income tax returns in the U.S. federal jurisdiction and in California. The Company’s U.S. federal income tax returns remain subject to examination by the Internal Revenue Service. The Company’s California income tax returns remain subject to examination by the California Franchise Tax Board. The companies tax returns for calendar year 2022 and forward are subject to examination by the U.S. federal and state tax authorities. Generally accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company’s financial statements and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company adopted these provisions effective April 1, 2009. The Company had unrecognized tax benefits of $0 as of December 31, 2025. Due to the existence of the valuation allowance, future changes in unrecognized tax benefits would have no effect on the Company’s effective tax rate. The Company does not foresee any material changes over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2025, the Company has not accrued any interest or penalties related to uncertain tax positions.

6334

4602000

3831000

NOTE 19 — SUBSEQUENT EVENTS In January 2026, a total of <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20260101__20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zN9d8dgG7Vg2" title="Number of shares converted">3,926 shares of Series B Preferred Stock were converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20260101__20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z29f8DAovfQj" title="Common stock issued upon conversion">1,747,781 shares of common stock at a conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zZ9EmENFIsPg" title="Conversion price">2.246 per share. In February 2026, a total of <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20260201__20260228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzisvi4BKQDh" title="Conversion of stock shares converted">491 shares of Series B Preferred Stock were converted into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20260201__20260228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWPlnXjPhNc4" title="Conversion of stock shares converted">218,473 shares of common stock at a conversion price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20260228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKFwoWWkDXke" title="Share price">2.246 per share. In March 2026, a total of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20260301__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBPJNJQU5UO3" title="Conversion of stock shares converted">29,441 shares of Series B Preferred Stock were converted into <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20260301__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKQHaAFaaD1f" title="Conversion of stock shares converted">13,108,357 shares of common stock at a conversion price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJS6Ki0xWl3f" title="Share price">2.246 per share. In January 2026, the Company repaid $<span id="xdx_900_eus-gaap--RepaymentsOfNotesPayable_c20260101__20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalAnstaltMember_z0dvlpN5squa" title="Convertible notes outstanding repaid">132,000 to Alpha Capital Anstalt in satisfaction of their outstanding convertible note. In January 2026, the Company formed three new wholly owned subsidiaries, registered in Delaware, to structure our core digital asset an AI initiatives. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif">AIxCrypto Token Labs US, Inc.: Web3 infrastructure and protocol development.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif">AIxCrypto EAI, Inc.: EAI operations.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif">AIxCrypto C10 ETF, Inc. Evaluate potential institutional exchange traded products in the future. </td></tr> </table> In January 2026, the Company entered into an entrusted investment agreement (the “Entrusted Investment Agreement”) with GOLD KING ARTHUR HOLDING LIMITED (“GKA”) and Song Wang (“Song”), pursuant to which the Company entrusted to GKA the management of an investment involving shares (“FFAI Shares”) of Class A common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EntrustedInvestmentAgreementMember_zD68fMBYg4Vi" title="Common stock, par value">0.0001 per share (“FFAI Class A Common Stock”), of Faraday Future Intelligent Electric Inc. (“Faraday”). In connection with the Entrusted Investment Agreement, on the same date, GKA and Faraday entered into a securities purchase agreement (the “GKA SPA”) providing for the potential purchase of FFAI Shares for an aggregate consideration of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260101__20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgd3yN4ZH0n1" title="Shares consideration">10,000,000. The number of Faraday Shares to be issued under the GKA SPA will be determined based on the closing price of FFAI Class A Common Stock on the trading day immediately prior to the closing date, and the closing is subject to customary conditions. As these agreements were executed after the balance sheet date and do not provide evidence of conditions existing as of that date, they represent non-recognized subsequent events under ASC 855, and no adjustments have been made to the Company’s consolidated financial statements. On March 20, 2026, FFAI filed a Current Report on Form 8-K disclosing receipt of a deficiency notice from Nasdaq for failing to maintain the minimum $1.00 bid price required by Nasdaq Listing Rule 5550(a)(2). Given the recent $10.0 million investment in FFAI disclosed above, a potential delisting introduces significant liquidity and valuation risks to our holding if FFAI fails to regain compliance during its allotted cure period. Additional details regarding the deficiency notice and FFAI’s compliance plans can be found in the Form 8-K filed by FFAI.

3926

1747781

2.246

491

218473

2.246

29441

13108357

2.246

132000

0.0001

10000000

1.00

10000000.0

false false false false true Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto asstes held for investment The Company measures gains and losses by each asset held. These amounts include cumulative realized gains of $13,117, realized losses of $896,471, and unrealized losses of $2,704,752 during the year ended December 31, 2025 excludes 51,199 pre-funded warrants which have no expiration date Includes total total non-operating expenses, provision for income taxes, and loss from discontinued operations.